CA2493282C - Method and composition for inhibiting cancer cell growth using urease and weakly basic anti-cancer compounds - Google Patents
Method and composition for inhibiting cancer cell growth using urease and weakly basic anti-cancer compounds Download PDFInfo
- Publication number
- CA2493282C CA2493282C CA2493282A CA2493282A CA2493282C CA 2493282 C CA2493282 C CA 2493282C CA 2493282 A CA2493282 A CA 2493282A CA 2493282 A CA2493282 A CA 2493282A CA 2493282 C CA2493282 C CA 2493282C
- Authority
- CA
- Canada
- Prior art keywords
- urease
- cancer
- cells
- tumor
- enzyme
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108010046334 Urease Proteins 0.000 title claims abstract description 316
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 164
- 201000011510 cancer Diseases 0.000 title claims abstract description 75
- 150000001875 compounds Chemical class 0.000 title claims abstract description 70
- 239000000203 mixture Substances 0.000 title claims abstract description 70
- 230000001093 anti-cancer Effects 0.000 title claims abstract description 56
- 238000000034 method Methods 0.000 title abstract description 46
- 230000002401 inhibitory effect Effects 0.000 title abstract description 11
- 230000010261 cell growth Effects 0.000 title description 14
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims abstract description 90
- 239000004202 carbamide Substances 0.000 claims abstract description 46
- 230000012010 growth Effects 0.000 claims abstract description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 16
- 210000004027 cell Anatomy 0.000 claims description 142
- 230000008685 targeting Effects 0.000 claims description 44
- 239000003112 inhibitor Substances 0.000 claims description 26
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 23
- 239000000427 antigen Substances 0.000 claims description 21
- 102000036639 antigens Human genes 0.000 claims description 21
- 108091007433 antigens Proteins 0.000 claims description 21
- 102000004190 Enzymes Human genes 0.000 claims description 20
- 108090000790 Enzymes Proteins 0.000 claims description 20
- 230000000259 anti-tumor effect Effects 0.000 claims description 17
- 239000012634 fragment Substances 0.000 claims description 16
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 12
- 229960002949 fluorouracil Drugs 0.000 claims description 12
- 239000002601 urease inhibitor Substances 0.000 claims description 12
- 229940090496 Urease inhibitor Drugs 0.000 claims description 10
- 229960001156 mitoxantrone Drugs 0.000 claims description 10
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 10
- 229960004679 doxorubicin Drugs 0.000 claims description 9
- 239000003937 drug carrier Substances 0.000 claims description 9
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 8
- 230000000118 anti-neoplastic effect Effects 0.000 claims description 8
- 230000037396 body weight Effects 0.000 claims description 8
- 239000003085 diluting agent Substances 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 229960003048 vinblastine Drugs 0.000 claims description 8
- 229940034982 antineoplastic agent Drugs 0.000 claims description 7
- 241000196324 Embryophyta Species 0.000 claims description 6
- 229940122803 Vinca alkaloid Drugs 0.000 claims description 6
- 229940100198 alkylating agent Drugs 0.000 claims description 6
- 239000002168 alkylating agent Substances 0.000 claims description 6
- 210000004602 germ cell Anatomy 0.000 claims description 6
- 102000037865 fusion proteins Human genes 0.000 claims description 5
- 108020001507 fusion proteins Proteins 0.000 claims description 5
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims description 4
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 4
- 108010006654 Bleomycin Proteins 0.000 claims description 4
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims description 4
- 229930192392 Mitomycin Natural products 0.000 claims description 4
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 4
- 229960001561 bleomycin Drugs 0.000 claims description 4
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 4
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 4
- 230000007423 decrease Effects 0.000 claims description 4
- 229960001904 epirubicin Drugs 0.000 claims description 4
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims description 4
- 229960004857 mitomycin Drugs 0.000 claims description 4
- 150000003230 pyrimidines Chemical class 0.000 claims description 4
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 claims description 4
- 229960004528 vincristine Drugs 0.000 claims description 4
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 4
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 4
- 235000002198 Annona diversifolia Nutrition 0.000 claims description 3
- 230000001580 bacterial effect Effects 0.000 claims description 3
- 229960000975 daunorubicin Drugs 0.000 claims description 3
- WTSKMKRYHATLLL-UHFFFAOYSA-N (6-benzoyloxy-3-cyanopyridin-2-yl) 3-[3-(ethoxymethyl)-5-fluoro-2,6-dioxopyrimidine-1-carbonyl]benzoate Chemical compound O=C1N(COCC)C=C(F)C(=O)N1C(=O)C1=CC=CC(C(=O)OC=2C(=CC=C(OC(=O)C=3C=CC=CC=3)N=2)C#N)=C1 WTSKMKRYHATLLL-UHFFFAOYSA-N 0.000 claims description 2
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 claims description 2
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims description 2
- WYXSYVWAUAUWLD-SHUUEZRQSA-N 6-azauridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=N1 WYXSYVWAUAUWLD-SHUUEZRQSA-N 0.000 claims description 2
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims description 2
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims description 2
- AOCCBINRVIKJHY-UHFFFAOYSA-N Carmofur Chemical compound CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O AOCCBINRVIKJHY-UHFFFAOYSA-N 0.000 claims description 2
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical group C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 claims description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical group ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 2
- SAMRUMKYXPVKPA-VFKOLLTISA-N Enocitabine Chemical compound O=C1N=C(NC(=O)CCCCCCCCCCCCCCCCCCCCC)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 SAMRUMKYXPVKPA-VFKOLLTISA-N 0.000 claims description 2
- BBDAGFIXKZCXAH-CCXZUQQUSA-N ancitabine Chemical group N=C1C=CN2[C@@H]3O[C@H](CO)[C@@H](O)[C@@H]3OC2=N1 BBDAGFIXKZCXAH-CCXZUQQUSA-N 0.000 claims description 2
- 229950000242 ancitabine Drugs 0.000 claims description 2
- 229960002756 azacitidine Drugs 0.000 claims description 2
- 229960004117 capecitabine Drugs 0.000 claims description 2
- 229960003261 carmofur Drugs 0.000 claims description 2
- 229960002436 cladribine Drugs 0.000 claims description 2
- 229960004397 cyclophosphamide Drugs 0.000 claims description 2
- 229960000684 cytarabine Drugs 0.000 claims description 2
- 229960003603 decitabine Drugs 0.000 claims description 2
- ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 claims description 2
- 229950005454 doxifluridine Drugs 0.000 claims description 2
- 229950005450 emitefur Drugs 0.000 claims description 2
- 229950011487 enocitabine Drugs 0.000 claims description 2
- 229960000390 fludarabine Drugs 0.000 claims description 2
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims description 2
- 229960005277 gemcitabine Drugs 0.000 claims description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 2
- 229960002868 mechlorethamine hydrochloride Drugs 0.000 claims description 2
- QZIQJVCYUQZDIR-UHFFFAOYSA-N mechlorethamine hydrochloride Chemical compound Cl.ClCCN(C)CCCl QZIQJVCYUQZDIR-UHFFFAOYSA-N 0.000 claims description 2
- 229960001428 mercaptopurine Drugs 0.000 claims description 2
- 229960001674 tegafur Drugs 0.000 claims description 2
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 claims description 2
- YFTWHEBLORWGNI-UHFFFAOYSA-N tiamiprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC(N)=NC2=C1NC=N2 YFTWHEBLORWGNI-UHFFFAOYSA-N 0.000 claims description 2
- 229950011457 tiamiprine Drugs 0.000 claims description 2
- 229960003723 tiazofurine Drugs 0.000 claims description 2
- FVRDYQYEVDDKCR-DBRKOABJSA-N tiazofurine Chemical compound NC(=O)C1=CSC([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=N1 FVRDYQYEVDDKCR-DBRKOABJSA-N 0.000 claims description 2
- 229960003087 tioguanine Drugs 0.000 claims description 2
- 150000003212 purines Chemical class 0.000 claims 2
- 241000282842 Lama glama Species 0.000 claims 1
- 229960000961 floxuridine Drugs 0.000 claims 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 claims 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 29
- 239000002246 antineoplastic agent Substances 0.000 abstract description 24
- 230000001225 therapeutic effect Effects 0.000 abstract description 17
- 230000003389 potentiating effect Effects 0.000 abstract description 13
- 230000005764 inhibitory process Effects 0.000 abstract description 9
- 230000006872 improvement Effects 0.000 abstract description 7
- 238000001990 intravenous administration Methods 0.000 abstract description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 37
- 108090000765 processed proteins & peptides Proteins 0.000 description 37
- 230000000694 effects Effects 0.000 description 33
- 239000003795 chemical substances by application Substances 0.000 description 28
- 239000000243 solution Substances 0.000 description 27
- 239000013543 active substance Substances 0.000 description 25
- RRUDCFGSUDOHDG-UHFFFAOYSA-N acetohydroxamic acid Chemical compound CC(O)=NO RRUDCFGSUDOHDG-UHFFFAOYSA-N 0.000 description 24
- 229960001171 acetohydroxamic acid Drugs 0.000 description 24
- 238000002347 injection Methods 0.000 description 24
- 239000007924 injection Substances 0.000 description 24
- 210000001519 tissue Anatomy 0.000 description 24
- 102000004196 processed proteins & peptides Human genes 0.000 description 23
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 19
- 229910021529 ammonia Inorganic materials 0.000 description 17
- 229940088598 enzyme Drugs 0.000 description 17
- 239000000872 buffer Substances 0.000 description 16
- 229920001184 polypeptide Polymers 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 15
- 239000003814 drug Substances 0.000 description 14
- 238000011534 incubation Methods 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 13
- 229940041181 antineoplastic drug Drugs 0.000 description 13
- 235000018102 proteins Nutrition 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 208000026310 Breast neoplasm Diseases 0.000 description 11
- 230000008859 change Effects 0.000 description 11
- 230000003013 cytotoxicity Effects 0.000 description 11
- 231100000135 cytotoxicity Toxicity 0.000 description 11
- -1 hydroxide ions Chemical class 0.000 description 11
- 206010006187 Breast cancer Diseases 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 10
- 150000001413 amino acids Chemical group 0.000 description 10
- 230000014509 gene expression Effects 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 239000008363 phosphate buffer Substances 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 210000004881 tumor cell Anatomy 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 235000001014 amino acid Nutrition 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 210000003722 extracellular fluid Anatomy 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 230000004913 activation Effects 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 239000003623 enhancer Substances 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- JXLYSJRDGCGARV-CFWMRBGOSA-N vinblastine Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-CFWMRBGOSA-N 0.000 description 8
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 230000002255 enzymatic effect Effects 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 239000012216 imaging agent Substances 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 7
- 108020004707 nucleic acids Proteins 0.000 description 7
- 150000007523 nucleic acids Chemical class 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000002872 contrast media Substances 0.000 description 6
- 230000000875 corresponding effect Effects 0.000 description 6
- 231100000433 cytotoxic Toxicity 0.000 description 6
- 230000001472 cytotoxic effect Effects 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 238000002595 magnetic resonance imaging Methods 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 101000950981 Bacillus subtilis (strain 168) Catabolic NAD-specific glutamate dehydrogenase RocG Proteins 0.000 description 5
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 5
- 102000016901 Glutamate dehydrogenase Human genes 0.000 description 5
- 108060003951 Immunoglobulin Proteins 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 230000005907 cancer growth Effects 0.000 description 5
- 150000005829 chemical entities Chemical class 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Chemical compound NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- 102000018358 immunoglobulin Human genes 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 230000004807 localization Effects 0.000 description 5
- 208000020816 lung neoplasm Diseases 0.000 description 5
- 238000004949 mass spectrometry Methods 0.000 description 5
- 230000010076 replication Effects 0.000 description 5
- 239000003579 shift reagent Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 230000035899 viability Effects 0.000 description 5
- VDJKJPMLWJWQIH-UHFFFAOYSA-M 5-ethylphenazin-5-ium;ethyl sulfate Chemical compound CCOS([O-])(=O)=O.C1=CC=C2[N+](CC)=C(C=CC=C3)C3=NC2=C1 VDJKJPMLWJWQIH-UHFFFAOYSA-M 0.000 description 4
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- 101000808346 Canavalia ensiformis Urease Proteins 0.000 description 4
- 208000017604 Hodgkin disease Diseases 0.000 description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 108020004511 Recombinant DNA Proteins 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000012736 aqueous medium Substances 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 238000003570 cell viability assay Methods 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 230000002596 correlated effect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 230000002601 intratumoral effect Effects 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 230000005291 magnetic effect Effects 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 235000021317 phosphate Nutrition 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 3
- VNYMOTCMNHJGTG-JBDRJPRFSA-N Ala-Ile-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O VNYMOTCMNHJGTG-JBDRJPRFSA-N 0.000 description 3
- 235000010520 Canavalia ensiformis Nutrition 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 229910052688 Gadolinium Inorganic materials 0.000 description 3
- JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 description 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 3
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 238000001261 affinity purification Methods 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 238000011717 athymic nude mouse Methods 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000000356 contaminant Substances 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- 239000000032 diagnostic agent Substances 0.000 description 3
- 229940039227 diagnostic agent Drugs 0.000 description 3
- 238000002594 fluoroscopy Methods 0.000 description 3
- 108010049041 glutamylalanine Proteins 0.000 description 3
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 229910052747 lanthanoid Inorganic materials 0.000 description 3
- 150000002602 lanthanoids Chemical class 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 3
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 3
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- AOYNUTHNTBLRMT-SLPGGIOYSA-N 2-deoxy-2-fluoro-aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](F)C=O AOYNUTHNTBLRMT-SLPGGIOYSA-N 0.000 description 2
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- OMDNCNKNEGFOMM-BQBZGAKWSA-N Ala-Met-Gly Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)NCC(O)=O OMDNCNKNEGFOMM-BQBZGAKWSA-N 0.000 description 2
- KUFVXLQLDHJVOG-SHGPDSBTSA-N Ala-Thr-Thr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](C)N)O KUFVXLQLDHJVOG-SHGPDSBTSA-N 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 2
- 244000303258 Annona diversifolia Species 0.000 description 2
- UHFUZWSZQKMDSX-DCAQKATOSA-N Arg-Leu-Asn Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N UHFUZWSZQKMDSX-DCAQKATOSA-N 0.000 description 2
- QEYJFBMTSMLPKZ-ZKWXMUAHSA-N Asn-Ala-Val Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O QEYJFBMTSMLPKZ-ZKWXMUAHSA-N 0.000 description 2
- SEMWSADZTMJELF-BYULHYEWSA-N Asp-Ile-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(O)=O SEMWSADZTMJELF-BYULHYEWSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 244000045232 Canavalia ensiformis Species 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 229910052684 Cerium Inorganic materials 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 108010062580 Concanavalin A Proteins 0.000 description 2
- 239000004971 Cross linker Substances 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 229910052691 Erbium Inorganic materials 0.000 description 2
- 229910052693 Europium Inorganic materials 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- ITZOBNKQDZEOCE-NHCYSSNCSA-N Gly-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)CN ITZOBNKQDZEOCE-NHCYSSNCSA-N 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- VFBZWZXKCVBTJR-SRVKXCTJSA-N His-Leu-Asp Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CC1=CN=CN1)N VFBZWZXKCVBTJR-SRVKXCTJSA-N 0.000 description 2
- YAALVYQFVJNXIV-KKUMJFAQSA-N His-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CN=CN1 YAALVYQFVJNXIV-KKUMJFAQSA-N 0.000 description 2
- 229910052689 Holmium Inorganic materials 0.000 description 2
- NKVZTQVGUNLLQW-JBDRJPRFSA-N Ile-Ala-Ala Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)O)N NKVZTQVGUNLLQW-JBDRJPRFSA-N 0.000 description 2
- RCFDOSNHHZGBOY-UHFFFAOYSA-N L-isoleucyl-L-alanine Natural products CCC(C)C(N)C(=O)NC(C)C(O)=O RCFDOSNHHZGBOY-UHFFFAOYSA-N 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- XFIHDSBIPWEYJJ-YUMQZZPRSA-N Lys-Ala-Gly Chemical compound OC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN XFIHDSBIPWEYJJ-YUMQZZPRSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 2
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 229910052779 Neodymium Inorganic materials 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 229910052777 Praseodymium Inorganic materials 0.000 description 2
- DZZCICYRSZASNF-FXQIFTODSA-N Pro-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1 DZZCICYRSZASNF-FXQIFTODSA-N 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 229910052772 Samarium Inorganic materials 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000005708 Sodium hypochlorite Substances 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 description 2
- 206010057644 Testis cancer Diseases 0.000 description 2
- IMDMLDSVUSMAEJ-HJGDQZAQSA-N Thr-Leu-Asn Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O IMDMLDSVUSMAEJ-HJGDQZAQSA-N 0.000 description 2
- 229910052775 Thulium Inorganic materials 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- 101710120037 Toxin CcdB Proteins 0.000 description 2
- XGJLNBNZNMVJRS-NRPADANISA-N Val-Glu-Ala Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O XGJLNBNZNMVJRS-NRPADANISA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 108010047495 alanylglycine Proteins 0.000 description 2
- 231100000360 alopecia Toxicity 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 229940045799 anthracyclines and related substance Drugs 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 108010062796 arginyllysine Proteins 0.000 description 2
- 108010092854 aspartyllysine Proteins 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000001588 bifunctional effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 230000005880 cancer cell killing Effects 0.000 description 2
- 230000009702 cancer cell proliferation Effects 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 230000003467 diminishing effect Effects 0.000 description 2
- XEYBHCRIKKKOSS-UHFFFAOYSA-N disodium;azanylidyneoxidanium;iron(2+);pentacyanide Chemical compound [Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].[O+]#N XEYBHCRIKKKOSS-UHFFFAOYSA-N 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 108010050848 glycylleucine Proteins 0.000 description 2
- 108010081551 glycylphenylalanine Proteins 0.000 description 2
- 108010037850 glycylvaline Proteins 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 125000005647 linker group Chemical group 0.000 description 2
- 208000037841 lung tumor Diseases 0.000 description 2
- 108010003700 lysyl aspartic acid Proteins 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 230000011278 mitosis Effects 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 230000005298 paramagnetic effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000013037 reversible inhibitor Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 2
- 229940083618 sodium nitroprusside Drugs 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 201000003120 testicular cancer Diseases 0.000 description 2
- 108010031491 threonyl-lysyl-glutamic acid Proteins 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- 238000003325 tomography Methods 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 150000003672 ureas Chemical class 0.000 description 2
- 231100000747 viability assay Toxicity 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- XVZCXCTYGHPNEM-IHRRRGAJSA-N (2s)-1-[(2s)-2-[[(2s)-2-amino-4-methylpentanoyl]amino]-4-methylpentanoyl]pyrrolidine-2-carboxylic acid Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(O)=O XVZCXCTYGHPNEM-IHRRRGAJSA-N 0.000 description 1
- DIYPCWKHSODVAP-UHFFFAOYSA-N 1-[3-(2,5-dioxopyrrol-1-yl)benzoyl]oxy-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)C1=CC=CC(N2C(C=CC2=O)=O)=C1 DIYPCWKHSODVAP-UHFFFAOYSA-N 0.000 description 1
- JCLFHZLOKITRCE-UHFFFAOYSA-N 4-pentoxyphenol Chemical compound CCCCCOC1=CC=C(O)C=C1 JCLFHZLOKITRCE-UHFFFAOYSA-N 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- JBGSZRYCXBPWGX-BQBZGAKWSA-N Ala-Arg-Gly Chemical compound OC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](N)C)CCCN=C(N)N JBGSZRYCXBPWGX-BQBZGAKWSA-N 0.000 description 1
- KIUYPHAMDKDICO-WHFBIAKZSA-N Ala-Asp-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O KIUYPHAMDKDICO-WHFBIAKZSA-N 0.000 description 1
- GWFSQQNGMPGBEF-GHCJXIJMSA-N Ala-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C)N GWFSQQNGMPGBEF-GHCJXIJMSA-N 0.000 description 1
- ZVFVBBGVOILKPO-WHFBIAKZSA-N Ala-Gly-Ala Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(O)=O ZVFVBBGVOILKPO-WHFBIAKZSA-N 0.000 description 1
- NHLAEBFGWPXFGI-WHFBIAKZSA-N Ala-Gly-Asn Chemical compound C[C@@H](C(=O)NCC(=O)N[C@@H](CC(=O)N)C(=O)O)N NHLAEBFGWPXFGI-WHFBIAKZSA-N 0.000 description 1
- NIZKGBJVCMRDKO-KWQFWETISA-N Ala-Gly-Tyr Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 NIZKGBJVCMRDKO-KWQFWETISA-N 0.000 description 1
- CBCCCLMNOBLBSC-XVYDVKMFSA-N Ala-His-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(O)=O CBCCCLMNOBLBSC-XVYDVKMFSA-N 0.000 description 1
- PNALXAODQKTNLV-JBDRJPRFSA-N Ala-Ile-Ala Chemical compound C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O PNALXAODQKTNLV-JBDRJPRFSA-N 0.000 description 1
- LBYMZCVBOKYZNS-CIUDSAMLSA-N Ala-Leu-Asp Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O LBYMZCVBOKYZNS-CIUDSAMLSA-N 0.000 description 1
- WUHJHHGYVVJMQE-BJDJZHNGSA-N Ala-Leu-Ile Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O WUHJHHGYVVJMQE-BJDJZHNGSA-N 0.000 description 1
- MAEQBGQTDWDSJQ-LSJOCFKGSA-N Ala-Met-His Chemical compound C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N MAEQBGQTDWDSJQ-LSJOCFKGSA-N 0.000 description 1
- WEZNQZHACPSMEF-QEJZJMRPSA-N Ala-Phe-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CC=CC=C1 WEZNQZHACPSMEF-QEJZJMRPSA-N 0.000 description 1
- DYXOFPBJBAHWFY-JBDRJPRFSA-N Ala-Ser-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](C)N DYXOFPBJBAHWFY-JBDRJPRFSA-N 0.000 description 1
- ZVWXMTTZJKBJCI-BHDSKKPTSA-N Ala-Trp-Ala Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](N)C)C(=O)N[C@@H](C)C(O)=O)=CNC2=C1 ZVWXMTTZJKBJCI-BHDSKKPTSA-N 0.000 description 1
- IYKVSFNGSWTTNZ-GUBZILKMSA-N Ala-Val-Arg Chemical compound C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N IYKVSFNGSWTTNZ-GUBZILKMSA-N 0.000 description 1
- NLYYHIKRBRMAJV-AEJSXWLSSA-N Ala-Val-Pro Chemical compound C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N NLYYHIKRBRMAJV-AEJSXWLSSA-N 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 208000003120 Angiofibroma Diseases 0.000 description 1
- 102000000412 Annexin Human genes 0.000 description 1
- 108050008874 Annexin Proteins 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- OHYQKYUTLIPFOX-ZPFDUUQYSA-N Arg-Glu-Ile Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O OHYQKYUTLIPFOX-ZPFDUUQYSA-N 0.000 description 1
- CYXCAHZVPFREJD-LURJTMIESA-N Arg-Gly-Gly Chemical compound NC(=N)NCCC[C@H](N)C(=O)NCC(=O)NCC(O)=O CYXCAHZVPFREJD-LURJTMIESA-N 0.000 description 1
- NVUIWHJLPSZZQC-CYDGBPFRSA-N Arg-Ile-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O NVUIWHJLPSZZQC-CYDGBPFRSA-N 0.000 description 1
- YVTHEZNOKSAWRW-DCAQKATOSA-N Arg-Lys-Ala Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O YVTHEZNOKSAWRW-DCAQKATOSA-N 0.000 description 1
- UULLJGQFCDXVTQ-CYDGBPFRSA-N Arg-Pro-Ile Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(O)=O UULLJGQFCDXVTQ-CYDGBPFRSA-N 0.000 description 1
- JJIBHAOBNIFUEL-SRVKXCTJSA-N Arg-Pro-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)N JJIBHAOBNIFUEL-SRVKXCTJSA-N 0.000 description 1
- UVTGNSWSRSCPLP-UHFFFAOYSA-N Arg-Tyr Natural products NC(CCNC(=N)N)C(=O)NC(Cc1ccc(O)cc1)C(=O)O UVTGNSWSRSCPLP-UHFFFAOYSA-N 0.000 description 1
- PSUXEQYPYZLNER-QXEWZRGKSA-N Arg-Val-Asn Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O PSUXEQYPYZLNER-QXEWZRGKSA-N 0.000 description 1
- VYZBPPBKFCHCIS-WPRPVWTQSA-N Arg-Val-Gly Chemical compound OC(=O)CNC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCN=C(N)N VYZBPPBKFCHCIS-WPRPVWTQSA-N 0.000 description 1
- CMLGVVWQQHUXOZ-GHCJXIJMSA-N Asn-Ala-Ile Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O CMLGVVWQQHUXOZ-GHCJXIJMSA-N 0.000 description 1
- KXEGPPNPXOKKHK-ZLUOBGJFSA-N Asn-Asp-Ala Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(O)=O KXEGPPNPXOKKHK-ZLUOBGJFSA-N 0.000 description 1
- NKTLGLBAGUJEGA-BIIVOSGPSA-N Asn-Cys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CS)NC(=O)[C@H](CC(=O)N)N)C(=O)O NKTLGLBAGUJEGA-BIIVOSGPSA-N 0.000 description 1
- OPEPUCYIGFEGSW-WDSKDSINSA-N Asn-Gly-Glu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O OPEPUCYIGFEGSW-WDSKDSINSA-N 0.000 description 1
- JQSWHKKUZMTOIH-QWRGUYRKSA-N Asn-Gly-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CC(=O)N)N JQSWHKKUZMTOIH-QWRGUYRKSA-N 0.000 description 1
- ALHMNHZJBYBYHS-DCAQKATOSA-N Asn-Lys-Arg Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O ALHMNHZJBYBYHS-DCAQKATOSA-N 0.000 description 1
- NTWOPSIUJBMNRI-KKUMJFAQSA-N Asn-Lys-Tyr Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 NTWOPSIUJBMNRI-KKUMJFAQSA-N 0.000 description 1
- OROMFUQQTSWUTI-IHRRRGAJSA-N Asn-Phe-Arg Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N OROMFUQQTSWUTI-IHRRRGAJSA-N 0.000 description 1
- CBHVAFXKOYAHOY-NHCYSSNCSA-N Asn-Val-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O CBHVAFXKOYAHOY-NHCYSSNCSA-N 0.000 description 1
- CASGONAXMZPHCK-FXQIFTODSA-N Asp-Asn-Arg Chemical compound C(C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)O)N)CN=C(N)N CASGONAXMZPHCK-FXQIFTODSA-N 0.000 description 1
- QRULNKJGYQQZMW-ZLUOBGJFSA-N Asp-Asn-Asp Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O QRULNKJGYQQZMW-ZLUOBGJFSA-N 0.000 description 1
- ACEDJCOOPZFUBU-CIUDSAMLSA-N Asp-Cys-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CC(=O)O)N ACEDJCOOPZFUBU-CIUDSAMLSA-N 0.000 description 1
- RATOMFTUDRYMKX-ACZMJKKPSA-N Asp-Glu-Cys Chemical compound C(CC(=O)O)[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(=O)O)N RATOMFTUDRYMKX-ACZMJKKPSA-N 0.000 description 1
- VIRHEUMYXXLCBF-WDSKDSINSA-N Asp-Gly-Glu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O VIRHEUMYXXLCBF-WDSKDSINSA-N 0.000 description 1
- QCVXMEHGFUMKCO-YUMQZZPRSA-N Asp-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC(O)=O QCVXMEHGFUMKCO-YUMQZZPRSA-N 0.000 description 1
- PZXPWHFYZXTFBI-YUMQZZPRSA-N Asp-Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC(O)=O PZXPWHFYZXTFBI-YUMQZZPRSA-N 0.000 description 1
- RQYMKRMRZWJGHC-BQBZGAKWSA-N Asp-Gly-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CC(=O)O)N RQYMKRMRZWJGHC-BQBZGAKWSA-N 0.000 description 1
- SVABRQFIHCSNCI-FOHZUACHSA-N Asp-Gly-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O SVABRQFIHCSNCI-FOHZUACHSA-N 0.000 description 1
- NHSDEZURHWEZPN-SXTJYALSSA-N Asp-Ile-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)NC(=O)[C@H](CC(=O)O)N NHSDEZURHWEZPN-SXTJYALSSA-N 0.000 description 1
- IVPNEDNYYYFAGI-GARJFASQSA-N Asp-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC(=O)O)N IVPNEDNYYYFAGI-GARJFASQSA-N 0.000 description 1
- AHWRSSLYSGLBGD-CIUDSAMLSA-N Asp-Pro-Glu Chemical compound OC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O AHWRSSLYSGLBGD-CIUDSAMLSA-N 0.000 description 1
- MVRGBQGZSDJBSM-GMOBBJLQSA-N Asp-Pro-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC(=O)O)N MVRGBQGZSDJBSM-GMOBBJLQSA-N 0.000 description 1
- MGSVBZIBCCKGCY-ZLUOBGJFSA-N Asp-Ser-Ser Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O MGSVBZIBCCKGCY-ZLUOBGJFSA-N 0.000 description 1
- PLNJUJGNLDSFOP-UWJYBYFXSA-N Asp-Tyr-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C)C(O)=O PLNJUJGNLDSFOP-UWJYBYFXSA-N 0.000 description 1
- 208000035404 Autolysis Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000220451 Canavalia Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 1
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 1
- 208000010667 Carcinoma of liver and intrahepatic biliary tract Diseases 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 244000037364 Cinnamomum aromaticum Species 0.000 description 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- VBPGTULCFGKGTF-ACZMJKKPSA-N Cys-Glu-Asp Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O VBPGTULCFGKGTF-ACZMJKKPSA-N 0.000 description 1
- XZKJEOMFLDVXJG-KATARQTJSA-N Cys-Leu-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)N)O XZKJEOMFLDVXJG-KATARQTJSA-N 0.000 description 1
- IQXSTXKVEMRMMB-XAVMHZPKSA-N Cys-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CS)N)O IQXSTXKVEMRMMB-XAVMHZPKSA-N 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 229910052692 Dysprosium Inorganic materials 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000448280 Elates Species 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 230000004668 G2/M phase Effects 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- UTKUTMJSWKKHEM-WDSKDSINSA-N Glu-Ala-Gly Chemical compound OC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(O)=O UTKUTMJSWKKHEM-WDSKDSINSA-N 0.000 description 1
- ITYRYNUZHPNCIK-GUBZILKMSA-N Glu-Ala-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O ITYRYNUZHPNCIK-GUBZILKMSA-N 0.000 description 1
- CKOFNWCLWRYUHK-XHNCKOQMSA-N Glu-Asp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)N)C(=O)O CKOFNWCLWRYUHK-XHNCKOQMSA-N 0.000 description 1
- WATXSTJXNBOHKD-LAEOZQHASA-N Glu-Asp-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O WATXSTJXNBOHKD-LAEOZQHASA-N 0.000 description 1
- RQNYYRHRKSVKAB-GUBZILKMSA-N Glu-Cys-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(O)=O RQNYYRHRKSVKAB-GUBZILKMSA-N 0.000 description 1
- BUZMZDDKFCSKOT-CIUDSAMLSA-N Glu-Glu-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O BUZMZDDKFCSKOT-CIUDSAMLSA-N 0.000 description 1
- AIGROOHQXCACHL-WDSKDSINSA-N Glu-Gly-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(O)=O AIGROOHQXCACHL-WDSKDSINSA-N 0.000 description 1
- UHVIQGKBMXEVGN-WDSKDSINSA-N Glu-Gly-Asn Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O UHVIQGKBMXEVGN-WDSKDSINSA-N 0.000 description 1
- LRPXYSGPOBVBEH-IUCAKERBSA-N Glu-Gly-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O LRPXYSGPOBVBEH-IUCAKERBSA-N 0.000 description 1
- ZCOJVESMNGBGLF-GRLWGSQLSA-N Glu-Ile-Ile Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O ZCOJVESMNGBGLF-GRLWGSQLSA-N 0.000 description 1
- QXDXIXFSFHUYAX-MNXVOIDGSA-N Glu-Ile-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CCC(O)=O QXDXIXFSFHUYAX-MNXVOIDGSA-N 0.000 description 1
- NWOUBJNMZDDGDT-AVGNSLFASA-N Glu-Leu-His Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 NWOUBJNMZDDGDT-AVGNSLFASA-N 0.000 description 1
- GMAGZGCAYLQBKF-NHCYSSNCSA-N Glu-Met-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(O)=O GMAGZGCAYLQBKF-NHCYSSNCSA-N 0.000 description 1
- CQAHWYDHKUWYIX-YUMQZZPRSA-N Glu-Pro-Gly Chemical compound OC(=O)CC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O CQAHWYDHKUWYIX-YUMQZZPRSA-N 0.000 description 1
- JVYNYWXHZWVJEF-NUMRIWBASA-N Glu-Thr-Asn Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)O)N)O JVYNYWXHZWVJEF-NUMRIWBASA-N 0.000 description 1
- HVKAAUOFFTUSAA-XDTLVQLUSA-N Glu-Tyr-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C)C(O)=O HVKAAUOFFTUSAA-XDTLVQLUSA-N 0.000 description 1
- LZEUDRYSAZAJIO-AUTRQRHGSA-N Glu-Val-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O LZEUDRYSAZAJIO-AUTRQRHGSA-N 0.000 description 1
- BRFJMRSRMOMIMU-WHFBIAKZSA-N Gly-Ala-Asn Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(O)=O BRFJMRSRMOMIMU-WHFBIAKZSA-N 0.000 description 1
- VSVZIEVNUYDAFR-YUMQZZPRSA-N Gly-Ala-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)CN VSVZIEVNUYDAFR-YUMQZZPRSA-N 0.000 description 1
- UPOJUWHGMDJUQZ-IUCAKERBSA-N Gly-Arg-Arg Chemical compound NC(=N)NCCC[C@H](NC(=O)CN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O UPOJUWHGMDJUQZ-IUCAKERBSA-N 0.000 description 1
- DTPOVRRYXPJJAZ-FJXKBIBVSA-N Gly-Arg-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CCCN=C(N)N DTPOVRRYXPJJAZ-FJXKBIBVSA-N 0.000 description 1
- PDUHNKAFQXQNLH-ZETCQYMHSA-N Gly-Lys-Gly Chemical compound NCCCC[C@H](NC(=O)CN)C(=O)NCC(O)=O PDUHNKAFQXQNLH-ZETCQYMHSA-N 0.000 description 1
- FJWSJWACLMTDMI-WPRPVWTQSA-N Gly-Met-Val Chemical compound [H]NCC(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(O)=O FJWSJWACLMTDMI-WPRPVWTQSA-N 0.000 description 1
- WNZOCXUOGVYYBJ-CDMKHQONSA-N Gly-Phe-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CN)O WNZOCXUOGVYYBJ-CDMKHQONSA-N 0.000 description 1
- GLACUWHUYFBSPJ-FJXKBIBVSA-N Gly-Pro-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)CN GLACUWHUYFBSPJ-FJXKBIBVSA-N 0.000 description 1
- LCRDMSSAKLTKBU-ZDLURKLDSA-N Gly-Ser-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)CN LCRDMSSAKLTKBU-ZDLURKLDSA-N 0.000 description 1
- FFJQHWKSGAWSTJ-BFHQHQDPSA-N Gly-Thr-Ala Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O FFJQHWKSGAWSTJ-BFHQHQDPSA-N 0.000 description 1
- YXTFLTJYLIAZQG-FJXKBIBVSA-N Gly-Thr-Arg Chemical compound NCC(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N YXTFLTJYLIAZQG-FJXKBIBVSA-N 0.000 description 1
- JQFILXICXLDTRR-FBCQKBJTSA-N Gly-Thr-Gly Chemical compound NCC(=O)N[C@@H]([C@H](O)C)C(=O)NCC(O)=O JQFILXICXLDTRR-FBCQKBJTSA-N 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 206010073069 Hepatic cancer Diseases 0.000 description 1
- HTZKFIYQMHJWSQ-INTQDDNPSA-N His-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CN=CN2)N HTZKFIYQMHJWSQ-INTQDDNPSA-N 0.000 description 1
- MWAJSVTZZOUOBU-IHRRRGAJSA-N His-Arg-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC1=CN=CN1 MWAJSVTZZOUOBU-IHRRRGAJSA-N 0.000 description 1
- SDTPKSOWFXBACN-GUBZILKMSA-N His-Glu-Asp Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O SDTPKSOWFXBACN-GUBZILKMSA-N 0.000 description 1
- KAFZDWMZKGQDEE-SRVKXCTJSA-N His-His-Asp Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CC(=O)O)C(=O)O)N KAFZDWMZKGQDEE-SRVKXCTJSA-N 0.000 description 1
- LNDVNHOSZQPJGI-AVGNSLFASA-N His-Pro-Pro Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(O)=O)C1=CN=CN1 LNDVNHOSZQPJGI-AVGNSLFASA-N 0.000 description 1
- CUEQQFOGARVNHU-VGDYDELISA-N His-Ser-Ile Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O CUEQQFOGARVNHU-VGDYDELISA-N 0.000 description 1
- XHQYFGPIRUHQIB-PBCZWWQYSA-N His-Thr-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H]([C@H](O)C)NC(=O)[C@@H](N)CC1=CN=CN1 XHQYFGPIRUHQIB-PBCZWWQYSA-N 0.000 description 1
- QTMKFZAYZKBFRC-BZSNNMDCSA-N His-Tyr-His Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)NC(=O)[C@H](CC3=CN=CN3)N)O QTMKFZAYZKBFRC-BZSNNMDCSA-N 0.000 description 1
- CKONPJHGMIDMJP-IHRRRGAJSA-N His-Val-His Chemical compound C([C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CN=CN1 CKONPJHGMIDMJP-IHRRRGAJSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000609947 Homo sapiens Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- JRHFQUPIZOYKQP-KBIXCLLPSA-N Ile-Ala-Glu Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCC(O)=O JRHFQUPIZOYKQP-KBIXCLLPSA-N 0.000 description 1
- AQCUAZTZSPQJFF-ZKWXMUAHSA-N Ile-Ala-Gly Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O AQCUAZTZSPQJFF-ZKWXMUAHSA-N 0.000 description 1
- HDOYNXLPTRQLAD-JBDRJPRFSA-N Ile-Ala-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)O)N HDOYNXLPTRQLAD-JBDRJPRFSA-N 0.000 description 1
- HLYBGMZJVDHJEO-CYDGBPFRSA-N Ile-Arg-Arg Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N HLYBGMZJVDHJEO-CYDGBPFRSA-N 0.000 description 1
- YPQDTQJBOFOTJQ-SXTJYALSSA-N Ile-Asn-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)N YPQDTQJBOFOTJQ-SXTJYALSSA-N 0.000 description 1
- UKTUOMWSJPXODT-GUDRVLHUSA-N Ile-Asn-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N1CCC[C@@H]1C(=O)O)N UKTUOMWSJPXODT-GUDRVLHUSA-N 0.000 description 1
- NBJAAWYRLGCJOF-UGYAYLCHSA-N Ile-Asp-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)N NBJAAWYRLGCJOF-UGYAYLCHSA-N 0.000 description 1
- XLDYDEDTGMHUCZ-GHCJXIJMSA-N Ile-Asp-Cys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CS)C(=O)O)N XLDYDEDTGMHUCZ-GHCJXIJMSA-N 0.000 description 1
- IDAHFEPYTJJZFD-PEFMBERDSA-N Ile-Asp-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N IDAHFEPYTJJZFD-PEFMBERDSA-N 0.000 description 1
- DFJJAVZIHDFOGQ-MNXVOIDGSA-N Ile-Glu-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O)N DFJJAVZIHDFOGQ-MNXVOIDGSA-N 0.000 description 1
- NHJKZMDIMMTVCK-QXEWZRGKSA-N Ile-Gly-Arg Chemical compound CC[C@H](C)[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCN=C(N)N NHJKZMDIMMTVCK-QXEWZRGKSA-N 0.000 description 1
- PDTMWFVVNZYWTR-NHCYSSNCSA-N Ile-Gly-Lys Chemical compound CC[C@H](C)[C@H](N)C(=O)NCC(=O)N[C@@H](CCCCN)C(O)=O PDTMWFVVNZYWTR-NHCYSSNCSA-N 0.000 description 1
- URWXDJAEEGBADB-TUBUOCAGSA-N Ile-His-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N URWXDJAEEGBADB-TUBUOCAGSA-N 0.000 description 1
- PWDSHAAAFXISLE-SXTJYALSSA-N Ile-Ile-Asp Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(O)=O PWDSHAAAFXISLE-SXTJYALSSA-N 0.000 description 1
- CSQNHSGHAPRGPQ-YTFOTSKYSA-N Ile-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)O)N CSQNHSGHAPRGPQ-YTFOTSKYSA-N 0.000 description 1
- PFPUFNLHBXKPHY-HTFCKZLJSA-N Ile-Ile-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)O)N PFPUFNLHBXKPHY-HTFCKZLJSA-N 0.000 description 1
- TVYWVSJGSHQWMT-AJNGGQMLSA-N Ile-Leu-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)O)N TVYWVSJGSHQWMT-AJNGGQMLSA-N 0.000 description 1
- PARSHQDZROHERM-NHCYSSNCSA-N Ile-Lys-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)O)N PARSHQDZROHERM-NHCYSSNCSA-N 0.000 description 1
- RCMNUBZKIIJCOI-ZPFDUUQYSA-N Ile-Met-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N RCMNUBZKIIJCOI-ZPFDUUQYSA-N 0.000 description 1
- KCTIFOCXAIUQQK-QXEWZRGKSA-N Ile-Pro-Gly Chemical compound CC[C@H](C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O KCTIFOCXAIUQQK-QXEWZRGKSA-N 0.000 description 1
- QHUREMVLLMNUAX-OSUNSFLBSA-N Ile-Thr-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)O)N QHUREMVLLMNUAX-OSUNSFLBSA-N 0.000 description 1
- APQYGMBHIVXFML-OSUNSFLBSA-N Ile-Val-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N APQYGMBHIVXFML-OSUNSFLBSA-N 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 125000003580 L-valyl group Chemical compound [H]N([H])[C@]([H])(C(=O)[*])C(C([H])([H])[H])(C([H])([H])[H])[H] 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- ZRLUISBDKUWAIZ-CIUDSAMLSA-N Leu-Ala-Asp Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC(O)=O ZRLUISBDKUWAIZ-CIUDSAMLSA-N 0.000 description 1
- CQQGCWPXDHTTNF-GUBZILKMSA-N Leu-Ala-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCC(O)=O CQQGCWPXDHTTNF-GUBZILKMSA-N 0.000 description 1
- XIRYQRLFHWWWTC-QEJZJMRPSA-N Leu-Ala-Phe Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 XIRYQRLFHWWWTC-QEJZJMRPSA-N 0.000 description 1
- MDVZJYGNAGLPGJ-KKUMJFAQSA-N Leu-Asn-Phe Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MDVZJYGNAGLPGJ-KKUMJFAQSA-N 0.000 description 1
- MYGQXVYRZMKRDB-SRVKXCTJSA-N Leu-Asp-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCCN MYGQXVYRZMKRDB-SRVKXCTJSA-N 0.000 description 1
- XVSJMWYYLHPDKY-DCAQKATOSA-N Leu-Asp-Met Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(O)=O XVSJMWYYLHPDKY-DCAQKATOSA-N 0.000 description 1
- CLVUXCBGKUECIT-HJGDQZAQSA-N Leu-Asp-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O CLVUXCBGKUECIT-HJGDQZAQSA-N 0.000 description 1
- DZQMXBALGUHGJT-GUBZILKMSA-N Leu-Glu-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O DZQMXBALGUHGJT-GUBZILKMSA-N 0.000 description 1
- LAPSXOAUPNOINL-YUMQZZPRSA-N Leu-Gly-Asp Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC(O)=O LAPSXOAUPNOINL-YUMQZZPRSA-N 0.000 description 1
- BTNXKBVLWJBTNR-SRVKXCTJSA-N Leu-His-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(N)=O)C(O)=O BTNXKBVLWJBTNR-SRVKXCTJSA-N 0.000 description 1
- IFMPDNRWZZEZSL-SRVKXCTJSA-N Leu-Leu-Cys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(O)=O IFMPDNRWZZEZSL-SRVKXCTJSA-N 0.000 description 1
- XVZCXCTYGHPNEM-UHFFFAOYSA-N Leu-Leu-Pro Natural products CC(C)CC(N)C(=O)NC(CC(C)C)C(=O)N1CCCC1C(O)=O XVZCXCTYGHPNEM-UHFFFAOYSA-N 0.000 description 1
- DCGXHWINSHEPIR-SRVKXCTJSA-N Leu-Lys-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)O)N DCGXHWINSHEPIR-SRVKXCTJSA-N 0.000 description 1
- BGZCJDGBBUUBHA-KKUMJFAQSA-N Leu-Lys-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O BGZCJDGBBUUBHA-KKUMJFAQSA-N 0.000 description 1
- NHRINZSPIUXYQZ-DCAQKATOSA-N Leu-Met-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CS)C(=O)O)N NHRINZSPIUXYQZ-DCAQKATOSA-N 0.000 description 1
- VULJUQZPSOASBZ-SRVKXCTJSA-N Leu-Pro-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O VULJUQZPSOASBZ-SRVKXCTJSA-N 0.000 description 1
- SBANPBVRHYIMRR-UHFFFAOYSA-N Leu-Ser-Pro Natural products CC(C)CC(N)C(=O)NC(CO)C(=O)N1CCCC1C(O)=O SBANPBVRHYIMRR-UHFFFAOYSA-N 0.000 description 1
- DAYQSYGBCUKVKT-VOAKCMCISA-N Leu-Thr-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(O)=O DAYQSYGBCUKVKT-VOAKCMCISA-N 0.000 description 1
- WFCKERTZVCQXKH-KBPBESRZSA-N Leu-Tyr-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(O)=O WFCKERTZVCQXKH-KBPBESRZSA-N 0.000 description 1
- IRNSXVOWSXSULE-DCAQKATOSA-N Lys-Ala-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN IRNSXVOWSXSULE-DCAQKATOSA-N 0.000 description 1
- YNNPKXBBRZVIRX-IHRRRGAJSA-N Lys-Arg-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(O)=O YNNPKXBBRZVIRX-IHRRRGAJSA-N 0.000 description 1
- HKCCVDWHHTVVPN-CIUDSAMLSA-N Lys-Asp-Ala Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(O)=O HKCCVDWHHTVVPN-CIUDSAMLSA-N 0.000 description 1
- GPJGFSFYBJGYRX-YUMQZZPRSA-N Lys-Gly-Asp Chemical compound NCCCC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC(O)=O GPJGFSFYBJGYRX-YUMQZZPRSA-N 0.000 description 1
- MXMDJEJWERYPMO-XUXIUFHCSA-N Lys-Ile-Arg Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O MXMDJEJWERYPMO-XUXIUFHCSA-N 0.000 description 1
- VMTYLUGCXIEDMV-QWRGUYRKSA-N Lys-Leu-Gly Chemical compound OC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCCCN VMTYLUGCXIEDMV-QWRGUYRKSA-N 0.000 description 1
- LJADEBULDNKJNK-IHRRRGAJSA-N Lys-Leu-Val Chemical compound CC(C)C[C@H](NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O LJADEBULDNKJNK-IHRRRGAJSA-N 0.000 description 1
- PLDJDCJLRCYPJB-VOAKCMCISA-N Lys-Lys-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PLDJDCJLRCYPJB-VOAKCMCISA-N 0.000 description 1
- MTBLFIQZECOEBY-IHRRRGAJSA-N Lys-Met-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(O)=O MTBLFIQZECOEBY-IHRRRGAJSA-N 0.000 description 1
- WGILOYIKJVQUPT-DCAQKATOSA-N Lys-Pro-Asp Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(O)=O WGILOYIKJVQUPT-DCAQKATOSA-N 0.000 description 1
- YTJFXEDRUOQGSP-DCAQKATOSA-N Lys-Pro-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O YTJFXEDRUOQGSP-DCAQKATOSA-N 0.000 description 1
- VHTOGMKQXXJOHG-RHYQMDGZSA-N Lys-Thr-Val Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O VHTOGMKQXXJOHG-RHYQMDGZSA-N 0.000 description 1
- PPNCMJARTHYNEC-MEYUZBJRSA-N Lys-Tyr-Thr Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H]([C@H](O)C)C(O)=O)CC1=CC=C(O)C=C1 PPNCMJARTHYNEC-MEYUZBJRSA-N 0.000 description 1
- QFSYGUMEANRNJE-DCAQKATOSA-N Lys-Val-Cys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCCCN)N QFSYGUMEANRNJE-DCAQKATOSA-N 0.000 description 1
- RPWQJSBMXJSCPD-XUXIUFHCSA-N Lys-Val-Ile Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)C(C)C)C(O)=O RPWQJSBMXJSCPD-XUXIUFHCSA-N 0.000 description 1
- 231100000070 MTS assay Toxicity 0.000 description 1
- 238000000719 MTS assay Methods 0.000 description 1
- WDTLNWHPIPCMMP-AVGNSLFASA-N Met-Arg-Leu Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(O)=O WDTLNWHPIPCMMP-AVGNSLFASA-N 0.000 description 1
- ACYHZNZHIZWLQF-BQBZGAKWSA-N Met-Asn-Gly Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O ACYHZNZHIZWLQF-BQBZGAKWSA-N 0.000 description 1
- MVMNUCOHQGYYKB-PEDHHIEDSA-N Met-Ile-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)NC(=O)[C@H](CCSC)N MVMNUCOHQGYYKB-PEDHHIEDSA-N 0.000 description 1
- LBNFTWKGISQVEE-AVGNSLFASA-N Met-Leu-Met Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCSC LBNFTWKGISQVEE-AVGNSLFASA-N 0.000 description 1
- HSJIGJRZYUADSS-IHRRRGAJSA-N Met-Lys-Leu Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O HSJIGJRZYUADSS-IHRRRGAJSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 1
- PESQCPHRXOFIPX-UHFFFAOYSA-N N-L-methionyl-L-tyrosine Natural products CSCCC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 PESQCPHRXOFIPX-UHFFFAOYSA-N 0.000 description 1
- QWZFVMCWPLMLTL-UHFFFAOYSA-N N-diaminophosphoryl-4-fluorobenzamide Chemical compound NP(N)(=O)NC(=O)C1=CC=C(F)C=C1 QWZFVMCWPLMLTL-UHFFFAOYSA-N 0.000 description 1
- 108010002311 N-glycylglutamic acid Proteins 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- CYZBFPYMSJGBRL-DRZSPHRISA-N Phe-Ala-Glu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O CYZBFPYMSJGBRL-DRZSPHRISA-N 0.000 description 1
- XMPUYNHKEPFERE-IHRRRGAJSA-N Phe-Asp-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 XMPUYNHKEPFERE-IHRRRGAJSA-N 0.000 description 1
- XEXSSIBQYNKFBX-KBPBESRZSA-N Phe-Gly-His Chemical compound C([C@H](N)C(=O)NCC(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)C1=CC=CC=C1 XEXSSIBQYNKFBX-KBPBESRZSA-N 0.000 description 1
- BIYWZVCPZIFGPY-QWRGUYRKSA-N Phe-Gly-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N[C@@H](CO)C(O)=O BIYWZVCPZIFGPY-QWRGUYRKSA-N 0.000 description 1
- KRYSMKKRRRWOCZ-QEWYBTABSA-N Phe-Ile-Glu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(O)=O KRYSMKKRRRWOCZ-QEWYBTABSA-N 0.000 description 1
- IWZRODDWOSIXPZ-IRXDYDNUSA-N Phe-Phe-Gly Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(O)=O)C1=CC=CC=C1 IWZRODDWOSIXPZ-IRXDYDNUSA-N 0.000 description 1
- PTDAGKJHZBGDKD-OEAJRASXSA-N Phe-Thr-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N)O PTDAGKJHZBGDKD-OEAJRASXSA-N 0.000 description 1
- YUPRIZTWANWWHK-DZKIICNBSA-N Phe-Val-Glu Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N YUPRIZTWANWWHK-DZKIICNBSA-N 0.000 description 1
- MGDFPGCFVJFITQ-CIUDSAMLSA-N Pro-Glu-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O MGDFPGCFVJFITQ-CIUDSAMLSA-N 0.000 description 1
- WVOXLKUUVCCCSU-ZPFDUUQYSA-N Pro-Glu-Ile Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O WVOXLKUUVCCCSU-ZPFDUUQYSA-N 0.000 description 1
- VTFXTWDFPTWNJY-RHYQMDGZSA-N Pro-Leu-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O VTFXTWDFPTWNJY-RHYQMDGZSA-N 0.000 description 1
- MKGIILKDUGDRRO-FXQIFTODSA-N Pro-Ser-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H]1CCCN1 MKGIILKDUGDRRO-FXQIFTODSA-N 0.000 description 1
- PKHDJFHFMGQMPS-RCWTZXSCSA-N Pro-Thr-Arg Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O PKHDJFHFMGQMPS-RCWTZXSCSA-N 0.000 description 1
- AIOWVDNPESPXRB-YTWAJWBKSA-N Pro-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@@H]2CCCN2)O AIOWVDNPESPXRB-YTWAJWBKSA-N 0.000 description 1
- ZAUHSLVPDLNTRZ-QXEWZRGKSA-N Pro-Val-Asn Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O ZAUHSLVPDLNTRZ-QXEWZRGKSA-N 0.000 description 1
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 1
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 description 1
- 102100039177 Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha Human genes 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- FCRMLGJMPXCAHD-FXQIFTODSA-N Ser-Arg-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(O)=O FCRMLGJMPXCAHD-FXQIFTODSA-N 0.000 description 1
- YUSRGTQIPCJNHQ-CIUDSAMLSA-N Ser-Arg-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O YUSRGTQIPCJNHQ-CIUDSAMLSA-N 0.000 description 1
- OYEDZGNMSBZCIM-XGEHTFHBSA-N Ser-Arg-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OYEDZGNMSBZCIM-XGEHTFHBSA-N 0.000 description 1
- UGJRQLURDVGULT-LKXGYXEUSA-N Ser-Asn-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O UGJRQLURDVGULT-LKXGYXEUSA-N 0.000 description 1
- MMAPOBOTRUVNKJ-ZLUOBGJFSA-N Ser-Asp-Ser Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CO)N)C(=O)O MMAPOBOTRUVNKJ-ZLUOBGJFSA-N 0.000 description 1
- RNFKSBPHLTZHLU-WHFBIAKZSA-N Ser-Cys-Gly Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)NCC(=O)O)N)O RNFKSBPHLTZHLU-WHFBIAKZSA-N 0.000 description 1
- YRBGKVIWMNEVCZ-WDSKDSINSA-N Ser-Glu-Gly Chemical compound OC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O YRBGKVIWMNEVCZ-WDSKDSINSA-N 0.000 description 1
- IOVHBRCQOGWAQH-ZKWXMUAHSA-N Ser-Gly-Ile Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(O)=O IOVHBRCQOGWAQH-ZKWXMUAHSA-N 0.000 description 1
- SFTZTYBXIXLRGQ-JBDRJPRFSA-N Ser-Ile-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O SFTZTYBXIXLRGQ-JBDRJPRFSA-N 0.000 description 1
- OWCVUSJMEBGMOK-YUMQZZPRSA-N Ser-Lys-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O OWCVUSJMEBGMOK-YUMQZZPRSA-N 0.000 description 1
- NUEHQDHDLDXCRU-GUBZILKMSA-N Ser-Pro-Arg Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O NUEHQDHDLDXCRU-GUBZILKMSA-N 0.000 description 1
- FLONGDPORFIVQW-XGEHTFHBSA-N Ser-Pro-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CO FLONGDPORFIVQW-XGEHTFHBSA-N 0.000 description 1
- XQJCEKXQUJQNNK-ZLUOBGJFSA-N Ser-Ser-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O XQJCEKXQUJQNNK-ZLUOBGJFSA-N 0.000 description 1
- WUXCHQZLUHBSDJ-LKXGYXEUSA-N Ser-Thr-Asp Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CC(O)=O)C(O)=O WUXCHQZLUHBSDJ-LKXGYXEUSA-N 0.000 description 1
- OQSQCUWQOIHECT-YJRXYDGGSA-N Ser-Tyr-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OQSQCUWQOIHECT-YJRXYDGGSA-N 0.000 description 1
- BEBVVQPDSHHWQL-NRPADANISA-N Ser-Val-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O BEBVVQPDSHHWQL-NRPADANISA-N 0.000 description 1
- SIEBDTCABMZCLF-XGEHTFHBSA-N Ser-Val-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SIEBDTCABMZCLF-XGEHTFHBSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 1
- NJEMRSFGDNECGF-GCJQMDKQSA-N Thr-Ala-Asp Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC(O)=O NJEMRSFGDNECGF-GCJQMDKQSA-N 0.000 description 1
- SKHPKKYKDYULDH-HJGDQZAQSA-N Thr-Asn-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O SKHPKKYKDYULDH-HJGDQZAQSA-N 0.000 description 1
- BNGDYRRHRGOPHX-IFFSRLJSSA-N Thr-Glu-Val Chemical compound CC(C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)[C@@H](C)O)C(O)=O BNGDYRRHRGOPHX-IFFSRLJSSA-N 0.000 description 1
- NIEWSKWFURSECR-FOHZUACHSA-N Thr-Gly-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O NIEWSKWFURSECR-FOHZUACHSA-N 0.000 description 1
- MSIYNSBKKVMGFO-BHNWBGBOSA-N Thr-Gly-Pro Chemical compound C[C@H]([C@@H](C(=O)NCC(=O)N1CCC[C@@H]1C(=O)O)N)O MSIYNSBKKVMGFO-BHNWBGBOSA-N 0.000 description 1
- RFKVQLIXNVEOMB-WEDXCCLWSA-N Thr-Leu-Gly Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)O)N)O RFKVQLIXNVEOMB-WEDXCCLWSA-N 0.000 description 1
- SCSVNSNWUTYSFO-WDCWCFNPSA-N Thr-Lys-Glu Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O SCSVNSNWUTYSFO-WDCWCFNPSA-N 0.000 description 1
- WFAUDCSNCWJJAA-KXNHARMFSA-N Thr-Lys-Pro Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@@H]1C(O)=O WFAUDCSNCWJJAA-KXNHARMFSA-N 0.000 description 1
- HSQXHRIRJSFDOH-URLPEUOOSA-N Thr-Phe-Ile Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O HSQXHRIRJSFDOH-URLPEUOOSA-N 0.000 description 1
- JMBRNXUOLJFURW-BEAPCOKYSA-N Thr-Phe-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N2CCC[C@@H]2C(=O)O)N)O JMBRNXUOLJFURW-BEAPCOKYSA-N 0.000 description 1
- BBPCSGKKPJUYRB-UVOCVTCTSA-N Thr-Thr-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O BBPCSGKKPJUYRB-UVOCVTCTSA-N 0.000 description 1
- CURFABYITJVKEW-QTKMDUPCSA-N Thr-Val-His Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N)O CURFABYITJVKEW-QTKMDUPCSA-N 0.000 description 1
- 208000033781 Thyroid carcinoma Diseases 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- KCPFDGNYAMKZQP-KBPBESRZSA-N Tyr-Gly-Leu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O KCPFDGNYAMKZQP-KBPBESRZSA-N 0.000 description 1
- OLWFDNLLBWQWCP-STQMWFEESA-N Tyr-Gly-Met Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(=O)N[C@@H](CCSC)C(O)=O OLWFDNLLBWQWCP-STQMWFEESA-N 0.000 description 1
- JHORGUYURUBVOM-KKUMJFAQSA-N Tyr-His-Ser Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(O)=O JHORGUYURUBVOM-KKUMJFAQSA-N 0.000 description 1
- USYGMBIIUDLYHJ-GVARAGBVSA-N Tyr-Ile-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 USYGMBIIUDLYHJ-GVARAGBVSA-N 0.000 description 1
- JJNXZIPLIXIGBX-HJPIBITLSA-N Tyr-Ile-Cys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N JJNXZIPLIXIGBX-HJPIBITLSA-N 0.000 description 1
- DMWNPLOERDAHSY-MEYUZBJRSA-N Tyr-Leu-Thr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O DMWNPLOERDAHSY-MEYUZBJRSA-N 0.000 description 1
- SCZJKZLFSSPJDP-ACRUOGEOSA-N Tyr-Phe-Leu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O SCZJKZLFSSPJDP-ACRUOGEOSA-N 0.000 description 1
- LVFZXRQQQDTBQH-IRIUXVKKSA-N Tyr-Thr-Glu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O LVFZXRQQQDTBQH-IRIUXVKKSA-N 0.000 description 1
- ZZDYJFVIKVSUFA-WLTAIBSBSA-N Tyr-Thr-Gly Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O ZZDYJFVIKVSUFA-WLTAIBSBSA-N 0.000 description 1
- NWEGIYMHTZXVBP-JSGCOSHPSA-N Tyr-Val-Gly Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O NWEGIYMHTZXVBP-JSGCOSHPSA-N 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- PAPWZOJOLKZEFR-AVGNSLFASA-N Val-Arg-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)O)N PAPWZOJOLKZEFR-AVGNSLFASA-N 0.000 description 1
- IVXJODPZRWHCCR-JYJNAYRXSA-N Val-Arg-Phe Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N IVXJODPZRWHCCR-JYJNAYRXSA-N 0.000 description 1
- IDKGBVZGNTYYCC-QXEWZRGKSA-N Val-Asn-Pro Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(O)=O IDKGBVZGNTYYCC-QXEWZRGKSA-N 0.000 description 1
- YLHLNFUXDBOAGX-DCAQKATOSA-N Val-Cys-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N YLHLNFUXDBOAGX-DCAQKATOSA-N 0.000 description 1
- PIFJAFRUVWZRKR-QMMMGPOBSA-N Val-Gly-Gly Chemical compound CC(C)[C@H]([NH3+])C(=O)NCC(=O)NCC([O-])=O PIFJAFRUVWZRKR-QMMMGPOBSA-N 0.000 description 1
- SYOMXKPPFZRELL-ONGXEEELSA-N Val-Gly-Lys Chemical compound CC(C)[C@@H](C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)O)N SYOMXKPPFZRELL-ONGXEEELSA-N 0.000 description 1
- LAYSXAOGWHKNED-XPUUQOCRSA-N Val-Gly-Ser Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O LAYSXAOGWHKNED-XPUUQOCRSA-N 0.000 description 1
- KDKLLPMFFGYQJD-CYDGBPFRSA-N Val-Ile-Arg Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](C(C)C)N KDKLLPMFFGYQJD-CYDGBPFRSA-N 0.000 description 1
- APQIVBCUIUDSMB-OSUNSFLBSA-N Val-Ile-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](C(C)C)N APQIVBCUIUDSMB-OSUNSFLBSA-N 0.000 description 1
- ZHQWPWQNVRCXAX-XQQFMLRXSA-N Val-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](C(C)C)N ZHQWPWQNVRCXAX-XQQFMLRXSA-N 0.000 description 1
- RWOGENDAOGMHLX-DCAQKATOSA-N Val-Lys-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)N RWOGENDAOGMHLX-DCAQKATOSA-N 0.000 description 1
- IEBGHUMBJXIXHM-AVGNSLFASA-N Val-Lys-Met Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)O)N IEBGHUMBJXIXHM-AVGNSLFASA-N 0.000 description 1
- PWCJARIQERIIGF-BZSNNMDCSA-N Val-Met-Trp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N PWCJARIQERIIGF-BZSNNMDCSA-N 0.000 description 1
- NHXZRXLFOBFMDM-AVGNSLFASA-N Val-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)C(C)C NHXZRXLFOBFMDM-AVGNSLFASA-N 0.000 description 1
- SSYBNWFXCFNRFN-GUBZILKMSA-N Val-Pro-Ser Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O SSYBNWFXCFNRFN-GUBZILKMSA-N 0.000 description 1
- KSFXWENSJABBFI-ZKWXMUAHSA-N Val-Ser-Asn Chemical compound [H]N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O KSFXWENSJABBFI-ZKWXMUAHSA-N 0.000 description 1
- VIKZGAUAKQZDOF-NRPADANISA-N Val-Ser-Glu Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O VIKZGAUAKQZDOF-NRPADANISA-N 0.000 description 1
- PGQUDQYHWICSAB-NAKRPEOUSA-N Val-Ser-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)N PGQUDQYHWICSAB-NAKRPEOUSA-N 0.000 description 1
- QTPQHINADBYBNA-DCAQKATOSA-N Val-Ser-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCCN QTPQHINADBYBNA-DCAQKATOSA-N 0.000 description 1
- OFTXTCGQJXTNQS-XGEHTFHBSA-N Val-Thr-Ser Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](C(C)C)N)O OFTXTCGQJXTNQS-XGEHTFHBSA-N 0.000 description 1
- PFMSJVIPEZMKSC-DZKIICNBSA-N Val-Tyr-Glu Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N PFMSJVIPEZMKSC-DZKIICNBSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 229910052769 Ytterbium Inorganic materials 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 238000003916 acid precipitation Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 108010008685 alanyl-glutamyl-aspartic acid Proteins 0.000 description 1
- 108010076324 alanyl-glycyl-glycine Proteins 0.000 description 1
- 108010078114 alanyl-tryptophyl-alanine Proteins 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003817 anthracycline antibiotic agent Substances 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 108010013835 arginine glutamate Proteins 0.000 description 1
- 108010089442 arginyl-leucyl-alanyl-arginine Proteins 0.000 description 1
- 108010043240 arginyl-leucyl-glycine Proteins 0.000 description 1
- 108010060035 arginylproline Proteins 0.000 description 1
- 108010010430 asparagine-proline-alanine Proteins 0.000 description 1
- 108010077245 asparaginyl-proline Proteins 0.000 description 1
- 108010040443 aspartyl-aspartic acid Proteins 0.000 description 1
- 108010093581 aspartyl-proline Proteins 0.000 description 1
- 108010038633 aspartylglutamate Proteins 0.000 description 1
- 108010068265 aspartyltyrosine Proteins 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000010405 clearance mechanism Effects 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000010580 coupled enzyme reaction Methods 0.000 description 1
- 108010016616 cysteinylglycine Proteins 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 108010054813 diprotin B Proteins 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- BJAJDJDODCWPNS-UHFFFAOYSA-N dotp Chemical compound O=C1N2CCOC2=NC2=C1SC=C2 BJAJDJDODCWPNS-UHFFFAOYSA-N 0.000 description 1
- 229940115080 doxil Drugs 0.000 description 1
- 229960002918 doxorubicin hydrochloride Drugs 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 150000002222 fluorine compounds Chemical class 0.000 description 1
- 229950007143 flurofamide Drugs 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 108010008237 glutamyl-valyl-glycine Proteins 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 1
- 108010090037 glycyl-alanyl-isoleucine Proteins 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 150000002366 halogen compounds Chemical class 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 201000011066 hemangioma Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 208000029824 high grade glioma Diseases 0.000 description 1
- 108010028295 histidylhistidine Proteins 0.000 description 1
- 108010092114 histidylphenylalanine Proteins 0.000 description 1
- 238000013427 histology analysis Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000004293 human mammary gland Anatomy 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 229910000040 hydrogen fluoride Inorganic materials 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- RSAZYXZUJROYKR-UHFFFAOYSA-N indophenol Chemical compound C1=CC(O)=CC=C1N=C1C=CC(=O)C=C1 RSAZYXZUJROYKR-UHFFFAOYSA-N 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 229920000831 ionic polymer Polymers 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 229910021644 lanthanide ion Inorganic materials 0.000 description 1
- 108010076756 leucyl-alanyl-phenylalanine Proteins 0.000 description 1
- 108010091871 leucylmethionine Proteins 0.000 description 1
- 108010057821 leucylproline Proteins 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000002250 liver carcinoma Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 108010025153 lysyl-alanyl-alanine Proteins 0.000 description 1
- 108010064235 lysylglycine Proteins 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 201000011614 malignant glioma Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 108010005942 methionylglycine Proteins 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000001139 pH measurement Methods 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- JZRYQZJSTWVBBD-UHFFFAOYSA-N pentaporphyrin i Chemical compound N1C(C=C2NC(=CC3=NC(=C4)C=C3)C=C2)=CC=C1C=C1C=CC4=N1 JZRYQZJSTWVBBD-UHFFFAOYSA-N 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 229940083251 peripheral vasodilators purine derivative Drugs 0.000 description 1
- 239000007793 ph indicator Substances 0.000 description 1
- 108010084525 phenylalanyl-phenylalanyl-glycine Proteins 0.000 description 1
- 108010012581 phenylalanylglutamate Proteins 0.000 description 1
- 150000008039 phosphoramides Chemical class 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920001977 poly(N,N-diethylacrylamides) Polymers 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 108010031719 prolyl-serine Proteins 0.000 description 1
- 108010070643 prolylglutamic acid Proteins 0.000 description 1
- 108010090894 prolylleucine Proteins 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000005588 protonation Effects 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 208000020615 rectal carcinoma Diseases 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 201000010174 renal carcinoma Diseases 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 150000003335 secondary amines Chemical group 0.000 description 1
- 230000028043 self proteolysis Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 108010048818 seryl-histidine Proteins 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 235000019832 sodium triphosphate Nutrition 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 108010005652 splenotritin Proteins 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 108010061238 threonyl-glycine Proteins 0.000 description 1
- 108010071097 threonyl-lysyl-proline Proteins 0.000 description 1
- 108010072986 threonyl-seryl-lysine Proteins 0.000 description 1
- PWWGCBMGIAPMHQ-UHFFFAOYSA-N thulium(3+) Chemical compound [Tm+3] PWWGCBMGIAPMHQ-UHFFFAOYSA-N 0.000 description 1
- 208000013077 thyroid gland carcinoma Diseases 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000007723 transport mechanism Effects 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-I triphosphate(5-) Chemical compound [O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O UNXRWKVEANCORM-UHFFFAOYSA-I 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 108010035534 tyrosyl-leucyl-alanine Proteins 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 238000012762 unpaired Student’s t-test Methods 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- AQTQHPDCURKLKT-PNYVAJAMSA-N vincristine sulfate Chemical compound OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 AQTQHPDCURKLKT-PNYVAJAMSA-N 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 239000008136 water-miscible vehicle Substances 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Improvements in methods of treating cancer with weakly basic anti-cancer compounds are provided. In one aspect, the invention provides an improvement in a method of treating cancer cells whose extracellular environment contains 1-8 mM urea, by exposing the cells to a weakly basic anti-cancer compound which is effective in inhibiting the growth of the cells. The improvement includes (a) exposing the cells to a urease enzyme composition and, (b) by step (a), reducing the amount of anti- cancer compound required to produce a given extent of inhibition in the growth of the cells when the cells are exposed to the anti-cancer agent. Methods of potentiating the specific therapeutic activity of a weakly basic anti-cancer compound in the treatment of a given mammalian cancer which is responsive to the compound are provided as are pharmaceutical compositions for use in intravenous administration to a subject are also provided.
Description
=
METHOD AND COMPOSITION FOR INHIBITING
CANCER CELL GROWTH
=
USING UREASE AND WEAKLY BASIC ANTI-CANCER COMPOUNDS
=
=
!
Field of the Invention The present invention relates to anticancer therapeutic methods employing urease in combination With a weakly basic anti-cancer compound.
Background of the Invention Cancer accounts for one-fifth of the, total mortality In the United States, and is the second leading cause of death, Cancer is typically characterized by the uncontrolled division of a population of cells. This uncontrolled division may Involve blood cells, such as various types of lymphomas, or cells that aggregate In or are native to a particular tissue or organ, e.g., solid tumors, such as secondary or primary tumors of the breast;
lung, liver, esophagus, stomach, intestines, brain, bone, or prostate.
A variety of treatment modalities have been proposed for' cancer therapy.
These generally include surgical resection of solid tumors, treatment with radiation, such as x-ray, chemotherapy, immune therapy, and gene Therapy. The type(s) of therapy that are selected for a given cancer Will depend on such factors as patient age; degree of =
localization of the cancer, and the type and stage of the cancer. Often the therapy will involve a combination of two or more modalities, such as x-ray therapy in combination' with chemotherapy, or with immunotherapyin combination with chemotherapy.
A' large number of chemotherapeutic compounds and compositions and . strategies have been employed in treating cancers. Many anti-neoplastic compounds are designed to disrupt replication in rapidly dividing cells, or to inhibit a key metabolic link in actively proliferating cells. Although such approaches have met with levels of = 1 success in certain types of cancers, or cancers at certain stages, chemotherapy is generally associated with unpleasant to debilitating side effects, such as malaise, nausea, loss of appetite, alopecia, and anemia, and in the extreme, loss of immune function and/or loss of digestive activity. Further, compounds which act at the level of cell replication, either by introducing nucleotide analogs into dividing cells, or by disrupting normal replication, have the potential of introducing widespread genetic mutations in normal cells in the subject. In addition, cancer cells may develop resistance to many types of anti-cancer agents, either by limiting uptake of the agent into the cells, or by altering the metabolism of the agent within the cells.
to In response to these limitations, attempts to modify chemotherapeutic agents to reduce their side effects, overcome problems of resistance, or improve their targeting to selected tumor sites have been developed. While these efforts have yielded improved therapeutic results in some cases, there remains a need to provide an improved chemotherapeutic agent and method. In particular, such an agent and method should be effective in killing or inhibiting the growth of cancer cells, should be relatively non-toxic at therapeutically effective doses, and preferably deliverable in a form that allows direct introduction into a tumor or selective targeting to tumors.
Summary of the Invention It has been discovered that the efficacy of a weakly basic anti-cancer compound can be enhanced when cancer cells, a patient or other subject is also treated with urease. That is, the amount of the weakly basic anti-cancer compound required to achieve a specified amount of growth inhibition in the presence of urease is less than in the absence of urease. Accordingly, the specific therapeutic efficacy of a given amount of anti-cancer drug in a mammalian subject can be enhanced (potentiated), by co-treating the subject with urease, typically by pretreating the subject with urease.
Accordingly, improvements in a method of treating cancer cells are provided.
Methods of potentiating the specific therapeutic activity of a weakly basic anti-cancer compound are provided, as are pharmaceutical compositions for use in intravenous administration of a subject.
In one aspect of the invention, improvements in a method of treating cancer cells whose extracellular environment contains 1-8 mM urea by exposing the cells to a weakly basic anti-cancer compound which is effective in inhibiting the growth of the cells
METHOD AND COMPOSITION FOR INHIBITING
CANCER CELL GROWTH
=
USING UREASE AND WEAKLY BASIC ANTI-CANCER COMPOUNDS
=
=
!
Field of the Invention The present invention relates to anticancer therapeutic methods employing urease in combination With a weakly basic anti-cancer compound.
Background of the Invention Cancer accounts for one-fifth of the, total mortality In the United States, and is the second leading cause of death, Cancer is typically characterized by the uncontrolled division of a population of cells. This uncontrolled division may Involve blood cells, such as various types of lymphomas, or cells that aggregate In or are native to a particular tissue or organ, e.g., solid tumors, such as secondary or primary tumors of the breast;
lung, liver, esophagus, stomach, intestines, brain, bone, or prostate.
A variety of treatment modalities have been proposed for' cancer therapy.
These generally include surgical resection of solid tumors, treatment with radiation, such as x-ray, chemotherapy, immune therapy, and gene Therapy. The type(s) of therapy that are selected for a given cancer Will depend on such factors as patient age; degree of =
localization of the cancer, and the type and stage of the cancer. Often the therapy will involve a combination of two or more modalities, such as x-ray therapy in combination' with chemotherapy, or with immunotherapyin combination with chemotherapy.
A' large number of chemotherapeutic compounds and compositions and . strategies have been employed in treating cancers. Many anti-neoplastic compounds are designed to disrupt replication in rapidly dividing cells, or to inhibit a key metabolic link in actively proliferating cells. Although such approaches have met with levels of = 1 success in certain types of cancers, or cancers at certain stages, chemotherapy is generally associated with unpleasant to debilitating side effects, such as malaise, nausea, loss of appetite, alopecia, and anemia, and in the extreme, loss of immune function and/or loss of digestive activity. Further, compounds which act at the level of cell replication, either by introducing nucleotide analogs into dividing cells, or by disrupting normal replication, have the potential of introducing widespread genetic mutations in normal cells in the subject. In addition, cancer cells may develop resistance to many types of anti-cancer agents, either by limiting uptake of the agent into the cells, or by altering the metabolism of the agent within the cells.
to In response to these limitations, attempts to modify chemotherapeutic agents to reduce their side effects, overcome problems of resistance, or improve their targeting to selected tumor sites have been developed. While these efforts have yielded improved therapeutic results in some cases, there remains a need to provide an improved chemotherapeutic agent and method. In particular, such an agent and method should be effective in killing or inhibiting the growth of cancer cells, should be relatively non-toxic at therapeutically effective doses, and preferably deliverable in a form that allows direct introduction into a tumor or selective targeting to tumors.
Summary of the Invention It has been discovered that the efficacy of a weakly basic anti-cancer compound can be enhanced when cancer cells, a patient or other subject is also treated with urease. That is, the amount of the weakly basic anti-cancer compound required to achieve a specified amount of growth inhibition in the presence of urease is less than in the absence of urease. Accordingly, the specific therapeutic efficacy of a given amount of anti-cancer drug in a mammalian subject can be enhanced (potentiated), by co-treating the subject with urease, typically by pretreating the subject with urease.
Accordingly, improvements in a method of treating cancer cells are provided.
Methods of potentiating the specific therapeutic activity of a weakly basic anti-cancer compound are provided, as are pharmaceutical compositions for use in intravenous administration of a subject.
In one aspect of the invention, improvements in a method of treating cancer cells whose extracellular environment contains 1-8 mM urea by exposing the cells to a weakly basic anti-cancer compound which is effective in inhibiting the growth of the cells
2 is provided. In a general embodiment, the improvement includes (a) exposing the cells to a urease enzyme composition and (b) by step (a) reducing the amount of anti-cancer compound required to produce a given extent of inhibition in the growth of the cells when the cells are exposed to the anti-cancer agent.
The amount of urease to which the cells are exposed is preferably sufficient to raise the pH of the extracellular environment of the cells by at least about 0.1 pH units, typically between 0.1 to 0.5 or more pH units. The amount of anti-cancer compound required to achieve the same extent of cell-growth inhibition may be between about 2-fold and 5-fold less than in the absence of step the urease administration.
Exemplary anti-cancer agents include doxorubicin, daunorubicin, mitoxantrone, epirubicin, mitomycin, bleomycin, a vinca alkaloid, an alkylating agent, and antineoplastic purine and pyrimidine derivatives.
The urease composition may include a targeting moiety, such as an antibody directed against a tumor-specific antigen, an anti-hCG antibody, and a ligand capable of binding specifically to a cancer-cell surface receptor. The targeting moiety may be covalently attached to the urease enzyme. One exemplary targeting moiety is a single-chain antibody, such as a single-chain antibody derived from llama germline.
For use in treating a cancer in a mammalian subject, by administrating the anti-cancer compound to the subject, the urease composition administered to the subject is effective to localize at the site of the cancer into the subject. The urease composition may be administered intravenously, e.g., in an amount of between 25 and 2000 pmoles urease enzyme/kg subject body weight, at least 24 hours prior to administration of the anti-cancer compound. A urease composition administered by IV drip may include a urease inhibitor, in an amount of at least about 6 moles inhibitor/mole urease enzyme.
Alternatively, for use in treating a solid tumor, the urease composition may be administered directly in the tumor in an amount effective to raise the pH
total of the extracellular fluid of the tumor, as evidenced by detectable change in a pH
indicator present in the tumor extracellular fluid.
In another aspect, the invention includes a method of treating a cancer that is responsive to a selected weakly basic anti-tumor compound in mammalian subject. The method includes administering to the subject, such weakly basic anti-cancer compound, and an amount of urease sufficient to potentiate the therapeutic effect of the compound with respect to the therapeutic effect obtained in the absence of said urease
The amount of urease to which the cells are exposed is preferably sufficient to raise the pH of the extracellular environment of the cells by at least about 0.1 pH units, typically between 0.1 to 0.5 or more pH units. The amount of anti-cancer compound required to achieve the same extent of cell-growth inhibition may be between about 2-fold and 5-fold less than in the absence of step the urease administration.
Exemplary anti-cancer agents include doxorubicin, daunorubicin, mitoxantrone, epirubicin, mitomycin, bleomycin, a vinca alkaloid, an alkylating agent, and antineoplastic purine and pyrimidine derivatives.
The urease composition may include a targeting moiety, such as an antibody directed against a tumor-specific antigen, an anti-hCG antibody, and a ligand capable of binding specifically to a cancer-cell surface receptor. The targeting moiety may be covalently attached to the urease enzyme. One exemplary targeting moiety is a single-chain antibody, such as a single-chain antibody derived from llama germline.
For use in treating a cancer in a mammalian subject, by administrating the anti-cancer compound to the subject, the urease composition administered to the subject is effective to localize at the site of the cancer into the subject. The urease composition may be administered intravenously, e.g., in an amount of between 25 and 2000 pmoles urease enzyme/kg subject body weight, at least 24 hours prior to administration of the anti-cancer compound. A urease composition administered by IV drip may include a urease inhibitor, in an amount of at least about 6 moles inhibitor/mole urease enzyme.
Alternatively, for use in treating a solid tumor, the urease composition may be administered directly in the tumor in an amount effective to raise the pH
total of the extracellular fluid of the tumor, as evidenced by detectable change in a pH
indicator present in the tumor extracellular fluid.
In another aspect, the invention includes a method of treating a cancer that is responsive to a selected weakly basic anti-tumor compound in mammalian subject. The method includes administering to the subject, such weakly basic anti-cancer compound, and an amount of urease sufficient to potentiate the therapeutic effect of the compound with respect to the therapeutic effect obtained in the absence of said urease
3 administration. The urease may be administered at least 24 hours prior to administering the anti-cancer compound, allowing clearance of at least a significant portion of the urease, prior to administering the anti-cancer compound. The amount of urease administered may be effective to raise the pH of the extracellular environment of the cancer cells by at least 0.1 pH unit. The amount of urease administered may be effective, for example, to reduce the amount of said anti-cancer compound required to achieve the same extent of cell-growth inhibition by a factor of between 2 and 5.
In still another aspect, the invention includes a pharmaceutical composition for use in intravenous administration to a subject. The composition may include at least about 20 Units urease enzyme/ml; a urease inhibitor at a concentration effective to inhibit the urease enzyme, and a physiological carrier suitable for administering the composition intravenously. In one embodiment, where the enzyme has six enzymatic subunits, the molar ratio of inhibitor to enzyme is preferably at least about 6:1.
The urease enzyme may be covalently linked to a targeting agent selected from the group consisting of an antibody directed against a tumor antigen, an anti-hCG
antibody, and a ligand capable of binding specifically to a cancer-cell surface receptor.
The urease inhibitor may be a hydroxamic acid derivative or other urea analog.
In accordance with an aspect of the present invention there is provided the use of a pharmaceutical composition in a subject with a tumor for reducing the amount of a weakly basic anti-cancer compound required for reducing growth of said tumor, the composition comprising:
a unit dose selected from the group consisting of 10, 20, 30, 40 and 50 units/mL of urease enzyme;
a targeting moiety conjugated to said urease enzyme forming a conjugate, wherein said targeting moiety is an anti-tumor antigen antibody or an anti-tumor antigen-binding fragment thereof, said targeting moiety being effective to enhance the delivery of the enzyme to cells of the solid tumor, when the composition is for administration to said subject; and a pharmaceutically acceptable carrier, diluent, or excipient, wherein said unit dose of urease enzyme reduces the amount of said weakly basic anti-cancer compound 2-5 fold lower than without urease.
In accordance with a further aspect of the present invention there is provided the use of a first pharmaceutical composition for treating cancer cells in an environment of 1-8 mM urea, wherein said first composition comprises a urease
In still another aspect, the invention includes a pharmaceutical composition for use in intravenous administration to a subject. The composition may include at least about 20 Units urease enzyme/ml; a urease inhibitor at a concentration effective to inhibit the urease enzyme, and a physiological carrier suitable for administering the composition intravenously. In one embodiment, where the enzyme has six enzymatic subunits, the molar ratio of inhibitor to enzyme is preferably at least about 6:1.
The urease enzyme may be covalently linked to a targeting agent selected from the group consisting of an antibody directed against a tumor antigen, an anti-hCG
antibody, and a ligand capable of binding specifically to a cancer-cell surface receptor.
The urease inhibitor may be a hydroxamic acid derivative or other urea analog.
In accordance with an aspect of the present invention there is provided the use of a pharmaceutical composition in a subject with a tumor for reducing the amount of a weakly basic anti-cancer compound required for reducing growth of said tumor, the composition comprising:
a unit dose selected from the group consisting of 10, 20, 30, 40 and 50 units/mL of urease enzyme;
a targeting moiety conjugated to said urease enzyme forming a conjugate, wherein said targeting moiety is an anti-tumor antigen antibody or an anti-tumor antigen-binding fragment thereof, said targeting moiety being effective to enhance the delivery of the enzyme to cells of the solid tumor, when the composition is for administration to said subject; and a pharmaceutically acceptable carrier, diluent, or excipient, wherein said unit dose of urease enzyme reduces the amount of said weakly basic anti-cancer compound 2-5 fold lower than without urease.
In accordance with a further aspect of the present invention there is provided the use of a first pharmaceutical composition for treating cancer cells in an environment of 1-8 mM urea, wherein said first composition comprises a urease
4 enzyme and a pharmaceutically acceptable carrier, diluent, or excipient, said use further comprising use of a second pharmaceutical composition comprising a weakly basic anti-cancer compound and a pharmaceutically acceptable carrier, diluent, or excipient;
wherein use of said first composition reduces the dose of the second composition 2-5 fold compared to without use of said first composition.
In accordance with a further aspect of the present invention there is provided the use of urease enzyme as a pretreatment for a solid tumor at least 24 hours prior to use of a weakly basic anti-cancer compound, wherein the urease enzyme is provided in an amount selected from the group consisting of 25, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900 and pmoles urease enzyme/kg subject body weight, optionally with a urease inhibitor in an amount of at least 6 moles inhibitor/mole urease enzyme, further wherein said pretreatment results in a 2-5 fold decrease of a dose used of the weakly basic anti-cancer compound compared to without urease enzyme pretreatment.
In accordance with a further aspect of the present invention there is provided the use of a pharmaceutical composition in a subject with a tumor for reducing the amount of fluorouracil required for reducing growth of said tumor, the composition comprising:
a unit dose selected from the group consisting of 10, 20, 30, 40 and 50 units/mL of urease enzyme;
a targeting moiety conjugated to said urease enzyme forming a conjugate, wherein said targeting moiety is an anti-tumor antigen antibody or an anti-tumor antigen-binding fragment thereof, said targeting moiety being effective to enhance the delivery of the enzyme to cells of the solid tumor, when the composition is for administration to said subject; and a pharmaceutically acceptable carrier, diluent, or excipient;
wherein said unit dose of urease enzyme reduces the amount of fluorouracil 2-fold lower than without urease.
These and other objects and advantages of the present invention will be apparent from the description herein.
4a Brief Description of the Drawings Figs. 1A-1D illustrate the steps of the urease reaction. Urea is cleaved by urease to produce one molecule of ammonia and one of carbamate (A). Carbam ate spontaneously decomposes to ammonia and carbonic acid (B). The carbonic acid equilibrates in water (C), as do the two molecules of ammonia, which become protonated to yield ammonium and hydroxide ions (D). The reaction results in a rise in the pH of the reaction environment.
Fig. 2 shows the mass spectrometry profile of a crude sample containing urease prepared in accordance with one embodiment of the invention.
Fig. 3 illustrates the affinity purification profiles of urease during various stages of the purification process, in accordance with another embodiment of the invention.
Fig. 4 illustrates the purification of E-coil-ahEGFR IgG conjugate by a protein-G column prepared according to one embodiment of the invention.
4b Fig. 5 shows the antibody titer of purified E-coil-ahEGFR IgG conjugate prepared according to one embodiment of the invention as determined by immobilized K-coil ELISA.
Fig. 6A is a graph showing a dose-response curve of urea on the viability of (A) and MDA-MB-231 (0) cells. Cells were incubated in 0-40 mM urea, treated with 2 U/ml of urease and incubated at 37 C for 2 hours as more fully described in Example 7.
Viability of the treated cells began to drop as the urea level increased. Urea alone has no effects on A549 (Lx) and MDA-MB-231 (0) controls.
Fig. 6B is a graph showing a dose-response curve of urease on the viability of io A549 (A) and MDA-MB-231 (0) cells. Cells were incubated in 20 mM urea and treated with 2 Wm! of urease for 2 hours as described in Example 7. A549 (A) were more susceptible to urease than MDA-MB-231 (0) cells.
Fig. 6C is a graph showing total ammonium ion as a function of urea treatment in pooled incubation buffer collected from A549 cells treated with urease as described for is FIG. 6A and as more fully described in Example 8. Hydrolysis of urea by urease (M) caused an increase in ammonium content as compared to the control (0). Values are means S.D. of 4 replicates from 3 experiments.
Fig. 6D is a graph of pH as a function of urea treatment in pooled incubation buffer collected from A549 cells treated with urease as described for Fig. 6A
and as 20 more fully described in Example 8. Hydrolysis of urea by urease (MI) caused an increase in pH as compared to the control (0). Values are means S.D. of 4 replicates from 3 experiments.
Figs. 7A-7F are graphs depicting the protective effects of acetohydroxamic acid (AHA) on urease cytotoxicity as described in Example 9. (A) A549 cells (A) and (B) 25 MDA-MB-231 cells (0) treated with 2 U/ml of urease were protected from the cytotoxic effects by addition of acetohydroxamic acid to the incubation buffer. AHA
alone at concentrations up to 6 mM was not toxic to both cell lines (no urease controls: L, A549;
0, MDA-MB-231). Complete protection was observed at dose 2mM. (C) AHA
inhibited ammonium production by urease (M), which corresponds to an increase in 30 .. survival rate of both cell lines as shown in (A) and (B). Higher amount of AHA (6 mM) can reduce the ammonium level close to that of control (0). Values are means S.D.
of 4 replicates from 3 experiments. (D) AHA inhibited ammonium production by urease at indicated urea concentrations; (E) A549 cells; or MDA-MB-231 cells incubated in the
wherein use of said first composition reduces the dose of the second composition 2-5 fold compared to without use of said first composition.
In accordance with a further aspect of the present invention there is provided the use of urease enzyme as a pretreatment for a solid tumor at least 24 hours prior to use of a weakly basic anti-cancer compound, wherein the urease enzyme is provided in an amount selected from the group consisting of 25, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900 and pmoles urease enzyme/kg subject body weight, optionally with a urease inhibitor in an amount of at least 6 moles inhibitor/mole urease enzyme, further wherein said pretreatment results in a 2-5 fold decrease of a dose used of the weakly basic anti-cancer compound compared to without urease enzyme pretreatment.
In accordance with a further aspect of the present invention there is provided the use of a pharmaceutical composition in a subject with a tumor for reducing the amount of fluorouracil required for reducing growth of said tumor, the composition comprising:
a unit dose selected from the group consisting of 10, 20, 30, 40 and 50 units/mL of urease enzyme;
a targeting moiety conjugated to said urease enzyme forming a conjugate, wherein said targeting moiety is an anti-tumor antigen antibody or an anti-tumor antigen-binding fragment thereof, said targeting moiety being effective to enhance the delivery of the enzyme to cells of the solid tumor, when the composition is for administration to said subject; and a pharmaceutically acceptable carrier, diluent, or excipient;
wherein said unit dose of urease enzyme reduces the amount of fluorouracil 2-fold lower than without urease.
These and other objects and advantages of the present invention will be apparent from the description herein.
4a Brief Description of the Drawings Figs. 1A-1D illustrate the steps of the urease reaction. Urea is cleaved by urease to produce one molecule of ammonia and one of carbamate (A). Carbam ate spontaneously decomposes to ammonia and carbonic acid (B). The carbonic acid equilibrates in water (C), as do the two molecules of ammonia, which become protonated to yield ammonium and hydroxide ions (D). The reaction results in a rise in the pH of the reaction environment.
Fig. 2 shows the mass spectrometry profile of a crude sample containing urease prepared in accordance with one embodiment of the invention.
Fig. 3 illustrates the affinity purification profiles of urease during various stages of the purification process, in accordance with another embodiment of the invention.
Fig. 4 illustrates the purification of E-coil-ahEGFR IgG conjugate by a protein-G column prepared according to one embodiment of the invention.
4b Fig. 5 shows the antibody titer of purified E-coil-ahEGFR IgG conjugate prepared according to one embodiment of the invention as determined by immobilized K-coil ELISA.
Fig. 6A is a graph showing a dose-response curve of urea on the viability of (A) and MDA-MB-231 (0) cells. Cells were incubated in 0-40 mM urea, treated with 2 U/ml of urease and incubated at 37 C for 2 hours as more fully described in Example 7.
Viability of the treated cells began to drop as the urea level increased. Urea alone has no effects on A549 (Lx) and MDA-MB-231 (0) controls.
Fig. 6B is a graph showing a dose-response curve of urease on the viability of io A549 (A) and MDA-MB-231 (0) cells. Cells were incubated in 20 mM urea and treated with 2 Wm! of urease for 2 hours as described in Example 7. A549 (A) were more susceptible to urease than MDA-MB-231 (0) cells.
Fig. 6C is a graph showing total ammonium ion as a function of urea treatment in pooled incubation buffer collected from A549 cells treated with urease as described for is FIG. 6A and as more fully described in Example 8. Hydrolysis of urea by urease (M) caused an increase in ammonium content as compared to the control (0). Values are means S.D. of 4 replicates from 3 experiments.
Fig. 6D is a graph of pH as a function of urea treatment in pooled incubation buffer collected from A549 cells treated with urease as described for Fig. 6A
and as 20 more fully described in Example 8. Hydrolysis of urea by urease (MI) caused an increase in pH as compared to the control (0). Values are means S.D. of 4 replicates from 3 experiments.
Figs. 7A-7F are graphs depicting the protective effects of acetohydroxamic acid (AHA) on urease cytotoxicity as described in Example 9. (A) A549 cells (A) and (B) 25 MDA-MB-231 cells (0) treated with 2 U/ml of urease were protected from the cytotoxic effects by addition of acetohydroxamic acid to the incubation buffer. AHA
alone at concentrations up to 6 mM was not toxic to both cell lines (no urease controls: L, A549;
0, MDA-MB-231). Complete protection was observed at dose 2mM. (C) AHA
inhibited ammonium production by urease (M), which corresponds to an increase in 30 .. survival rate of both cell lines as shown in (A) and (B). Higher amount of AHA (6 mM) can reduce the ammonium level close to that of control (0). Values are means S.D.
of 4 replicates from 3 experiments. (D) AHA inhibited ammonium production by urease at indicated urea concentrations; (E) A549 cells; or MDA-MB-231 cells incubated in the
5 , indicated amounts of urea and treated with 2U/mlurease were protected from the cytotoxic effects of urease by addition of acetohydroxamic acid to the incubation buffer.
Figs. 8A-8B are graphs which depict the growth inhibitor effects of urease on tumor cell line xenografts as described in Example 10. (A) urease inhibits the growth of established MCF-7 xenografts. The breast tumor stopped to grow after the second injection of high-dose of urease (10 U/injection, solid bars) on day 9 as compared to the controls (open bars). Time of intratumoral injections are indicated by A below the x-axis. (B) effects of multiple low-dose (1 U/injection, hatched bars) and medium-dose (4 U/injection, solid bars) injections of urease on established A549 xenografts.
Intratumoral injections were performed on days 5, 7, 9, 11 and 13 (A). Delay of tumor growth was observed from days 17 onwards as compared to the controls (open bars).
Significance was determined using the two-tailed unpaired Student's t test: *P
< 0.05 and **P < 0.005.
Figs. 9A-9B are graphs depicting the effects of urease on the cytotoxicity of is weakly basic anticancer drugs as described in Example 11. (A) lung tumor A549 and (B) breast tumor MDA-MB-231 incubated in 0, 2 or 8 mM urea, were treated with 2 U/m1 of urease, and either 50 pM of doxorubicin or 100 pM of vinblastine at pH 6.8 overnight.
The antitumor efficacies of the two compounds were enhanced at the presence of urease (solid bars) and urea as compared to the control (open bars). The solid circle (0) indicates the pH of urease-treated group measured after treatment. Values are means S.D. of 4 replicates from 3 experiments.
Figs. 10A-10B are graphs showing the effects of urease on the cytotoxicity of weakly basic anticancer drugs as described in Example 11. Lung tumor A549 (A) and breast tumor MDA-MB-231 (B) were incubated in urea and treated with D0S47 (2 Wm!), and either Fluorouracil (13.3 mM) or Mitoxantrone (5 pM) at pH 6.8 overnight.
The enhanced anticancer effect (solid bar) of Mitoxantrone is only observed in MDA-MB-231 but not in A549 cells. D0S47 also enhances the anticancer effects of Fluorouracil in A549 but not in MDA-MB-231. The solid circle (*) denotes the pH of D0547 group measured after treatment. Values are means S.D. of 4 replicates from 3 different experiments.
Detailed Description of the Invention
Figs. 8A-8B are graphs which depict the growth inhibitor effects of urease on tumor cell line xenografts as described in Example 10. (A) urease inhibits the growth of established MCF-7 xenografts. The breast tumor stopped to grow after the second injection of high-dose of urease (10 U/injection, solid bars) on day 9 as compared to the controls (open bars). Time of intratumoral injections are indicated by A below the x-axis. (B) effects of multiple low-dose (1 U/injection, hatched bars) and medium-dose (4 U/injection, solid bars) injections of urease on established A549 xenografts.
Intratumoral injections were performed on days 5, 7, 9, 11 and 13 (A). Delay of tumor growth was observed from days 17 onwards as compared to the controls (open bars).
Significance was determined using the two-tailed unpaired Student's t test: *P
< 0.05 and **P < 0.005.
Figs. 9A-9B are graphs depicting the effects of urease on the cytotoxicity of is weakly basic anticancer drugs as described in Example 11. (A) lung tumor A549 and (B) breast tumor MDA-MB-231 incubated in 0, 2 or 8 mM urea, were treated with 2 U/m1 of urease, and either 50 pM of doxorubicin or 100 pM of vinblastine at pH 6.8 overnight.
The antitumor efficacies of the two compounds were enhanced at the presence of urease (solid bars) and urea as compared to the control (open bars). The solid circle (0) indicates the pH of urease-treated group measured after treatment. Values are means S.D. of 4 replicates from 3 experiments.
Figs. 10A-10B are graphs showing the effects of urease on the cytotoxicity of weakly basic anticancer drugs as described in Example 11. Lung tumor A549 (A) and breast tumor MDA-MB-231 (B) were incubated in urea and treated with D0S47 (2 Wm!), and either Fluorouracil (13.3 mM) or Mitoxantrone (5 pM) at pH 6.8 overnight.
The enhanced anticancer effect (solid bar) of Mitoxantrone is only observed in MDA-MB-231 but not in A549 cells. D0S47 also enhances the anticancer effects of Fluorouracil in A549 but not in MDA-MB-231. The solid circle (*) denotes the pH of D0547 group measured after treatment. Values are means S.D. of 4 replicates from 3 different experiments.
Detailed Description of the Invention
6 The present invention provides improvements in selected methods of treating cancer cells, methods of potentiating the specific therapeutic activity of a weakly basic anti-cancer compound, and pharmaceutical compositions for inhibiting the growth of cancer cell, e.g., in a mammalian patient. It has been discovered that the pharmaceutical efficacy of a weakly basic anti-cancer compound can be enhanced when a mammalian subject, such as a human subject, is also treated, preferably pretreated with urease.
I. Definitions io Unless otherwise indicated, all technical and scientific terms used herein have the same meaning as they would to one skilled in the art of the present invention.
The term "urease" refers to an enzyme having the enzymatic activity of a urea amidohydrolase (E.C. 3.5.1.5), either naturally occurring or obtained by e.g., recombinant nucleic acid techniques and/or chemical synthesis. Urease also includes fusion proteins comprising the entire urease, subunits, or fragments thereof, and/or urease with amino acid substitutions, deletions or additions that preserve the urea amidohydrolase activity of the polypeptide. A truncated urease sequence as used herein is a fragment of urease that is free from a portion of the intact urease sequence beginning at either the amino or carboxy terminus of urease. Methods for isolating native urease, for synthesizing urease recombinantly, and for identifying active fragments and modified urease polypeptides are given below.
The term "cancer is meant to refer to an abnormal cell or cells, or a mass of tissue. The growth of these cells or tissues exceeds and is uncoordinated with that of the normal tissues or cells, and persists in the same excessive manner after cessation of the stimuli which evoked the change. These neoplastic tissues or cells show a lack of structural organization and coordination relative to normal tissues or cells which may result in a mass of tissues or cells which can be either benign or malignant.
As used herein, cancer includes any neoplasm. This includes, but is not limited to, melanoma, adenocarcinoma, malignant glioma, prostatic carcinoma, kidney carcinoma, bladder carcinoma, pancreatic carcinoma, thyroid carcinoma, lung carcinoma, colon carcinoma, rectal carcinoma, brain carcinoma, liver carcinoma, breast carcinoma, ovary carcinoma, and the like.
I. Definitions io Unless otherwise indicated, all technical and scientific terms used herein have the same meaning as they would to one skilled in the art of the present invention.
The term "urease" refers to an enzyme having the enzymatic activity of a urea amidohydrolase (E.C. 3.5.1.5), either naturally occurring or obtained by e.g., recombinant nucleic acid techniques and/or chemical synthesis. Urease also includes fusion proteins comprising the entire urease, subunits, or fragments thereof, and/or urease with amino acid substitutions, deletions or additions that preserve the urea amidohydrolase activity of the polypeptide. A truncated urease sequence as used herein is a fragment of urease that is free from a portion of the intact urease sequence beginning at either the amino or carboxy terminus of urease. Methods for isolating native urease, for synthesizing urease recombinantly, and for identifying active fragments and modified urease polypeptides are given below.
The term "cancer is meant to refer to an abnormal cell or cells, or a mass of tissue. The growth of these cells or tissues exceeds and is uncoordinated with that of the normal tissues or cells, and persists in the same excessive manner after cessation of the stimuli which evoked the change. These neoplastic tissues or cells show a lack of structural organization and coordination relative to normal tissues or cells which may result in a mass of tissues or cells which can be either benign or malignant.
As used herein, cancer includes any neoplasm. This includes, but is not limited to, melanoma, adenocarcinoma, malignant glioma, prostatic carcinoma, kidney carcinoma, bladder carcinoma, pancreatic carcinoma, thyroid carcinoma, lung carcinoma, colon carcinoma, rectal carcinoma, brain carcinoma, liver carcinoma, breast carcinoma, ovary carcinoma, and the like.
7 A "tumor" 'or "solid tumor" refers to a cohesive mass of cancer cells, including but not limited to semi-solid and solid tumors, solid tumor metastases, angiofibromas, retrolental fibroplasia, hemangiomas, and Karposi's sarcoma.
As used herein, the term "targeting moiety" refers to a molecule that is associated with urease and which is effective to promote localization of urease at cancer cells, e.g., within a solid tumor. In one general embodiment, the targeting moiety is a binding molecule covalently attached to urease and capable of binding a receptor, an oligonucleotide, an enzymatic substrate, an antigenic determinant, or other binding site present on or in the target cell or cell population. An exemplary targeting moiety is io an antibody, including antibody fragments and constructs, such as a single-chain antibody, and/or an antibody derived from human germline. In another general embodiment, the targeting agent is a long-circulating particle, such as PEG-coated liposomes capable of localizing at tumor sites by extravasation, and containing encapsulated or surface bound urease.
As used herein, the term "inhibits growth of cancer cells" or "inhibiting growth of cancer cells" refers to any slowing of the rate of cancer cell proliferation and/or migration, arrest of cancer cell proliferation and/or migration, or killing of cancer cells, such that the rate of cancer cell growth is reduced in comparison with the observed or predicted rate of growth of an untreated control cancer cell. The term "inhibits growth"
can also refer to a reduction in size or disappearance of a cancer cell or tumor, as well as to a reduction in its metastatic potential. Preferably, such an inhibition at the cellular level may reduce the size, deter the growth, reduce the aggressiveness, or prevent or inhibit metastasis of a cancer in a patient. Those skilled in the art can readily determine, by any of a variety of suitable indicia, whether cancer cell growth is inhibited.
Inhibition of cancer cell growth may be evidenced, for example, by arrest of cancer cells in a particular phase of the cell cycle, e.g., arrest at the G2/M phase of the cell cycle. Inhibition of cancer cell growth can also be evidenced by direct or indirect measurement of cancer cell or tumor size. In human cancer patients, such measurements generally are made using well known imaging methods such as magnetic resonance imaging, computerized axial tomography and X-rays. Cancer cell growth can also be determined indirectly, such as by determining the levels of circulating carcinoembryonic antigen, prostate specific antigen or other cancer-specific antigens that are correlated with cancer cell growth. Inhibition of cancer growth is also
As used herein, the term "targeting moiety" refers to a molecule that is associated with urease and which is effective to promote localization of urease at cancer cells, e.g., within a solid tumor. In one general embodiment, the targeting moiety is a binding molecule covalently attached to urease and capable of binding a receptor, an oligonucleotide, an enzymatic substrate, an antigenic determinant, or other binding site present on or in the target cell or cell population. An exemplary targeting moiety is io an antibody, including antibody fragments and constructs, such as a single-chain antibody, and/or an antibody derived from human germline. In another general embodiment, the targeting agent is a long-circulating particle, such as PEG-coated liposomes capable of localizing at tumor sites by extravasation, and containing encapsulated or surface bound urease.
As used herein, the term "inhibits growth of cancer cells" or "inhibiting growth of cancer cells" refers to any slowing of the rate of cancer cell proliferation and/or migration, arrest of cancer cell proliferation and/or migration, or killing of cancer cells, such that the rate of cancer cell growth is reduced in comparison with the observed or predicted rate of growth of an untreated control cancer cell. The term "inhibits growth"
can also refer to a reduction in size or disappearance of a cancer cell or tumor, as well as to a reduction in its metastatic potential. Preferably, such an inhibition at the cellular level may reduce the size, deter the growth, reduce the aggressiveness, or prevent or inhibit metastasis of a cancer in a patient. Those skilled in the art can readily determine, by any of a variety of suitable indicia, whether cancer cell growth is inhibited.
Inhibition of cancer cell growth may be evidenced, for example, by arrest of cancer cells in a particular phase of the cell cycle, e.g., arrest at the G2/M phase of the cell cycle. Inhibition of cancer cell growth can also be evidenced by direct or indirect measurement of cancer cell or tumor size. In human cancer patients, such measurements generally are made using well known imaging methods such as magnetic resonance imaging, computerized axial tomography and X-rays. Cancer cell growth can also be determined indirectly, such as by determining the levels of circulating carcinoembryonic antigen, prostate specific antigen or other cancer-specific antigens that are correlated with cancer cell growth. Inhibition of cancer growth is also
8 generally correlated with prolonged survival and/or increased health and well-being of the subject.
As used herein, the term "induces apoptosis" refers to the promotion of a form of programmed cell death characterized by DNA fragmentation. Apoptosis can be determined by methods known in the art. For example, kits are commercially available that detect the presence of fragmented DNA by in situ immunohistochemistry (e.g., Apoptag, available from Intergen, Purchase, N.Y.). Additionally, apoptosis can also be determined by FACS analysis, in which apoptotic cells exhibit a sub-G1 DNA
content, indicating DNA fragmentation.
io As used herein, an "antibody" refers to a peptide, polypeptide, or protein comprising one or more peptides or polypeptides substantially or partially encoded by at least one immunoglobulin nucleic acid molecule or immunoglobulin gene or fragment of at least one immunoglobulin molecule or immunoglobulin gene. The recognized immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon and mu is constant region genes, as well as myriad immunoglobulin variable region genes. Light chains are classified as either kappa or lambda. Heavy chains are classified as gamma, mu, alpha, delta, or epsilon, which in turn define the immunoglobulin classes, IgG, IgM, IgA, IgD and IgE, respectively. A typical immunoglobulin (e.g., antibody) structural unit comprises a tetramer. Each tetramer is composed of two identical pairs 20 of polypeptide chains, each pair having one "light" chain (about 25 kD) and one "heavy"
chain (about 50-70 kD). The N-terminus of each chain defines a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition.
The terms "variable light chain" (VL) and "variable heavy chain" (VH) refer to these light and heavy chains, respectively. Antibodies exist as intact immunoglobulins or as a 25 number of well characterized fragments produced by digestion with various peptidases.
Thus, for example, pepsin digests an antibody below the disulfide linkages in the hinge region to produce F(ab)'2, a dimer of Fab which itself is a light chain joined to VH-CH1 by a disulfide bond. The F(ab)'2 may be reduced under mild conditions to break the disulfide linkage in the hinge region, thereby converting the (Fab)'2 dimer into an Fab' 30 monomer. The Fab' monomer is essentially a Fab with part of the hinge region (see Fundamental Immunology, ,W W. E. Paul, ed., Raven Press, N.Y. (1993), for a more detailed description of other antibody fragments). While various antibody fragments are defined in terms of the digestion of an intact antibody, one of ordinary skill in the art
As used herein, the term "induces apoptosis" refers to the promotion of a form of programmed cell death characterized by DNA fragmentation. Apoptosis can be determined by methods known in the art. For example, kits are commercially available that detect the presence of fragmented DNA by in situ immunohistochemistry (e.g., Apoptag, available from Intergen, Purchase, N.Y.). Additionally, apoptosis can also be determined by FACS analysis, in which apoptotic cells exhibit a sub-G1 DNA
content, indicating DNA fragmentation.
io As used herein, an "antibody" refers to a peptide, polypeptide, or protein comprising one or more peptides or polypeptides substantially or partially encoded by at least one immunoglobulin nucleic acid molecule or immunoglobulin gene or fragment of at least one immunoglobulin molecule or immunoglobulin gene. The recognized immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon and mu is constant region genes, as well as myriad immunoglobulin variable region genes. Light chains are classified as either kappa or lambda. Heavy chains are classified as gamma, mu, alpha, delta, or epsilon, which in turn define the immunoglobulin classes, IgG, IgM, IgA, IgD and IgE, respectively. A typical immunoglobulin (e.g., antibody) structural unit comprises a tetramer. Each tetramer is composed of two identical pairs 20 of polypeptide chains, each pair having one "light" chain (about 25 kD) and one "heavy"
chain (about 50-70 kD). The N-terminus of each chain defines a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition.
The terms "variable light chain" (VL) and "variable heavy chain" (VH) refer to these light and heavy chains, respectively. Antibodies exist as intact immunoglobulins or as a 25 number of well characterized fragments produced by digestion with various peptidases.
Thus, for example, pepsin digests an antibody below the disulfide linkages in the hinge region to produce F(ab)'2, a dimer of Fab which itself is a light chain joined to VH-CH1 by a disulfide bond. The F(ab)'2 may be reduced under mild conditions to break the disulfide linkage in the hinge region, thereby converting the (Fab)'2 dimer into an Fab' 30 monomer. The Fab' monomer is essentially a Fab with part of the hinge region (see Fundamental Immunology, ,W W. E. Paul, ed., Raven Press, N.Y. (1993), for a more detailed description of other antibody fragments). While various antibody fragments are defined in terms of the digestion of an intact antibody, one of ordinary skill in the art
9 Will appreciate that such Fab' fragments may be synthesized de novo either chemically or by utilizing recombinant DNA methodology. Thus, the term "antibody", as used herein, also includes antibody fragments either produced by the modification of whole antibodies or synthesized de novo using recombinant DNA methodologies.
Antibodies include single chain antibodies, including single chain Fv (sFv) antibodies in which a VH
and a VL are joined together (directly or through a peptide linker) to form a continuous polypeptide. One preferred antibody is a single-chain antibody derived from a human germline.
An "antigen-binding fragment" of an antibody is a peptide or polypeptide fragment to of the antibody that binds an antigen. An antigen-binding site is formed by those amino acids of the antibody that contribute to, are involved in, or affect the binding of the antigen. See Scott, T. A. and Mercer, E. I., CONCISE ENCYCLOPEDIA:
BIOCHEMISTRY AND MOLECULAR BIOLOGY (de Gruyter, 3d ed. 1997) and Watson, J. D. et al., RECOMBINANT DNA (al ed. 1992),.
The term "antibody fragment" also includes any synthetic or genetically engineered protein that acts like an antibody by binding to a specific antigen to form a complex.
The terms "active agent", "drug" and "pharmacologically active agent' are used interchangeably herein to refer to a chemical material or compound which, when ao administered to a subject induces a desired pharmacologic effect, and is intended to include a diagnostic or therapeutic agent, including radionuclides, drugs, anti-cancer agents, toxins and the like. Preferably, the terrn active agent includes proteins, glycoproteins, natural and synthetic peptides, alkaloids, polysaccharides, nucleic acid molecules, small molecules and the like. More preferably, the term active agent refers to proteins. An exemplary active agent is urease.
= A "pH-sensitive" active agent refers to an active agent whose ability to induce a desired pharmacologic effect depends, at least in part, on the pH of the surrounding extracellular environment.
The term "clearing agent", as used herein, refers to an agent capable of binding, cOMpleXing or otherwise associating with an administered moiety, e.g., targeting moiety-ligand, targeting moiety-anti-ligand or anti-ligand alone, present in the recipient's circulation, thereby facilitating circulating moiety clearance from the recipient's body, removal from blood circulation, or inactivation thereof in circulation. The clearing agent is preferably characterized by physical properties, such as size, charge, configuration or a combination thereof, that limit clearing agent access to the population of target cells recognized by a targeting moiety used in the same treatment protocol as the clearing agent.
The term "imaging agent" is meant to refer to compounds which can be detected.
The term "adjuvant" refers to a substance or agent added to a formulation or composition to aid the operation of the main ingredient.
The terms "interstitial" and "extracellular" fluid refer to the fluid lying between or bathing the cells of mammals.
The terms "subject", "individual" and "patient" are used interchangeably herein to refer to any target of the treatment. Also provided by the present invention is a method of treating tumor cells in situ, or in their normal position or location, for example, neoplastic cells of breast or prostate tumors. These in situ tumors can be located within or on a wide variety of hosts; for example, human hosts, canine hosts, feline hosts, equine hosts, bovine hosts, porcine hosts, and the like. Any host in which is found a tumor or tumor cells can be treated and is in accordance with the present invention. A
subject thus includes a vertebrate, preferably a mammal, more preferably a human.
By "target cell retention time" is intended the amount of time that a urease molecule or other active agent remains at the target cell surface or within the target cell.
As used herein, the term "conjugate" encompasses chemical conjugates (covalently or non-covalently bound), fusion proteins and the like.
The terms "protein", "polypeptide" or "peptide", as used herein, refer interchangeably to a biopolymer composed of amino acid or amino acid analog subunits, typically some or all of the 20 common L-amino acids found in biological proteins, linked by peptide intersubunit linkages, or other intersubunit linkages. The protein has a primary structure represented by its subunit sequence, and may have secondary helical or pleat structures, as well as overall three-dimensional structure. Although "protein"
commonly refers to a relatively large polypeptide, e.g., containing 100 or more amino acids, and "peptide" to smaller polypeptides, the terms are used interchangeably herein.
That is, the term "protein" may refer to a larger polypeptide, as well as to a smaller peptide, and vice versa.
A "modulator of urease" is either an inhibitor of urease or an enhancer of urease.
An "inhibitor of urease" comprises a molecule or group of molecules that interferes with: (1) the expression, modification, regulation, activation or degradation of urease; or (2) one or more of the normal functions of urease. The normal functions of urease include the hydrolysis of urea, leading to the production of carbamate and ammonia. An inhibitor "acts directly on urease" when the inhibitor binds to urease via electrostatic or chemical interactions. Such interactions may or may not be mediated by other molecules. An inhibitor acts "indirectly on urease" when its most immediate effect is on a molecule other than urease which influences the expression, activation or functioning of urease.
io An "enhancer of urease" comprises a molecule or group of molecules that enhances: (1) the expression, modification, regulation or activation of urease; or (2) one or more of the normal functions of urease. An enhancer acts "indirectly on urease"
when its most immediate effect is on a molecule other than urease which influences the expression, activation or functioning of urease.
The term "pharmaceutical composition" means a composition suitable for pharmaceutical use in a subject, including an animal or human. A
pharmaceutical composition generally comprises an effective amount of an active agent and a carrier, including, e.g., a pharmaceutically acceptable carrier.
A "pharmaceutically acceptable formulation" comprises a formulation that is suitable for administering the active agent (e.g., urease or urease modulator) in a manner that gives the desired results and does not also produce adverse side effects sufficient to convince a physician that the potential harm to a patient is greater than the potential benefit to that patient. The basic ingredient for an injectable formulation is typically a water vehicle. Aqueous vehicles that are useful include sodium chloride .. (NaCl) solution, Ringer's solution, NaCl/dextrose solution, and the like.
Water-miscible vehicles are also useful to effect full solubility of the active agent.
Antimicrobial agents, buffers and antioxidants may be useful, depending on the need. Similarly, a "pharmaceutically acceptable" salt or a "pharmaceutically acceptable"
derivative of a compound, as provided herein, is a salt or other derivative which is not biologically or otherwise undesirable.
A "therapeutic treatment" is a treatment administered to a subject who displays symptoms or signs of pathology, disease, or disorder, in which treatment is administered to the subject for the purpose of diminishing or eliminating those signs or symptoms of pathology, disease, or disorder. A "therapeutic activity" is an activity of an agent, such as a nucleic acid, vector, gene, polypeptide, protein, substance, or composition thereof, that eliminates or diminishes signs or symptoms of pathology, disease or disorder, when administered to a subject suffering from such signs or symptoms. A "therapeutically useful" agent or compound (e.g., nucleic acid or polypeptide) indicates that an agent or compound is useful in diminishing, treating, or eliminating such signs or symptoms of a pathology, disease or disorder.
The term "small molecule" includes a compound or molecular complex, either synthetic, naturally derived, or partially synthetic, and which preferably has a molecular lo weight of less than 5,000 Da!tons. More preferably, a small molecule has a molecular weight of between 100 and 1,500 Daltons.
As used herein, "effective amount "or "pharmaceutically effective amount" of an active agent refers to an amount sufficient to derive a measurable change in a physiological parameter of the target cell or subject and/or to provide or modulate active is agent expression or activity through administration of one or more of the pharmaceutical dosage units. Such effective amount may vary from person to person depending on their condition, height, weight, age, and/or health, the mode of administering the active agent (e.g., urease or urease modulator), the particular active agent administered, and other factors. As a result, it may be useful to empirically determine an effective amount 20 for a particular patient under a particular set of circumstances.
The term "specific therapeutic efficacy" of an active agent as used herein means the amount of an active agent which isTequirecl to achieve a specified amount or degree of therapeutic efficacy, e.g., by inhibition of cancer cell growth or killing of cancer cells or shrinkage of tumor size.
II. Compositions used in the treatment methods This section considers the urease composition and anti-cancer compounds used in practicing the method of the invention.
A. Urease composition As noted above, the urease composition includes urease enzyme and may additional include a targeting agent associated with the enzyme for localizing urease at a target, e.g., tumor site. The urease may be of any origin, including, e.g., bacteria, plants, fungi and viruses. A number of studies have provided detailed information about the genetics of ureases from a variety of evolutionarily diverse bacteria, plants, fungi and viruses (Mobley, H.L.T. etal. (1995) Microbiol. Rev. 59: 451-480; Eur. J.
Biochem., 175, 151-165 (1988); Labigne, A. (1990) International publication No. WO
90/04030;
Clayton, C. L. et at. (1990) Nucleic Acid Res. 18, 362; and U.S. Patent Nos.
6,248,330 and 5,298,399). Of particular interest is urease that is found in plants (Sirko, A. and Brodzik, R. (2000) Acta Biochim Poi 47(4):1189-95). One exemplary plant urease is jack bean urease, which is described in Examples 2-3. An exemplary amino acid sequence of jack bean urease is represented by SEQ ID NO: 1 below.
Useful urease sequences may be identified in public databases, e.g., Entrez.
Additionally, primers that are useful for amplifying .. ureases from a wide variety of organisms may be utilized as described by Baker, K. M.
and Collier, J. L.
or using the CODEHOP (COnsensus-DEgenerate Hybrid Oligonucleotide Primer) as described in Rose, etal. (1998) Nucl. Acids Res.
26:1628.
The urease may contact the tumor cells, be positioned in the extracellular zo environment or interstitial fluid surrounding the tumor cells, or be expressed within the cancer cells or cells nearby the cancer cells. While not wishing to be bound by any specific molecular mechanisms underlying the successful inhibition of growth of cancer cells by urease, the urease compound acts to raise the pH of interstitial fluid in which the cancer cells are bathed, by conversion of urea, which is typically present in an amount between about 1-8 mM , typically about 1.5-5 mM urea, in interstitial or extracellular fluid, to ammonia and carbamate (Figs. 1A-1D). The environment around a cancer cell is typically acidic, e.g., about 6.8, (Webb, S.D., etal. (2001) Novartis Found Symp 240:169-81). Thus, by raising the pH of the extracellular environment in this manner, growth of the cancer cell is inhibited. Accordingly, addition of the active agent in certain embodiments of the invention causes the pH of the interstitial fluid to be raised by about 0.1 pH unit, e.g., 0.1 ¨ 0.5 pH units or greater.
Thus, active agents of the urease composition include the naturally occurring forms of urease as well as functionally active variants thereof. The nature of these active variants is more fully described in the above cited, co-owned U.S.
patent application (publication No. 2004/0115186 Al, also referred to herein as the '186 application) , Al Taraeting agent The urease composition employed in the method of the invention may include a chemical entity associated with urease to enhance its localization at target cancer cells.
A variety of associated chemical entities are contemplated and are described in the above-cited, co-owned 186 application. One preferred chemical entity is covalently bound targeting agent, also as detailed in the '186 application. As described there, io targeting moieties useful in localizing the urease composition to a target site include antibodies and antibody fragments, peptides, and hormones, Proteins corresponding to known cell surface receptors (including low density lipoproteins, transferrin and insulin), fibrinolytic enzymes, antl-HER2, platelet binding proteins such as annexins, and biological response modifiers (including interleukin, interferon, erythropoietin and is colony-stimulating factor) are also contemplated targeting moieties.
Oligonucleotides, e.g., antisense oligonucleotides that are complementary to a portion of a target cell nucleic acid, may be used as targeting moieties in the present invention. Targeting moieties may also be oligonucleotides that bind to a target cell surface, Analogs of the above-listed targeting moieties that retain the ability to bind to a 20 defined target cell population may also be used as targeting moieties.
Preferred targeting moieties of the present invention are antibodies, peptides, oligonucleotides or the like, that are reactive with an antigen on the surface of a target cell. Both polyclonal and monoclonal antibodies which are either available commercially or described in the literature may be employed. The antibodies may be whole z5 antibodies or fragments thereof. Monoclonal antibodies and fragments may be produced in accordance with conventional techniques, such as hybridoma synthesis, recombinant DNA techniques and protein synthesis. Useful monoclonal antibodies and fragments may be derived from any species (including humans) or may be formed as chimeric proteins which employ sequences from more than one species. In one 30 embodiment, the antibody is a single-chain antibody derived form a mammalian germline, e.g., llama germline. Methods for preparing conjugate composition between urease and such targeting agents are detailed in the above-cited '186 application.
A2. Entrapped Active Agents , In certain embodiments, the invention contemplates the use of vesicles such as liposomes and/or nanocapsules as chemical entities for the delivery of an active agent or active agents, e.g., urease to cancer cells. Such formulations may be preferred for the introduction of pharmaceutically-acceptable formulations of the polypeptides, pharmaceuticals, and/or antibodies disclosed herein. The formation and use of liposomes is generally known to those of skill in the art. (See, e.g., Backer, M.V., et al.
(2002) Bioconjug Chem 13(3):462-7). In a preferred embodiment, the disclosed composition may be entrapped in a liposome. Particle-entrapped urease compositions suitable for use in the invention are detailed in the above-cited '186 application.
A3. Urease inhibitor or activator Active agent modulators are also contemplated as associated chemical entities by the instant invention. A preferred active agent modulator is a urease modulator. A
"urease modulator" is either an inhibitor of urease or an enhancer of urease.
The modulator in the compositions (e.g., pharmaceutical compositions) accordingly may be selected from among all or portions of urease polynucleotide sequences, urease antisense molecules, urease polypeptides, protein, peptide, or organic modulators of urease bioactivity, such as inhibitors, antagonists (including antibodies) or agonists.
Preferably, the modulator is active in treating a medical condition that is mediated by, or , ameliorated by, urease expression or urease activity.
An "inhibitor of urease" comprises a molecule or group of molecules that interferes with: (1) the expression, modification, regulation, activation or degradation of urease: or (2) one or more of the normal functions of urease, including the hydrolysis of urea leading to the production of carbamate and ammonia. An inhibitor "acts directly on urease" when the inhibitor binds to urease via electrostatic or chemical interactions.
Such interactions may or may not be mediated by other molecules. Where the inhibitor acts directly on urease, such as where the inhibitor is a reversible inhibitor, a preferred inhibitor will dissociate from urease when urease is diluted in the blood circulatory system and/or when it reaches its cellular target. An inhibitor acts "indirectly on urease"
when its most immediate effect is on a molecule other than urease which influences the expression, activation or functioning of urease.
Urease inhibitors, which serve to slow the conversion of urea to ammonium ions, include but are not limited to hydroxamic acid derivatives and other urea analogs, (e.g., acetohydroxamic acid), phosphoramide derivatives (e.g., flurofamide), phosphates, thiols (e.g., 2-mercaptoethanol etc.), boric acid, halogen compounds (e.g., fluorides etc.), and cassia bark extract. Additional urease inhibitors are known to those of skill in the art and are described in U.S. Pat. No, 4,824,783 (Apr. 25, 1989).
The effect of a urease inhibitor, such as s acetohydroxamic acid (AHA), on urease cytotoxicity in tumor cells in culture is seen in Example 9. In this example, it is seen that tumor cells are protected from urease cytotoxidty in the presence of a urease inhibitor. Therefore, possible toxicity to the patient caused by local high concentrations of urease can be mitigated through the use of a urease inhibitor, such as AHA, especially when the enzyme is applied in bolus form.
to e.g., by IV drip, to reduce localized toxicity effects. AHA is commercially available under the trade name Lithostate, and has been approved for human use.
An "enhancer of urease" comprises a molecule or group of molecules that enhances: (1) the expression, modification, regulation or activation of urease; or (2) one or more of the normal functions of urease. An enhancer "acts directly on urease" when is the enhancer binds to urease via electrostatic or chemical interactions.
Such interactions may or may not be mediated by other molecules. An enhancer acts Indirectly on urease" when its most immediate effect is on a molecule other than urease which influences the expression, activation or functioning of urease.
In accordance with one aspect of the invention, a urease composition includes a 20 urease and an inhibitor, e.g., AHA, at a mole ratio of urease:inhibitor sufficient to bind to all of the urease active sites, e.g., all six active sites of a normal bacterial urease. This composition therefore contains inhibitor and urease at a mole ratio of 6:1 or greater, e.g., 10:1 inhibitorurease. At the relatively high concentration of urease employed injected or infused into a patient, the majority of the inhibitor will be in bound form, thus 25 inhibiting strongly inhibiting the activity of the enzyme and reducing enzyme toxicity at and near the site of administration. As the urease is carried toward the target site, e.9-, in the bloodstream, it will become more dilute, shifting the kinetics of inhibitor binding toward its unbound form, and thereby releasing the inhibitory effect on the enzyme with migration toward the target.
30 A pharmaceutical composition that includes urease enzyme and a urease inhibitor, such as the inhibitors previously described herein, may include at least about 1000 Units urease, where the concentration of enzyme and inhibitor will be determined by the solution volume to be infused or injected. Thus, a composition injected in a total volume of 10 ml will have a urease concentration 1/100 of that intended slow IV infusion in a 1 liter volume. The concentration of urease in the composition, when in aqueous form, is preferably at least about 20 Units/ml.
B. Weakly basic anti-cancer agents The method of the invention is based on the discovery herein that exposing cancer cells to urease, i.e., by localizing urease at the site of cancer in a mammalian subject, is effective in potentiating the anti-cancer effect of a weakly basic anti-cancer compound that is effective against that cancer. This effect may be exploited, in ro accordance with the invention, to achieve a comparable therapeutic effect at a reduced compound dose, e.g., a dose that is 2-5 fold lower than that otherwise required, and/or to achieve a superior therapeutic effect at the same or reduced dose.
Weakly basic anti-cancer compounds include any anti-cancer compound having one or more ionizable primary or secondary amine groups, and whose uptake into is cancer cells may be affected by the intracellular/lower extracellular pH
gradient in the extracellular environment of the cells. Exemplary weakly basic anti-cancer compounds include doxorubicin, daunorubicin, mitoxantrone, epirubicin, mitomycin, bleomycin, vinca alkaloids, such as vinblastine and vincristine, alkylating agents, such as cyclophosphamide and mechlorethamine hydrochloride, antineoplastic purine 20 derivatives, including cladribine, fludarabine, 6-mercaptopurine, thiamiprine, thioguanine or tiazofurin, and anti-neoplastic pyrimidine derivatives, including ancitabine, azacitidine, 6-azauridine, capecitabine, carmofur, cytarabine, decitabine, doxifluridine, emitefur, enocitabine, floxuridineõ gemcitabine or tegafur.
Although the invention is directed potentiating the anti-cancer effect of weakly 25 basic anti-cancer drugs, urease also appears to potentiate the anti-cancer effect of other anti-cancer drugs, such as fluorouracil (see examples below). The potentiating effect may be related to a shift in extracellular or intracellular pH caused by urease, or may involve one or more other mechanisms related to the anti-cancer effects of urease alone, detailed in the above-cited '186 application. Thus, in a more general aspect, the 30 present invention contemplates potentiating the anti-cancer activity of any anti-cancer compound, such as fluorouracil, whose activity is enhanced by the presence, in the extracellular fluid of target cancer cells, of an amount of urease effective to raise the pH
of such extracellular fluid.
C. pH-sensitive imaging agents Imaging agents may be included in the composition or in additional compositions, as detailed in the above-cited 1168 application. Of particular interest for the present invention are pH sensitive imaging agents that can be used to detect and monitor changes in the local pH environment of cancer cells, e.g., the extracellular matrix of a solid tumor. Thus, for example, in practicing the present invention, it may be advantageous, in determining a suitable initial dose of the urease composition, to monitor the subject tumor site for urease-induced pH changes. Typically, an increase in pH of at least 0.1 pH units is desired, with changes of between 0.1 to 0.5 pH
units or to greater being typical.
Both luminescent cyden-based lanthanide &elates and those primarily yielding magnetic resonance signatures have been shown to be sensitive to changes in pH.
Luminescent probes used for sensing pH changes typically detect changes in the fluorescence lifetime of the lanthanide ion as a function of pH. Analogously, magnetic 3 resonance contrast agents which modulate the water proton relaxivity via changes in pH
are useful in the instant invention. In both cases, by changing the pH in a given system, one can envision agents with enhanced contrast.
Accordingly, a pH sensitive contrast agent is utilized at or near the cancer cell.
The cancer cell or cells are also exposed to a urease composition containing urease 20 enzyme to cause a change in pH at or near the cancer cell. In this way, a change in p1-1 causes the nuclear magnetic resonance relaxation properties of water protons or other nuclei in the aqueous medium to be changed in a manner that is reflective of pH.
Examples of pH sensitive contrast agents that may be utilized include those agents that contain a lanthanide metal, such as Ce, Pr, Nd, Sm, Eu, Gd, Db, Dy, Ho, Er, Tm, Yb, 25 and the like, or another paramagnetic element, such as Fe, Mn, or the like. Specific contrast agents that may be utilized include GdDOTA-4AmP(5-) which is described in Magn Reson Mad, 2003 Feb;49(2):249-57, and Fe(III)meso-tetra(4-sulfonatophenyl)porphine (Fe-TPPS4) as described in Helpem at al. (1987) Magnetic Resonance in Medicine 5:302-306 and U.S. Patent No. 6,307,372..
30 In addition, Gd based with polyion, as described in Mikawa et al. Acad. Radio! (2002) 9(suppl 1):S109-S1111, may be used in the invention.
As another alternative, a shift reagent may be provided in the aqueous medium =
, surrounding the cancer cell. The shift reagent is configured such that a change in pH
affects the chemical shift properties of the water protons or other nuclei in a manner that is reflective of pH. The change in chemical shift properties may then be measured using nuclear magnetic resonance to determine whether the active agent is biologically active. Examplary shift reagents that may be used include those containing a lanthanide metal, such as Ce, Pr, Nd, Sm, Eu, Gd, Db, Dy, Ho, Er, Tm, or Yb, or another paramagnetic element. Examples of specific shift reagents that may be utilized include Tm(DOTP) (5-), the thulium (III) complex of 1,4,7,10-tetraazacylododecane-N, N',N",N'"-tetra(methylenephospate). Dy(PPP) (2)(7)-dysprosium tripolyphosphate, and the like.
In one embodiment of the invention, a dual-contrast-agent strategy using two gadolinium agents, such as the pH-insensitive GdDOTP(5-) and the pH-sensitive GdDOTA-4AmP(5-), may be utilized to generate pH maps by MRI, as described in Magn Reson Med (2003) Feb;49(2):249-57. Preferred agents for use with PET scan include 13N and fluorodeoxyglucose (FDG).
III. Method of potentiating a weakly basic anticancer compound The present invention provides a method of potentiating the specific therapeutic activity of a weakly basic anti-cancer compound in the treatment of a mammalian cancer that is responsive to that compound. In one general embodiment, a method includes administering to the subject an amount of a urease composition which, when given in the presence of urease, e.g., either by co-administration of urease and the compound or following administration or urease, is effective to reduce the amount of the compound needed to achieve a selected anti-cancer effect, e.g., tumor shrinkage.
The degree of potentiation achievable with the invention will depend upon a number of factors that can be readily assessed during treatment, and the compound dosaging can be adjusted accordingly during treatment. To the extent the potentiation of weakly basic anti-neoplastic agents is attributable to a shift in the external/internal pH
gradient of the cancer cells, the extent of potentiation will depend on the extent to which the shift in gradient enhances drug uptake. For example, compounds that are readily taken up with ambient gradients may show less potentiation than those whose uptake is strongly affected by a pH change in the range 6.8 to about 7.2 or higher.
Similarly, where the cancer cells have developed drug resistance that relies on pumping drug out of the cells, the tirease potentiation effect may be less pronounced. That is, the degree or extent of potentiation achieved will depend on a variety of factors, including the pK or pKas of the drug amine group(s); the presence or absence of drug-resistance mechanisms in the cancer cells, including those related to drug transport; the presence or absence of drug-specific transport mechanisms in the cancer cells; and the solubility of the drug in a lipid membrane. In a typical method, the extent of potentiation is between 2 and 5 fold; that is, the amount of compound needed to produce a given anti-cancer effect is 2- to 5-fold lower when the cells are pretreated by urease.
In selecting a weakly basic anti-cancer drug for treating a particular cancer, the physician will typically select a compound that has been routinely used or has demonstrated effectiveness against the particular type of cancer being treated. Table 2 below provides a partial list of weakly basic anti-cancer drugs that have been shown to be effective against a variety of human cancer types, as indicated in the table.
Table 2 Weakly Basic Agents Used in Cancer Treatment Which Can Be Potentiated by Increased Extracellular pH
Compound Application Comments Doxorubicin Breast Cancer An anthracycline (Adriamycin , Ovarian Cancer antibiotic from the Rubex , Doxil , Lung Cancer fungus Strep. It Caelyx , Myocete) Bladder Cancer interferes with DNA
Gastric Cancer production in the cell Thyroid Cancer Daunomycin Acute Myelogenous An anthracycline (Cerubidinee) Leukemia antibiotic. It interferes Acute Lymphocytic with DNA production Leukemia in the cell Epirubicin (Ellencee) Breast Cancer An anthracycline antibiotic. It interferes with DNA production in the cell Vinblastine (Velban , Breast Cancer A vinca alkaloid. It Velbee) Hodgkin's Disease inhibits cell division Kaposi's Sarcoma during early mitosis Testicular Cancer Vincristine (Oncovin , Acute Leukemia A vinca alkaloid. It Vincasar PFS , Rhabdoyosarcoma inhibits cell division Vincrexe) Neuroblastoma during early mitosis Lymphorecticular ¨ ______________________ Neoplasms Mitoxantrone Prostate Cancer An intercalating agent (Novantronee) Acute Nonlymphocytic that interacts with Leukemia DNA and blocks DNA
synthesis Bleomycin Squamous Cell A mixture of cytotoxic (Blenoxane8) Carcinomas antibiotics, thought to Hodgkin's Disease inhibit DNA synthesis Non-Hodgkin's and, to a lesser Lymphoma degree, RNA and Testicular Cancer protein synthesis Mitomycin Gastric Cancer An alkylating agent. It (Mutamycine) Anal Cancer is thought to inhibit Colon Cancer cell growth by causing Breast Cancer inter/intrastrand Non-Small Cell Lung crosslinkages in DNA, Cancer thereby causing Head and Neck Cancer miscoding, breakage Small Bladder and replication failures Papillomas Pancreatic Cancer Cervical Cancer Mechlorethamine Hodgkin's Disease An alkylating agent. It Hydrochloride is thought to inhibit (Mustargone) cell growth by causing inter/intra strand crosslinkages in DNA, thereby causing miscoding, breakage and replication failures In the treatment method, the subject is typically pretreated with a selected dose of the urease composition. Where a urease composition is injected directly into a tumor, an exemplary dose is 0.1 to 1,000 international units urease activity per mm3 tumor. For example, and assuming a relatively uniform distribution of the urease in the tumor is achieved, a dose of between 0.5 and 5 international units may be suitable. The placement of the injection needle may be guided by conventional image guidance techniques, e.g., fluoroscopy, so that the physician can view the position of the needle with respect to the target tissue. Such guidance tools can include ultrasound, fluoroscopy, CT, MRI, pr PET scan.
The effectiveness or distribution of the administered urease dose may be monitored, during or after direct injection of urease into the tumor, by monitoring the tumor tissue by a tool capable of detecting changes in pH within the cancerous tissue , region of the subject. Such tools may include a pH probe that can be inserted directly into the tumor, or a visualization tool, such as magnetic resonance imaging (MRI), computerized tomography (CT), or fluoroscopy. MRI interrogation may be carried out in the absence of additional imaging agents, based simply on differences in magnetic properties of tissue as a function of pH. CT or fluoroscopic imaging may require an additional pH-sensitive imaging agent whose opacity is affected by the pH of the tissue medium. Such agents are well known to those of skill in the art.
Before any urease injection, the tumor tissue can be visualized by its lower pH
relative to surrounding normal tissue. Thus, the normal tissue may have a normal pH of about 7.2, whereas the tumor tissue may be 0.1 to 0.4 or more pH units lower.
That is, before any urease is injected, the extent of tumor tissue can be defined by its lower pH.
Following urease administration, the pH of the tumor region having urease will begin to rise, and can be identified by comparing the resulting images with the earlier pre-dosing images.
By interrogating the tissue in this manner, the degree of change in pH and extent of tissue affected may be monitored. Based on this interrogation, the physician may administer additional urease composition to the site, and/or may administer composition at additional areas within the tumor site. This procedure may be repeated until a desired degree of pH changes, e.g., 0.2 to 0.4 pH units, has been achieved over the entire region of solid tumor.
Where the urease is administered parenterally by a method other than direct injection, e.g., by IV drip, an exemplary dose of the urease is 100-100,000 international units urease activity/kg subject body weight, or alternatively, between about pmoles, preferably 25-500 pmolesurease/kg subject body weight. As noted herein, the urease composition in this method preferably includes a targeting agent for targeting urease to the cancer cells, e.g., site of solid tumor, or for sequestering urease, e.g., in liposomal form, selectively at the tumor site. The composition described above containing urease in combination with stoichiometric amounts of an inhibitor is advantageous in intravenous administration for the reasons discussed above. As above, imaging techniques that are sensitive to changes in tissue pH, may be used to monitor urease dosing.
Where the urease composition is given by IV injection or drip, the urease is typically allowed to clear from the bodypil for a period of at least 24 hours prior to administration of the anti-cancer compound. The rate of clearance can be accelerated, if desired, by administering a clearing agent, such as an anti-urease antibody, that facilitates clearance by non-renal clearance mechanisms. Such methods are well known.
Once an adequate dose of the urease composition has been administered and localized at the target site, and preferably after a period that allows for clearance of a significant portion of the circulating urease, the anti-cancer compound is administered by conventional dosing methods, e.g., oral administration or IV drip.
According to an important feature of the invention, the urease localized at the cancer site potentiates the io anti-cancer drug, allowing a significantly reduced dose of the compound to be administered, and/or a greater therapeutic efficacy to be achieved at the same or reduced dose. As noted above, the reduction in dose of anti-cancer compound is typically 2- to 5-fold over that in the absence of urease, and these values can be used as a guide to dosing in the method. Thus, the physician may start with a dose that is %
that of conventional dosing, and if a good therapeutic result is achieved, the dose could be reduced further until a lowest effective dose is reached. Preferably, the dose administered will be the highest dose compatible with patient comfort and lack of undesired side effects, such as nausea, alopecia, malaise, and loss of a significant portion of white blood cells, allowing effective cancer therapy with substantially reduced discomfort and long-term risk to the patient.
In a typical anti-cancer treatment, the anti-cancer drug is administered at twice or three-times weekly dosing over a 2-4 week period, followed by a recovery and observation period of one to several months. In the present invention, this regimen may be supplemented by urease administration preceding each dosing, or preceding each dosing period, e.g., once a week or once every other week during the period of compound treatment. The frequency of urease administration may be assessed during treatment by periodic assessment of localized pH levels at the cancer site, using the above pH monitoring tools.
During the course of treatment, the size and shape of a tumor may be monitored .. by diagnostic tools, such as those described above. In particular, the subject can be interrogated with a diagnostic tool capable of detecting changes in extracellular pH in a subject's tissue, as described above. The diagnostic tool is preferably a pH-sensitive diagnostic agent, such as an imaging, contrast or shift reagent, as described in Section II, above, capable of localizing in the tumor that may be administered prior to, following or concurrently with the active agent. A tissue region is identified within the subject that shows an elevation in extracellular pH following the administration. Any tool capable of identifying the diagnostic agent may be used to detect the agent, such as MRI, PET
.. scan, and the like, as described above.
In one embodiment, the method includes administering urease to the subject employed in an anti-cancer therapy, and the identification is used for detecting the localization of urease in a solid tumor. The identifying may be used for monitoring the change in size and shape of the tumor in response to urease administration.
io In one embodiment employing PET scan, the subject is administered 13N-labelled ammonia. The patient is then administered urease in an amount effective to reach the tumor site. The urease hydrolyzes urea to produce non-labelled ammonia. Over time, the labelled ammonia is diluted or displaced, causing a gradual clearing on the scan.
In another embodiment employing PET scan, the subject is administered 13N-labelled urea. The patient is then administered urease in an amount effective to reach the tumor site. The urease hydrolyzes the labelled urea to produce labelled ammonia, which could be detected on the scan.
From the foregoing, it can be seen how various objects and features of the invention are met. The invention provides an effective and relatively simple method for potentiating the therapeutic effect of a large class of anti-cancer compounds.
This potentiation allows a comparable or superior anti-cancer effect to be achieved at a lower dose of compound, thus reducing patient discomfort, health risks to the patient, and improving patient compliance and prospects for recovery. The dosing and localization of urease can be readily monitored, according to localized pH changes, and these same changes can be used to monitor the efficacy of the treatment method, and to monitor the urease dosing administered.
The following examples further illustrate the invention described herein and are in no way intended to limit the scope of the invention.
A. Example 1 Al. Peptide Synthesis Peptides were prepared by solid-phase synthesis methodology using conventional N-t-butyloxycarbonyl (t-Boc) chemistry. Peptides were cleaved from the resin by reaction with hydrogen fluoride (20 ml/g resin) containing 10%
anisole and 2%
1,2-ethaneclithiol for 1.5 h at 4 C. Crude peptides were washed with cold ether, and extracted from the resin with glacial acetic acid and freeze-dried. Synthetic peptide was purified by reversed-phase HPLC on a Zorbax semi-preparative C-8 column (250 x
Antibodies include single chain antibodies, including single chain Fv (sFv) antibodies in which a VH
and a VL are joined together (directly or through a peptide linker) to form a continuous polypeptide. One preferred antibody is a single-chain antibody derived from a human germline.
An "antigen-binding fragment" of an antibody is a peptide or polypeptide fragment to of the antibody that binds an antigen. An antigen-binding site is formed by those amino acids of the antibody that contribute to, are involved in, or affect the binding of the antigen. See Scott, T. A. and Mercer, E. I., CONCISE ENCYCLOPEDIA:
BIOCHEMISTRY AND MOLECULAR BIOLOGY (de Gruyter, 3d ed. 1997) and Watson, J. D. et al., RECOMBINANT DNA (al ed. 1992),.
The term "antibody fragment" also includes any synthetic or genetically engineered protein that acts like an antibody by binding to a specific antigen to form a complex.
The terms "active agent", "drug" and "pharmacologically active agent' are used interchangeably herein to refer to a chemical material or compound which, when ao administered to a subject induces a desired pharmacologic effect, and is intended to include a diagnostic or therapeutic agent, including radionuclides, drugs, anti-cancer agents, toxins and the like. Preferably, the terrn active agent includes proteins, glycoproteins, natural and synthetic peptides, alkaloids, polysaccharides, nucleic acid molecules, small molecules and the like. More preferably, the term active agent refers to proteins. An exemplary active agent is urease.
= A "pH-sensitive" active agent refers to an active agent whose ability to induce a desired pharmacologic effect depends, at least in part, on the pH of the surrounding extracellular environment.
The term "clearing agent", as used herein, refers to an agent capable of binding, cOMpleXing or otherwise associating with an administered moiety, e.g., targeting moiety-ligand, targeting moiety-anti-ligand or anti-ligand alone, present in the recipient's circulation, thereby facilitating circulating moiety clearance from the recipient's body, removal from blood circulation, or inactivation thereof in circulation. The clearing agent is preferably characterized by physical properties, such as size, charge, configuration or a combination thereof, that limit clearing agent access to the population of target cells recognized by a targeting moiety used in the same treatment protocol as the clearing agent.
The term "imaging agent" is meant to refer to compounds which can be detected.
The term "adjuvant" refers to a substance or agent added to a formulation or composition to aid the operation of the main ingredient.
The terms "interstitial" and "extracellular" fluid refer to the fluid lying between or bathing the cells of mammals.
The terms "subject", "individual" and "patient" are used interchangeably herein to refer to any target of the treatment. Also provided by the present invention is a method of treating tumor cells in situ, or in their normal position or location, for example, neoplastic cells of breast or prostate tumors. These in situ tumors can be located within or on a wide variety of hosts; for example, human hosts, canine hosts, feline hosts, equine hosts, bovine hosts, porcine hosts, and the like. Any host in which is found a tumor or tumor cells can be treated and is in accordance with the present invention. A
subject thus includes a vertebrate, preferably a mammal, more preferably a human.
By "target cell retention time" is intended the amount of time that a urease molecule or other active agent remains at the target cell surface or within the target cell.
As used herein, the term "conjugate" encompasses chemical conjugates (covalently or non-covalently bound), fusion proteins and the like.
The terms "protein", "polypeptide" or "peptide", as used herein, refer interchangeably to a biopolymer composed of amino acid or amino acid analog subunits, typically some or all of the 20 common L-amino acids found in biological proteins, linked by peptide intersubunit linkages, or other intersubunit linkages. The protein has a primary structure represented by its subunit sequence, and may have secondary helical or pleat structures, as well as overall three-dimensional structure. Although "protein"
commonly refers to a relatively large polypeptide, e.g., containing 100 or more amino acids, and "peptide" to smaller polypeptides, the terms are used interchangeably herein.
That is, the term "protein" may refer to a larger polypeptide, as well as to a smaller peptide, and vice versa.
A "modulator of urease" is either an inhibitor of urease or an enhancer of urease.
An "inhibitor of urease" comprises a molecule or group of molecules that interferes with: (1) the expression, modification, regulation, activation or degradation of urease; or (2) one or more of the normal functions of urease. The normal functions of urease include the hydrolysis of urea, leading to the production of carbamate and ammonia. An inhibitor "acts directly on urease" when the inhibitor binds to urease via electrostatic or chemical interactions. Such interactions may or may not be mediated by other molecules. An inhibitor acts "indirectly on urease" when its most immediate effect is on a molecule other than urease which influences the expression, activation or functioning of urease.
io An "enhancer of urease" comprises a molecule or group of molecules that enhances: (1) the expression, modification, regulation or activation of urease; or (2) one or more of the normal functions of urease. An enhancer acts "indirectly on urease"
when its most immediate effect is on a molecule other than urease which influences the expression, activation or functioning of urease.
The term "pharmaceutical composition" means a composition suitable for pharmaceutical use in a subject, including an animal or human. A
pharmaceutical composition generally comprises an effective amount of an active agent and a carrier, including, e.g., a pharmaceutically acceptable carrier.
A "pharmaceutically acceptable formulation" comprises a formulation that is suitable for administering the active agent (e.g., urease or urease modulator) in a manner that gives the desired results and does not also produce adverse side effects sufficient to convince a physician that the potential harm to a patient is greater than the potential benefit to that patient. The basic ingredient for an injectable formulation is typically a water vehicle. Aqueous vehicles that are useful include sodium chloride .. (NaCl) solution, Ringer's solution, NaCl/dextrose solution, and the like.
Water-miscible vehicles are also useful to effect full solubility of the active agent.
Antimicrobial agents, buffers and antioxidants may be useful, depending on the need. Similarly, a "pharmaceutically acceptable" salt or a "pharmaceutically acceptable"
derivative of a compound, as provided herein, is a salt or other derivative which is not biologically or otherwise undesirable.
A "therapeutic treatment" is a treatment administered to a subject who displays symptoms or signs of pathology, disease, or disorder, in which treatment is administered to the subject for the purpose of diminishing or eliminating those signs or symptoms of pathology, disease, or disorder. A "therapeutic activity" is an activity of an agent, such as a nucleic acid, vector, gene, polypeptide, protein, substance, or composition thereof, that eliminates or diminishes signs or symptoms of pathology, disease or disorder, when administered to a subject suffering from such signs or symptoms. A "therapeutically useful" agent or compound (e.g., nucleic acid or polypeptide) indicates that an agent or compound is useful in diminishing, treating, or eliminating such signs or symptoms of a pathology, disease or disorder.
The term "small molecule" includes a compound or molecular complex, either synthetic, naturally derived, or partially synthetic, and which preferably has a molecular lo weight of less than 5,000 Da!tons. More preferably, a small molecule has a molecular weight of between 100 and 1,500 Daltons.
As used herein, "effective amount "or "pharmaceutically effective amount" of an active agent refers to an amount sufficient to derive a measurable change in a physiological parameter of the target cell or subject and/or to provide or modulate active is agent expression or activity through administration of one or more of the pharmaceutical dosage units. Such effective amount may vary from person to person depending on their condition, height, weight, age, and/or health, the mode of administering the active agent (e.g., urease or urease modulator), the particular active agent administered, and other factors. As a result, it may be useful to empirically determine an effective amount 20 for a particular patient under a particular set of circumstances.
The term "specific therapeutic efficacy" of an active agent as used herein means the amount of an active agent which isTequirecl to achieve a specified amount or degree of therapeutic efficacy, e.g., by inhibition of cancer cell growth or killing of cancer cells or shrinkage of tumor size.
II. Compositions used in the treatment methods This section considers the urease composition and anti-cancer compounds used in practicing the method of the invention.
A. Urease composition As noted above, the urease composition includes urease enzyme and may additional include a targeting agent associated with the enzyme for localizing urease at a target, e.g., tumor site. The urease may be of any origin, including, e.g., bacteria, plants, fungi and viruses. A number of studies have provided detailed information about the genetics of ureases from a variety of evolutionarily diverse bacteria, plants, fungi and viruses (Mobley, H.L.T. etal. (1995) Microbiol. Rev. 59: 451-480; Eur. J.
Biochem., 175, 151-165 (1988); Labigne, A. (1990) International publication No. WO
90/04030;
Clayton, C. L. et at. (1990) Nucleic Acid Res. 18, 362; and U.S. Patent Nos.
6,248,330 and 5,298,399). Of particular interest is urease that is found in plants (Sirko, A. and Brodzik, R. (2000) Acta Biochim Poi 47(4):1189-95). One exemplary plant urease is jack bean urease, which is described in Examples 2-3. An exemplary amino acid sequence of jack bean urease is represented by SEQ ID NO: 1 below.
Useful urease sequences may be identified in public databases, e.g., Entrez.
Additionally, primers that are useful for amplifying .. ureases from a wide variety of organisms may be utilized as described by Baker, K. M.
and Collier, J. L.
or using the CODEHOP (COnsensus-DEgenerate Hybrid Oligonucleotide Primer) as described in Rose, etal. (1998) Nucl. Acids Res.
26:1628.
The urease may contact the tumor cells, be positioned in the extracellular zo environment or interstitial fluid surrounding the tumor cells, or be expressed within the cancer cells or cells nearby the cancer cells. While not wishing to be bound by any specific molecular mechanisms underlying the successful inhibition of growth of cancer cells by urease, the urease compound acts to raise the pH of interstitial fluid in which the cancer cells are bathed, by conversion of urea, which is typically present in an amount between about 1-8 mM , typically about 1.5-5 mM urea, in interstitial or extracellular fluid, to ammonia and carbamate (Figs. 1A-1D). The environment around a cancer cell is typically acidic, e.g., about 6.8, (Webb, S.D., etal. (2001) Novartis Found Symp 240:169-81). Thus, by raising the pH of the extracellular environment in this manner, growth of the cancer cell is inhibited. Accordingly, addition of the active agent in certain embodiments of the invention causes the pH of the interstitial fluid to be raised by about 0.1 pH unit, e.g., 0.1 ¨ 0.5 pH units or greater.
Thus, active agents of the urease composition include the naturally occurring forms of urease as well as functionally active variants thereof. The nature of these active variants is more fully described in the above cited, co-owned U.S.
patent application (publication No. 2004/0115186 Al, also referred to herein as the '186 application) , Al Taraeting agent The urease composition employed in the method of the invention may include a chemical entity associated with urease to enhance its localization at target cancer cells.
A variety of associated chemical entities are contemplated and are described in the above-cited, co-owned 186 application. One preferred chemical entity is covalently bound targeting agent, also as detailed in the '186 application. As described there, io targeting moieties useful in localizing the urease composition to a target site include antibodies and antibody fragments, peptides, and hormones, Proteins corresponding to known cell surface receptors (including low density lipoproteins, transferrin and insulin), fibrinolytic enzymes, antl-HER2, platelet binding proteins such as annexins, and biological response modifiers (including interleukin, interferon, erythropoietin and is colony-stimulating factor) are also contemplated targeting moieties.
Oligonucleotides, e.g., antisense oligonucleotides that are complementary to a portion of a target cell nucleic acid, may be used as targeting moieties in the present invention. Targeting moieties may also be oligonucleotides that bind to a target cell surface, Analogs of the above-listed targeting moieties that retain the ability to bind to a 20 defined target cell population may also be used as targeting moieties.
Preferred targeting moieties of the present invention are antibodies, peptides, oligonucleotides or the like, that are reactive with an antigen on the surface of a target cell. Both polyclonal and monoclonal antibodies which are either available commercially or described in the literature may be employed. The antibodies may be whole z5 antibodies or fragments thereof. Monoclonal antibodies and fragments may be produced in accordance with conventional techniques, such as hybridoma synthesis, recombinant DNA techniques and protein synthesis. Useful monoclonal antibodies and fragments may be derived from any species (including humans) or may be formed as chimeric proteins which employ sequences from more than one species. In one 30 embodiment, the antibody is a single-chain antibody derived form a mammalian germline, e.g., llama germline. Methods for preparing conjugate composition between urease and such targeting agents are detailed in the above-cited '186 application.
A2. Entrapped Active Agents , In certain embodiments, the invention contemplates the use of vesicles such as liposomes and/or nanocapsules as chemical entities for the delivery of an active agent or active agents, e.g., urease to cancer cells. Such formulations may be preferred for the introduction of pharmaceutically-acceptable formulations of the polypeptides, pharmaceuticals, and/or antibodies disclosed herein. The formation and use of liposomes is generally known to those of skill in the art. (See, e.g., Backer, M.V., et al.
(2002) Bioconjug Chem 13(3):462-7). In a preferred embodiment, the disclosed composition may be entrapped in a liposome. Particle-entrapped urease compositions suitable for use in the invention are detailed in the above-cited '186 application.
A3. Urease inhibitor or activator Active agent modulators are also contemplated as associated chemical entities by the instant invention. A preferred active agent modulator is a urease modulator. A
"urease modulator" is either an inhibitor of urease or an enhancer of urease.
The modulator in the compositions (e.g., pharmaceutical compositions) accordingly may be selected from among all or portions of urease polynucleotide sequences, urease antisense molecules, urease polypeptides, protein, peptide, or organic modulators of urease bioactivity, such as inhibitors, antagonists (including antibodies) or agonists.
Preferably, the modulator is active in treating a medical condition that is mediated by, or , ameliorated by, urease expression or urease activity.
An "inhibitor of urease" comprises a molecule or group of molecules that interferes with: (1) the expression, modification, regulation, activation or degradation of urease: or (2) one or more of the normal functions of urease, including the hydrolysis of urea leading to the production of carbamate and ammonia. An inhibitor "acts directly on urease" when the inhibitor binds to urease via electrostatic or chemical interactions.
Such interactions may or may not be mediated by other molecules. Where the inhibitor acts directly on urease, such as where the inhibitor is a reversible inhibitor, a preferred inhibitor will dissociate from urease when urease is diluted in the blood circulatory system and/or when it reaches its cellular target. An inhibitor acts "indirectly on urease"
when its most immediate effect is on a molecule other than urease which influences the expression, activation or functioning of urease.
Urease inhibitors, which serve to slow the conversion of urea to ammonium ions, include but are not limited to hydroxamic acid derivatives and other urea analogs, (e.g., acetohydroxamic acid), phosphoramide derivatives (e.g., flurofamide), phosphates, thiols (e.g., 2-mercaptoethanol etc.), boric acid, halogen compounds (e.g., fluorides etc.), and cassia bark extract. Additional urease inhibitors are known to those of skill in the art and are described in U.S. Pat. No, 4,824,783 (Apr. 25, 1989).
The effect of a urease inhibitor, such as s acetohydroxamic acid (AHA), on urease cytotoxicity in tumor cells in culture is seen in Example 9. In this example, it is seen that tumor cells are protected from urease cytotoxidty in the presence of a urease inhibitor. Therefore, possible toxicity to the patient caused by local high concentrations of urease can be mitigated through the use of a urease inhibitor, such as AHA, especially when the enzyme is applied in bolus form.
to e.g., by IV drip, to reduce localized toxicity effects. AHA is commercially available under the trade name Lithostate, and has been approved for human use.
An "enhancer of urease" comprises a molecule or group of molecules that enhances: (1) the expression, modification, regulation or activation of urease; or (2) one or more of the normal functions of urease. An enhancer "acts directly on urease" when is the enhancer binds to urease via electrostatic or chemical interactions.
Such interactions may or may not be mediated by other molecules. An enhancer acts Indirectly on urease" when its most immediate effect is on a molecule other than urease which influences the expression, activation or functioning of urease.
In accordance with one aspect of the invention, a urease composition includes a 20 urease and an inhibitor, e.g., AHA, at a mole ratio of urease:inhibitor sufficient to bind to all of the urease active sites, e.g., all six active sites of a normal bacterial urease. This composition therefore contains inhibitor and urease at a mole ratio of 6:1 or greater, e.g., 10:1 inhibitorurease. At the relatively high concentration of urease employed injected or infused into a patient, the majority of the inhibitor will be in bound form, thus 25 inhibiting strongly inhibiting the activity of the enzyme and reducing enzyme toxicity at and near the site of administration. As the urease is carried toward the target site, e.9-, in the bloodstream, it will become more dilute, shifting the kinetics of inhibitor binding toward its unbound form, and thereby releasing the inhibitory effect on the enzyme with migration toward the target.
30 A pharmaceutical composition that includes urease enzyme and a urease inhibitor, such as the inhibitors previously described herein, may include at least about 1000 Units urease, where the concentration of enzyme and inhibitor will be determined by the solution volume to be infused or injected. Thus, a composition injected in a total volume of 10 ml will have a urease concentration 1/100 of that intended slow IV infusion in a 1 liter volume. The concentration of urease in the composition, when in aqueous form, is preferably at least about 20 Units/ml.
B. Weakly basic anti-cancer agents The method of the invention is based on the discovery herein that exposing cancer cells to urease, i.e., by localizing urease at the site of cancer in a mammalian subject, is effective in potentiating the anti-cancer effect of a weakly basic anti-cancer compound that is effective against that cancer. This effect may be exploited, in ro accordance with the invention, to achieve a comparable therapeutic effect at a reduced compound dose, e.g., a dose that is 2-5 fold lower than that otherwise required, and/or to achieve a superior therapeutic effect at the same or reduced dose.
Weakly basic anti-cancer compounds include any anti-cancer compound having one or more ionizable primary or secondary amine groups, and whose uptake into is cancer cells may be affected by the intracellular/lower extracellular pH
gradient in the extracellular environment of the cells. Exemplary weakly basic anti-cancer compounds include doxorubicin, daunorubicin, mitoxantrone, epirubicin, mitomycin, bleomycin, vinca alkaloids, such as vinblastine and vincristine, alkylating agents, such as cyclophosphamide and mechlorethamine hydrochloride, antineoplastic purine 20 derivatives, including cladribine, fludarabine, 6-mercaptopurine, thiamiprine, thioguanine or tiazofurin, and anti-neoplastic pyrimidine derivatives, including ancitabine, azacitidine, 6-azauridine, capecitabine, carmofur, cytarabine, decitabine, doxifluridine, emitefur, enocitabine, floxuridineõ gemcitabine or tegafur.
Although the invention is directed potentiating the anti-cancer effect of weakly 25 basic anti-cancer drugs, urease also appears to potentiate the anti-cancer effect of other anti-cancer drugs, such as fluorouracil (see examples below). The potentiating effect may be related to a shift in extracellular or intracellular pH caused by urease, or may involve one or more other mechanisms related to the anti-cancer effects of urease alone, detailed in the above-cited '186 application. Thus, in a more general aspect, the 30 present invention contemplates potentiating the anti-cancer activity of any anti-cancer compound, such as fluorouracil, whose activity is enhanced by the presence, in the extracellular fluid of target cancer cells, of an amount of urease effective to raise the pH
of such extracellular fluid.
C. pH-sensitive imaging agents Imaging agents may be included in the composition or in additional compositions, as detailed in the above-cited 1168 application. Of particular interest for the present invention are pH sensitive imaging agents that can be used to detect and monitor changes in the local pH environment of cancer cells, e.g., the extracellular matrix of a solid tumor. Thus, for example, in practicing the present invention, it may be advantageous, in determining a suitable initial dose of the urease composition, to monitor the subject tumor site for urease-induced pH changes. Typically, an increase in pH of at least 0.1 pH units is desired, with changes of between 0.1 to 0.5 pH
units or to greater being typical.
Both luminescent cyden-based lanthanide &elates and those primarily yielding magnetic resonance signatures have been shown to be sensitive to changes in pH.
Luminescent probes used for sensing pH changes typically detect changes in the fluorescence lifetime of the lanthanide ion as a function of pH. Analogously, magnetic 3 resonance contrast agents which modulate the water proton relaxivity via changes in pH
are useful in the instant invention. In both cases, by changing the pH in a given system, one can envision agents with enhanced contrast.
Accordingly, a pH sensitive contrast agent is utilized at or near the cancer cell.
The cancer cell or cells are also exposed to a urease composition containing urease 20 enzyme to cause a change in pH at or near the cancer cell. In this way, a change in p1-1 causes the nuclear magnetic resonance relaxation properties of water protons or other nuclei in the aqueous medium to be changed in a manner that is reflective of pH.
Examples of pH sensitive contrast agents that may be utilized include those agents that contain a lanthanide metal, such as Ce, Pr, Nd, Sm, Eu, Gd, Db, Dy, Ho, Er, Tm, Yb, 25 and the like, or another paramagnetic element, such as Fe, Mn, or the like. Specific contrast agents that may be utilized include GdDOTA-4AmP(5-) which is described in Magn Reson Mad, 2003 Feb;49(2):249-57, and Fe(III)meso-tetra(4-sulfonatophenyl)porphine (Fe-TPPS4) as described in Helpem at al. (1987) Magnetic Resonance in Medicine 5:302-306 and U.S. Patent No. 6,307,372..
30 In addition, Gd based with polyion, as described in Mikawa et al. Acad. Radio! (2002) 9(suppl 1):S109-S1111, may be used in the invention.
As another alternative, a shift reagent may be provided in the aqueous medium =
, surrounding the cancer cell. The shift reagent is configured such that a change in pH
affects the chemical shift properties of the water protons or other nuclei in a manner that is reflective of pH. The change in chemical shift properties may then be measured using nuclear magnetic resonance to determine whether the active agent is biologically active. Examplary shift reagents that may be used include those containing a lanthanide metal, such as Ce, Pr, Nd, Sm, Eu, Gd, Db, Dy, Ho, Er, Tm, or Yb, or another paramagnetic element. Examples of specific shift reagents that may be utilized include Tm(DOTP) (5-), the thulium (III) complex of 1,4,7,10-tetraazacylododecane-N, N',N",N'"-tetra(methylenephospate). Dy(PPP) (2)(7)-dysprosium tripolyphosphate, and the like.
In one embodiment of the invention, a dual-contrast-agent strategy using two gadolinium agents, such as the pH-insensitive GdDOTP(5-) and the pH-sensitive GdDOTA-4AmP(5-), may be utilized to generate pH maps by MRI, as described in Magn Reson Med (2003) Feb;49(2):249-57. Preferred agents for use with PET scan include 13N and fluorodeoxyglucose (FDG).
III. Method of potentiating a weakly basic anticancer compound The present invention provides a method of potentiating the specific therapeutic activity of a weakly basic anti-cancer compound in the treatment of a mammalian cancer that is responsive to that compound. In one general embodiment, a method includes administering to the subject an amount of a urease composition which, when given in the presence of urease, e.g., either by co-administration of urease and the compound or following administration or urease, is effective to reduce the amount of the compound needed to achieve a selected anti-cancer effect, e.g., tumor shrinkage.
The degree of potentiation achievable with the invention will depend upon a number of factors that can be readily assessed during treatment, and the compound dosaging can be adjusted accordingly during treatment. To the extent the potentiation of weakly basic anti-neoplastic agents is attributable to a shift in the external/internal pH
gradient of the cancer cells, the extent of potentiation will depend on the extent to which the shift in gradient enhances drug uptake. For example, compounds that are readily taken up with ambient gradients may show less potentiation than those whose uptake is strongly affected by a pH change in the range 6.8 to about 7.2 or higher.
Similarly, where the cancer cells have developed drug resistance that relies on pumping drug out of the cells, the tirease potentiation effect may be less pronounced. That is, the degree or extent of potentiation achieved will depend on a variety of factors, including the pK or pKas of the drug amine group(s); the presence or absence of drug-resistance mechanisms in the cancer cells, including those related to drug transport; the presence or absence of drug-specific transport mechanisms in the cancer cells; and the solubility of the drug in a lipid membrane. In a typical method, the extent of potentiation is between 2 and 5 fold; that is, the amount of compound needed to produce a given anti-cancer effect is 2- to 5-fold lower when the cells are pretreated by urease.
In selecting a weakly basic anti-cancer drug for treating a particular cancer, the physician will typically select a compound that has been routinely used or has demonstrated effectiveness against the particular type of cancer being treated. Table 2 below provides a partial list of weakly basic anti-cancer drugs that have been shown to be effective against a variety of human cancer types, as indicated in the table.
Table 2 Weakly Basic Agents Used in Cancer Treatment Which Can Be Potentiated by Increased Extracellular pH
Compound Application Comments Doxorubicin Breast Cancer An anthracycline (Adriamycin , Ovarian Cancer antibiotic from the Rubex , Doxil , Lung Cancer fungus Strep. It Caelyx , Myocete) Bladder Cancer interferes with DNA
Gastric Cancer production in the cell Thyroid Cancer Daunomycin Acute Myelogenous An anthracycline (Cerubidinee) Leukemia antibiotic. It interferes Acute Lymphocytic with DNA production Leukemia in the cell Epirubicin (Ellencee) Breast Cancer An anthracycline antibiotic. It interferes with DNA production in the cell Vinblastine (Velban , Breast Cancer A vinca alkaloid. It Velbee) Hodgkin's Disease inhibits cell division Kaposi's Sarcoma during early mitosis Testicular Cancer Vincristine (Oncovin , Acute Leukemia A vinca alkaloid. It Vincasar PFS , Rhabdoyosarcoma inhibits cell division Vincrexe) Neuroblastoma during early mitosis Lymphorecticular ¨ ______________________ Neoplasms Mitoxantrone Prostate Cancer An intercalating agent (Novantronee) Acute Nonlymphocytic that interacts with Leukemia DNA and blocks DNA
synthesis Bleomycin Squamous Cell A mixture of cytotoxic (Blenoxane8) Carcinomas antibiotics, thought to Hodgkin's Disease inhibit DNA synthesis Non-Hodgkin's and, to a lesser Lymphoma degree, RNA and Testicular Cancer protein synthesis Mitomycin Gastric Cancer An alkylating agent. It (Mutamycine) Anal Cancer is thought to inhibit Colon Cancer cell growth by causing Breast Cancer inter/intrastrand Non-Small Cell Lung crosslinkages in DNA, Cancer thereby causing Head and Neck Cancer miscoding, breakage Small Bladder and replication failures Papillomas Pancreatic Cancer Cervical Cancer Mechlorethamine Hodgkin's Disease An alkylating agent. It Hydrochloride is thought to inhibit (Mustargone) cell growth by causing inter/intra strand crosslinkages in DNA, thereby causing miscoding, breakage and replication failures In the treatment method, the subject is typically pretreated with a selected dose of the urease composition. Where a urease composition is injected directly into a tumor, an exemplary dose is 0.1 to 1,000 international units urease activity per mm3 tumor. For example, and assuming a relatively uniform distribution of the urease in the tumor is achieved, a dose of between 0.5 and 5 international units may be suitable. The placement of the injection needle may be guided by conventional image guidance techniques, e.g., fluoroscopy, so that the physician can view the position of the needle with respect to the target tissue. Such guidance tools can include ultrasound, fluoroscopy, CT, MRI, pr PET scan.
The effectiveness or distribution of the administered urease dose may be monitored, during or after direct injection of urease into the tumor, by monitoring the tumor tissue by a tool capable of detecting changes in pH within the cancerous tissue , region of the subject. Such tools may include a pH probe that can be inserted directly into the tumor, or a visualization tool, such as magnetic resonance imaging (MRI), computerized tomography (CT), or fluoroscopy. MRI interrogation may be carried out in the absence of additional imaging agents, based simply on differences in magnetic properties of tissue as a function of pH. CT or fluoroscopic imaging may require an additional pH-sensitive imaging agent whose opacity is affected by the pH of the tissue medium. Such agents are well known to those of skill in the art.
Before any urease injection, the tumor tissue can be visualized by its lower pH
relative to surrounding normal tissue. Thus, the normal tissue may have a normal pH of about 7.2, whereas the tumor tissue may be 0.1 to 0.4 or more pH units lower.
That is, before any urease is injected, the extent of tumor tissue can be defined by its lower pH.
Following urease administration, the pH of the tumor region having urease will begin to rise, and can be identified by comparing the resulting images with the earlier pre-dosing images.
By interrogating the tissue in this manner, the degree of change in pH and extent of tissue affected may be monitored. Based on this interrogation, the physician may administer additional urease composition to the site, and/or may administer composition at additional areas within the tumor site. This procedure may be repeated until a desired degree of pH changes, e.g., 0.2 to 0.4 pH units, has been achieved over the entire region of solid tumor.
Where the urease is administered parenterally by a method other than direct injection, e.g., by IV drip, an exemplary dose of the urease is 100-100,000 international units urease activity/kg subject body weight, or alternatively, between about pmoles, preferably 25-500 pmolesurease/kg subject body weight. As noted herein, the urease composition in this method preferably includes a targeting agent for targeting urease to the cancer cells, e.g., site of solid tumor, or for sequestering urease, e.g., in liposomal form, selectively at the tumor site. The composition described above containing urease in combination with stoichiometric amounts of an inhibitor is advantageous in intravenous administration for the reasons discussed above. As above, imaging techniques that are sensitive to changes in tissue pH, may be used to monitor urease dosing.
Where the urease composition is given by IV injection or drip, the urease is typically allowed to clear from the bodypil for a period of at least 24 hours prior to administration of the anti-cancer compound. The rate of clearance can be accelerated, if desired, by administering a clearing agent, such as an anti-urease antibody, that facilitates clearance by non-renal clearance mechanisms. Such methods are well known.
Once an adequate dose of the urease composition has been administered and localized at the target site, and preferably after a period that allows for clearance of a significant portion of the circulating urease, the anti-cancer compound is administered by conventional dosing methods, e.g., oral administration or IV drip.
According to an important feature of the invention, the urease localized at the cancer site potentiates the io anti-cancer drug, allowing a significantly reduced dose of the compound to be administered, and/or a greater therapeutic efficacy to be achieved at the same or reduced dose. As noted above, the reduction in dose of anti-cancer compound is typically 2- to 5-fold over that in the absence of urease, and these values can be used as a guide to dosing in the method. Thus, the physician may start with a dose that is %
that of conventional dosing, and if a good therapeutic result is achieved, the dose could be reduced further until a lowest effective dose is reached. Preferably, the dose administered will be the highest dose compatible with patient comfort and lack of undesired side effects, such as nausea, alopecia, malaise, and loss of a significant portion of white blood cells, allowing effective cancer therapy with substantially reduced discomfort and long-term risk to the patient.
In a typical anti-cancer treatment, the anti-cancer drug is administered at twice or three-times weekly dosing over a 2-4 week period, followed by a recovery and observation period of one to several months. In the present invention, this regimen may be supplemented by urease administration preceding each dosing, or preceding each dosing period, e.g., once a week or once every other week during the period of compound treatment. The frequency of urease administration may be assessed during treatment by periodic assessment of localized pH levels at the cancer site, using the above pH monitoring tools.
During the course of treatment, the size and shape of a tumor may be monitored .. by diagnostic tools, such as those described above. In particular, the subject can be interrogated with a diagnostic tool capable of detecting changes in extracellular pH in a subject's tissue, as described above. The diagnostic tool is preferably a pH-sensitive diagnostic agent, such as an imaging, contrast or shift reagent, as described in Section II, above, capable of localizing in the tumor that may be administered prior to, following or concurrently with the active agent. A tissue region is identified within the subject that shows an elevation in extracellular pH following the administration. Any tool capable of identifying the diagnostic agent may be used to detect the agent, such as MRI, PET
.. scan, and the like, as described above.
In one embodiment, the method includes administering urease to the subject employed in an anti-cancer therapy, and the identification is used for detecting the localization of urease in a solid tumor. The identifying may be used for monitoring the change in size and shape of the tumor in response to urease administration.
io In one embodiment employing PET scan, the subject is administered 13N-labelled ammonia. The patient is then administered urease in an amount effective to reach the tumor site. The urease hydrolyzes urea to produce non-labelled ammonia. Over time, the labelled ammonia is diluted or displaced, causing a gradual clearing on the scan.
In another embodiment employing PET scan, the subject is administered 13N-labelled urea. The patient is then administered urease in an amount effective to reach the tumor site. The urease hydrolyzes the labelled urea to produce labelled ammonia, which could be detected on the scan.
From the foregoing, it can be seen how various objects and features of the invention are met. The invention provides an effective and relatively simple method for potentiating the therapeutic effect of a large class of anti-cancer compounds.
This potentiation allows a comparable or superior anti-cancer effect to be achieved at a lower dose of compound, thus reducing patient discomfort, health risks to the patient, and improving patient compliance and prospects for recovery. The dosing and localization of urease can be readily monitored, according to localized pH changes, and these same changes can be used to monitor the efficacy of the treatment method, and to monitor the urease dosing administered.
The following examples further illustrate the invention described herein and are in no way intended to limit the scope of the invention.
A. Example 1 Al. Peptide Synthesis Peptides were prepared by solid-phase synthesis methodology using conventional N-t-butyloxycarbonyl (t-Boc) chemistry. Peptides were cleaved from the resin by reaction with hydrogen fluoride (20 ml/g resin) containing 10%
anisole and 2%
1,2-ethaneclithiol for 1.5 h at 4 C. Crude peptides were washed with cold ether, and extracted from the resin with glacial acetic acid and freeze-dried. Synthetic peptide was purified by reversed-phase HPLC on a Zorbax semi-preparative C-8 column (250 x
10 mm I.D., 6.5-pm particle size, 300-A pore size) with a linear AB gradient (ranging from 0.2 to 1.0% B/min) at a flow rate of 2 mi/min, where solvent A is aqueous 0.05%
trifluoroacetic acid (TFA) and solvent B is 0.05% TFA in acetonitrile.
Homogeneity of io .. the purified peptides was verified by analytical reversed phased-HPLC, amino acid analysis and MALDI mass spectrometry.
A2. Affinity Purification of Urease The affinity column was prepared by reacting hydroxyurea to epoxy-activated Sepharose36B (Amersham Biosciences). Remaining active groups were blocked using 1 M ethanolamine, Purification was performed as follows. The column was equilibrated with PEB
(0.02 M phosphate, 1 mM EDTA, 1 mM p-mercaptoethanol, pH 7.0). A crude urease sample (Fig. 2) was applied (0.5 mg/ml in PEB, total 8 ml). The column was washed with 15 ml of PB (0.02 M phosphate, 1 mM p-mercaptoethanol, pH 7.0). The column was then washed with 8 ml of each of the following: PB + 0.1 M NaCI, PB + 0.5 M
NaCI, and PB + 0.95 M NaCI. The urease was eluted with 8 ml of EB (0.2 M
phosphate, 1 mM J3-mercaptoethanol, pH 4.6), collecting 1 ml fractions. Fractions were checked by reading OD at 280nm (Fig. 3) and HPLC (C5 column) analysis. The column was stored in 0.01% NaN3 B, Example 2 ¨ Preparation of the Urease-Coil Conjugate Urease coil conjugate was prepared by dissolving 10 mg of Jack bean Urease in 300 Iof 2mM phosphate buffer pH 7.2. Then 5 mg of the bifunctional cross-linker Sulfo-MBS was added to the solution and the mixture was slowly stirred for one hour at room temperature. The mixture was then dialyzed against 2mM phosphate buffer at pH
7.2 to remove excess linker.
Trademark*
K-coil or E-coil with a C-terminal cys linker (1.5 mg) was added to the linker-modified urease solution and slowly mixed for 3 hours at room temperature. The coil urease conjugate was dialyzed against fresh 2mM phosphate buffer at pH 7.2 overnight to remove unconjugated coil peptide. Dialyzed urease conjugate was lyophilized, then s dissolved in 1 mL of 2mM phosphate buffer pH 7.2 and applied to sephadex4b75 column for further purification. The void volume fractions, which contained the coil urease conjugate, were pooled, freeze-dried arid stored at 4 C.
The purity of the conjugate and the ratio of the coil to urease in the preparation were determined by amino acid analysis and MALDI mass spectrometry using standard procedures.
C. Example 3 -- Activity assay of Urease and Urease conimate The enzymatic activity of urease or urease conjugate was carried out in a coupled enzyme reaction with glutamate dehydrogenase (GLDH). The amount of NADH oxidized was determined by measuring the change in absorbance at 340 rim (Kaltwasser, H. and Schlegel, H.G., Anal. Biochem., 16, 132, 1966). The reagents used were: 0.10 M Potassium phosphate buffer, pH 7.6; 1.80 M Urea prepared in phosphate buffer; 0.025 M Adenosine-5'-diphosphate (ADP) (10.7 mg/m1) in buffer; 0.008 M
NADH
(5 mg/m1) in phosphate buffer; 0.025 M e-Ketoglutarate (3.7 mg/ml) in phosphate buffer;
.. Glutamate dehydrogenase (GLDH) solution, free from ammonium ions; 50 U/mi phosphate buffer prepared fresh prior to assay. Urease solution was prepared by dissolving in phosphate buffer to yield a concentration of 0,1-0.5 U/ml. This solution was prepared fresh prior to assay.
Assay was initiated by adding the following 2.0 mL of Phosphate buffer 2.40 ml, 0.10 ml each of urea, ADP, NADH, GLDH and a-Ketoglutarate in a cuvette. The spectrophotometer was adjusted to 340 rim and 25 C. The cuvette with the added ingredients was placed in the spectrophotometer at 25 C for 5 minutes to attain temperature equilibration and then establish blank rate, if any, at 340 nm.
To initiate the enzymatic reaction 0.1 ml of the urease solution was added to the .. ouvefte. The changes in the absorbance at 340 rim were recorded for 15 min.
Enzyme activity was correlated with a decrease in absorbance at 340nm per min.
D. Example 4 ¨ Preparation of Coil Antibody Coniuqate, Trademark*
Materials include: (1) Rat Anti-hEGFR IgG2a (Serotec), 200 pg/0.2 ml (i.e. 1 mg/mI); (2) E-coil (N-linker); (3) Sodium m-periodate (Pierce); and (4)Bifunctional crosslinker, KMUH (Pierce).
Functional modification of E-coil was performed by performing the following steps:
a. Dissolve KMUH in DMS0 to prepare a 10 mg/ml solution (2.5 mg in 250 pl of DMS0).
b. Dissolve E-coil in PB (-2 mg in 392 pl of 10 mM PB, pH 7.4 + 4 pl of TCEP, 100 mM stock) to c. Add 1 pl of Tris (2 M) to neutralize the E-coil solution d. Add E-coil solution to the KMUH solution and incubate at R.T. for 2 hr e. Keep solution at 4 C overnight f. Next morning, centrifuge at 12000 rpm for 5 min. to remove insoluble precipitate.
g. Remove KMUH arid DMSO on a GB HPLC column (0-20% acetonitrile/ H20 with 0.05% TFA) and collect all peptide fractions (750/0 acetonitrile).
g. Lyophilize the peptide fractions and check by MS.
The antibody was oxidized by the following steps:
a. For each 2 mg of antibody, weigh 20 mg of periodate in an amber vial.
b. Add 2 ml of PBS, pH 7.2 and 2 ml of stock antibody to the vial (final [antibody] is 0.5 mg/ml) and gently swirl until the periodate powder was dissolved.
c. Incubate at room temp. for 30 min.
d. Remove periodate by dialyzing 3 times vs 100 mM acetate buffer, pH 5.5.
Conjugation was performed by the following steps:
a. Concentrate oxidized antibody (-2 mg in 4 ml) using Millipore Ultrafree Filter units (30k MWc/o).
b. Add 75 pl of the functionalized E-coil solution (4 pg/pl ddH20) to half of the oxidized antibody solution (containing - 0.75 mg of antibody in acetate buffer, pH 5.5).
c. Incubate at room temp. for 2 hr with shaking.
Trademark*
d. Purify the antibody mixture using a Protein G column (See Fig. 4).
e. Compare and analysis of sample (before and after affinity purification).
TM
E. Example 5 -- Biacore Analysis of Coil Urease Conjuc;ate and Coil Antibody Conjugate Cysteine containing K-coil peptide or the E-coil peptide was covalent coupled to the Pioneer B1 biosensor chip according to the manufacturer suggested protocol.
Briefly, the dextran surface of the sensor chip was first activated with NHS/EDC (15 41) followed by addition of PDEA (20 41). K-coil (or E-coil (50 g/ml) in 10 mM
sodium acetate buffer pH 4.3 was injected and allowed to react to give a surface density of approximately 200-400 RU. Remaining activated groups were then blocked by injection (10 I) of a 50 mM cysteine, 1 M NaCI, 0.1 M formate, pH 4.3 deactivation solution.
Kinetic experiments were performed on a BlAcore3000 instrument at 25 C. Each biosensor run consisted of (1) a 600s sample injection phase (coil urease or coil antibody), (2) a 60Ds dissociation phase, and (3) a 2x 15s regeneration phase (6M
guanidine HCI). A flow rate of 5 0/min was maintained throughout the cycle.
PBS was used as a buffer. The SPR signal was recorded in real time with sampling at every 0.5 s and plotted as RU versus time (sensorgram). Each sensorgram obtained was corrected for bulk refractive index changes by subtracting the corresponding sample zo injection cycle on a blank cell surface F. Example 6 -- Animal Studies Athymic nu/nu female mice with human mammary gland adenocarcinoma xenografts were used for testing. Animals selected were generally 5 to 7 weeks of age, and their body weights at treatment commencement range from approximately 15 to 28 grams.
MCF-cells were used to generate the xenografts. The cells were grown in MEM
media supplemented with Penicillin/Streptomycin 50U/ml, L-glutamine 2mM, Sodium pyruvate, nonessential amino acids, vitamins, and 10% FBS; The cell incubator was maintained with 5% CO2, 37.5 C, and 80% humidity. The cells were harvested with 0.25%(w/v) trypsin-0.03%(w/v) EDTA solution. Approximately 1 x 106 cells in 100 41_ was injected subcutaneously to the right flank of each mouse.
Tumor growth was allowed to proceed for about 6-8 days allowing the size of the tumor to reach at least 2 ¨4 mm in diameter. Doses were administered via intratumor injection. The dose volume for each animal was 504. Each solid tumor was injected with the given dose of test article in a "fanning fashion". Tumor volumes were taken by external caliper measurements. Body weights were taken at the start of the trial and at time of sacrifice.
Results, as shown in Table 3 below, show that tumors were not perceptible 24 hours following treatment.
Table 3 io Successful Treatment of Tumors in Mice Mou MCF cell 0.8 0.8 0.8 0.8 1.2 0.8 Tumor siz 22.E 33.E 15.( 31. 32.E 8.2 treat,. .
Urease amoL 50L 50U 50L 50L 40L 10L
Tumor size pc not pe not pe not pe not pe not pe not pe (24 ha G. Example 7 ¨Urease-mediated antitumor effects in vitro This example shows that urease is cytotoxic to A549 and MDA-MB-231 cells in culture.
Materials Urease from Canavalia ensiformis (jack beans) was obtained from BioVectra Ltd.
(PEI, Canada) and further purified by acid precipitation and ion exchange chromatography to remove the two major contaminants, canavalin and concanavalin A.
The purity of the enzyme was > 96% as determined by SDS polyacrylamide gel electrophoresis, HPLC and mass spectrometry. One unit of urease is defined as the production of 1 !mole of ammonia per minute at 25 C and pH 7.6.
Urea, trypsin, phenazine ethosulfate (PES), sodium nitroprusside, sodium hypochlorite solution, phenol, acetohydroxamic acid (AHA), doxorubicin hydrochloride and vinblastine were purchased from Sigma Chemical Co. (St. Louis, MO). 344,5-dimethylthiazol-2-y1)-5-(3-carboxymethoxypheny1)-2-(4-sulfopheny1)-2H-tetrazoliurn (MTS) was purchased from Promega Corp. (Madison, WI). Cell culture medium, serum, and antibiotics were obtained from Invitrogen Life Technologies (ON, Canada).
Female , .
athymic nude mice were supplied by Charles River Laboratories (Wilmington, MA).
Buffers used in the experiments: Dulbecco's phosphate-buffered saline (D-PBS) and modified Krebs Ringer buffer (KRB) containing NaCI (98.3 mM), KCI (4.73 mM), KH2PO4 (1.19 mM), MgSO4 (1.19 mM), NaHCO3 (3.57 mM), D-Glucose (11.7 mM), Na2HPO4 (11.1 mM) and NaH2PO4 (2.77 mM) at pH 7.2 or 6.8.
Cell culture and viability assay Human breast cancer cell lines (MDA-MB-231 and MCF-7) and lung cancer cell line (A549) were purchased from the American Type Culture Collection (Manassas, to VA). Cells were grown in DMEM/F12 (MDA-MB-231 and A549) or MEM (MCF-7) containing 10% fetal bovine serum and 50 U/ml penicillin and 50 pg/ml streptomycin at 37 C in a humidified incubator with 5% CO2.
Colorimetric MTS assay was employed to determine cell viability. MTS and PES
were dissolved in D-PBS and filtered to prepare 2 and 1 mg/ml stock solutions, respectively. After the cells were treated with test articles, the medium in the plate was replaced with 100 pl/well of plain culture medium, followed by the addition of 20 p1/well of MTS mix (MTS:PES at 20:1, vol/vol). The plate was incubated for 1-2 hours at 37 C
in a humidified, 5% CO2 atmosphere. The absorbance of soluble formazan produced by cellular reduction of MTS was measured at 490 nm with reference at 630 nm using an ELx808IU Microplate Reader (Bio-tek Instruments Inc., Winooski, VT).
In vitro cytotoxicitv of urease A549 cells (1.0x105 cells/ml) or MDA-MB-231 cells (1.5x105 cells/m1) were seeded into 96-well tissue culture plates (Becton Dickinson Labware, NJ) by transferring aliquot of 100 pl of the cell suspension to each well. The plate was incubated at 37 C
overnight. After incubation, the medium in the wells was removed using a multichannel pipette. Urease and urea at various dilutions were prepared in pre-warmed KRB, pH
7.2 and 50 pl of each was added to corresponding wells. After incubation for two hours at 37 C, buffer from each replicate was pooled and subjected to pH measurement and total ammonium determination as described in Example 8. MTS cell viability assay was then performed on the plate.
Results Human tumor cell lines A549 and MDA-MB-231 were susceptible to the enzymatic activity of jack bean urease. The survival rate of both cell lines decreased as the cells were treated with 2 U/ml of urease for 2 hours with an increasing amount of urea in the medium (Fig. 6 A). Urea alone (up to 40 mM as tested) was not toxic to the cells during the 2-hour incubation period. In the presence of 2 U/mlof urease, the IC50 of urea were found to be 13 mM for both cell lines (Fig. 6A). Furthermore, the cytotoxic effects were also dependent on the availability of urease. With fixed urea concentration at 20 mM in the medium, the IC50 of urease were found to be 0.22 and 0.45 U/ml, respectively, for A549 and MDA-MB231 cells (Fig. 6B). Sufficient amounts of ammonia to produced by urease therefore mediate cell death on both human lung and breast cell lines described herein. Urease can therefore be used alone through the direct cytotoxicity of ammonia.
It was found herein that significant amounts of canavalin and concanavalin A
contaminants were present in a commercial source of crystalline urease as detected by HPLC and mass spectrometry. These contaminants were able to increase in vitro cytotoxicity of the enzyme (unreported observation).
H. Example 8 ¨Effect of urease on pH and ammonium concentration of culture medium of A549 cells This example shows that urease increases the total ammonium content and the pH of culture medium from A549 cells in culture.
Methods The total ammonium present in the incubation buffer obtained from plates utilized in the in vitro cytotoxicity studies in Example 7 was determined by Berthelot's Indophenol reaction [Chaney, A.L. and Marback, E.P. Clin. Chem. 8:130-132 (1962)]. In brief, fresh phenol solution (Solution A) was prepared by dissolving 165 mg of phenol and 132 mg of NaOH pellets in 10 ml of water, and then 66 pl of sodium nitroprusside solution ( 1 0 mg/ml) was added. Fresh Solution B was prepared by adding 80 pl of sodium hypochlorite solution (10-13% chlorine) to 10 ml of water. Urease activity in the pooled sample was quenched by adding 50 pl of 1 N HCI to 100 pl of sample. The acidified samples were then diluted 200 times and transferred to a 96-well microplate at p1/well, followed by 50 pl of Solution A and 50 pl of Solution B. After incubation at 37 C
, , .
for 15 min, the plate was read at 630 nm using the microplate reader. The amount of ammonium ions present in the sample was determined from the NH4CIstandard curve.
Cell culture and viability assays were performed as described in Example 7.
Results The antitumor effects of urease observed in Example 7 were exerted through the hydrolysis of urea into ammonia (Fig. 6C) with a corresponding elevation of pH
(Fig. 6D) due to protonation of ammonia in aqueous medium. Figures 6C and 6D were the total ammonium and pH measured in the reaction buffer collected from experiments of io Figure 6A. It was found that urease cytotoxicity (Fig. 6A) correlated well with a corresponding increase of ammonium content and pH in the incubation buffer (Fig. 6C
and 6D). The rise in pH of the control as shown in Fig. 6D was probably due to autolysis of urea in aqueous medium resulted in the generation of a total of 3 to 5 mM of ammonium. However, separate experiments have shown that pH alone was insufficient is to cause any significant cytotoxicity on the two cell lines during a two-hour incubation window (data not shown). Therefore, it was the level of ammonium, or more specifically, availability of free ammonia, that mediated the rapid cell killing effects. An augmented pH in turn increases the availability of free ammonia to the cells according ]
to the following equation: pH =pK +log [NH3, where pK = 9.3 at 37 C (2).
[NH4]
I. Example 9 ¨Effects of acetohvdroxamic acid on urease cytotoxicitv in vitro and the ammonium content of culture media This example shows that acetohydroxamic acid decreases the total ammonium content of cell culture medium and protects tumor cells in the culture medium from urease cytotoxicity. Cells were cultured and viability was determined as described in Example 7. The ammonium content of culture medium was determined as described in Example 8.
Results Acetohydroxamic acid (AHA) is a potent reversible inhibitor of urease and is commercially available for the treatment of chronic urea-splitting urinary infection.
When AHA was added to the culture buffer containing.urease, it effectively inhibited the enzymatic activity of urease (Fig. 7C) and restored the survival rate of A549 (Fig. 7A) and MDA-MB-231 (Fig. 7B) cells to normal level at dose 2 mM. This result suggested that the cytotoxicity of urease is solely due to its enzymatic activity.
Similar results are shown in Fig. 8A-80 at different levels of urea. Two millimolar AHA can reduce ammonium production by 00S47 (urease) at 27 mM urea to a level similar to that of 3 mM urea, and thus protects cells from being killed (Fig. 70). It is estimated that AHA at 0.8 mM can reduce the ammonium production by half (Fig. 70). AHA at 2.5 mM can almost completely reverse the cytotoxic effects of 00S47 in KR-II buffer containing 25 io mM urea during a 2 hour incubation period for both A549 and MB-231 cells (Figs. 7E
and 7F). AHA is not toxic to both cell lines at concentrations as high as 12.5 mm (Figs.
7E and F). in comparing Figs. 6 and 8, it can be seen that short term in vitro urease treatment required much higher levels of urea than that of longer term in vivo treatment.
J. Example 10 ¨Anti-cancer effects of urease in vivo This example shows that MCF-7 and A549 xenografts from mice are susceptible to intratumoral injections of urease.
Methods A649 xenografts: Female athymic nude mice (7-9 weeks old) were injected subcutaneously in the right lateral thorax with 5 x 106 human A549 lung cancer cells.
When tumors reached 100-200 mg, the tumor-bearing animals were randomly selected and sorted into four groups, Group 1 contained ten untreated control mice.
Group 2 contained ten positive control mice treated with the reference chemotherapeutic agent Cispiatin. Groups 3 and 4 contained 15 mice each that received one of two different concentrations of urease (1 U or 4 U per injection). Each animal received five doses of injection scheduled at 48 hours between treatments (q2dx5). Urease was administered intratumorally, whereas cisplatin was administered via an intravenous tail vein injection.
Twenty-four hours after the fifth urease administration, five mice from each group were sent for necropsy and tumor collection. In addition, five mice from Groups 2-4 were euthanized and tumors were collected, dissociated, and cultured for viability testing. The remaining five animals from each group continued on study until study termination. Tumor size was recorded using calibrated hand-held Vernier calipers.
Throughout the study, the length (L) and width (W) of any tumors that developed were measured in millimeters. The tumor weight in mg was calculated using the formula: (L x W2)/2. Individual animal weights were taken twice weekly. The experimental protocol was covered under Charles River Laboratories Institutional Animal Care and Use Committee (IACUC).
MCF-7 xenograft: Female athymic nude mice were injected subcutaneously with 1.8x106 MCF-7 breast tumor cells. When tumor size reached approximately 9 mg, eight mice were injected intratumorally with two doses of urease (10 U/injection) at 48 hours interval (q2d). Five mice were treated with saline as control. The condition of all io .. animals and tumor size were monitored 24 hours after inoculation and then every other day. Animal care was in accordance with the guidelines of the Canadian Council on Animal Care (CCAC). At the end of the observation period, tumors were excised and prepared for histology analyses.
Results Both MCF-7 and A549 xenografts were susceptible to intratumoral injections of urease. Growth of MCF-7 was completely stopped after the second injection of 10 U of urease (Fig. 8A). Histological analysis of tumors excised from the treated mice showed that the tumor mass was dead and could not re-grow in culture medium.
In the case of A549 xenografts, delay in tumor growth was observed in mice treated with 5 injections of low dose (1 U) or medium dose (4 U) of urease (Fig. 88).
Growth regressions of the urease-treated groups were similar to that of the positive control group treated with 6 mg/kg Cisplatin (data not shown). Tumor tissue slices showed significant necrotic area compared to the control. However, cell viability was .. not affected (>82% ) in dissociated tumors taken from mice treated with urease. There were no significant differences in body weight of the treatment and control groups in both xenograft studies.
K. Example 11 ¨In vitro anti-cancer effects of urease in combination with .. selected anti-neoplastic drugs This example shows that urease enhances the anti-cancer effects of doxorubicin, vinblastine, fluorouracil, and mitoxantrone.
Methods Combined drug assays A549 and MDA-MB-231 plates were prepared as described in Example 7.
Urease, urea and the 4 weak-base anticancer drugs, doxorubicin, vinbiastine, fluorouracil and mitoxantrone were prepared in pre-warmed KRB, pH 6.8. After the medium in the plate was removed., 50 pl of urease, urea and drug solutions were added subsequently into corresponding wells. The final concentrations of doxorubicin, vinblastine, fluorouracil and mitoxantrone were 50 pM, 100 pM, 13.3 mM and 5 pM, respectively. After 2-hour incubation at 37 C, cell viability assays were performed as described in Example 7 and the buffer pH was measured.
Results Krebs Ringer buffer at pH 6.8 was used to mimic the acidic extracellular environment of solid tumor. At this incubation condition, the pH raised by the urease activity was lower than what was observed in Fig. 6D. However, the pH increase was sufficient to enhance the antitumor efficacy of the two weak-base anticancer drugs tested. At low urea level (2 mM), urease significantly enhanced the antitumor activity of doxorubicin on A549 (Fig. 9A) and MDA-MB-231 cells (Fig. 9B), as well as that of vinblastine on MDA-MB-231 cells (Fig. 9B). When urea level was increased to 8 mM, urease enhanced the activity of both drugs on both cell lines (Fig. 9).
The antitumor efficacy of another weak-base anticancer drug, mitoxantrone,-was also significantly enhanced by urease when used to treat MDA-MB-231 cells (Fig.
10B) but not on A549 cells (Fig. 10A). Interestingly, the activity of fluorouracil, which is not a weak-base drug, was also enhanced by urease on A549 cells (Fig. 10A). Although the invention has been described with respect to particular embodiments, it will be apparent to those skilled in the art that various changes and modifications can be made.
SEQUENCE LISTING
APPLICANT: Helix Biopharma Corp.
TITLE: Method and Composition for Inhibiting Cancer Cell Growth REFERENCE NUMBER; -08902325CA
CURRENT APPLICATION DATA
FILING NUMBER: 2,493,282 FILING DATE: January 31, 2005 NUMBER OF SEQUENCES: 1 SOFTWARE: FastSEQ for Windows Version 4.0 INFORMATION FOR SEQ ID NO. : 1 SEQUENCE CHARACTERISTICS
LENGTH: 840 TYPE: PROTEIN
ORGANISM : Canavalia ensiformis SEQUENCE DISCRIPTION : SEQ ID O. : 1 Met Lys Leu Ser Pro Arg Glu Val Glu Lys Leu Gly Leu His Asn Ala Gly Tyr Leu Ala Gin Lys Arg Leu Ala Arg Gly Val Arg Leu Asn Tyr Thr Glu Ala Val Ala Leu Ile Ala Ser Gin Ile Met Glu Tyr Ala Arg 35 40= 45 Asp Gly Glu Lys Thr Val Ala Gin Leu Met Cys Leu Gly Gin His Leu Leu Gly Arg Arg Gin Val Leu Pro Ala Val Pro His Leu Leu Asn Ala Val Gin Val Glu Ala Thr Phe Pro Asp Gly Thr Lys Leu Val Thr Val His Asp Pro Ile Ser Arg Glu Asn Gly Glu Leu Gin Glu Ala Leu Phe Gly Ser Leu Leu Pro Val Pro Ser Leu Asp Lys Phe Ala Glu Thr Lys Glu Asp Asn Arg Ile Pro Gly Glu Ile Leu Cys Glu Asp Glu Cys Leu Thr Leu Asn Ile Gly Arg Lys Ala Val Ile Leu Lys Val Thr Ser Lys Gly Asp Arg Pro Ile Gin Val Gly Ser His Tyr His Phe Ile Glu Val Asn Pro Tyr Leu Thr Phe Asp Arg Arg Lys Ala Tyr Gly Met Arg Leu Asn Ile Ala Ala Gly Thr Ala Val Arg Phe Glu Pro Gly Asp Cys Lys Ser Val Thr Lela Val Ser Ile Glu Gly Asn Lys Val Ile Arg Gly Gly Asn Ala Ile Ala Asp Gly Pro Val Asn Glu Thr Asn Leu Glu Ala Ala Met His Ala Val Arg Ser Lys Gly Phe Gly His Glu Glu Glu Lys Asp Ala Ser Glu Gly Phe Thr Lys Glu Asp Pro Asn Cys Pro Phe An Thr Phe Ile His Arg Lys Glu Tyr Ala Asn Lys Tyr Gly Pro Thr Thr Gly Asp Lys Ile Arg Leu Gly Asp Thr Asn Leu Leu Ala Glu Ile Glu Lys Asp Tyr Ala Leu Tyr Gly Asp Glu Cys Val the Gly Gly Gly Lye Val Ile Arg Asp Gly Met Gly Gin Ser Cys Gly His Pro Pro Ala Ile Ser Leu Asp Thr Val Ile Thr Asn Ala Val Ile Ile Asp Tyr Thr Gly Ile Ile Lys Ala Asp Ile Gly Ile Lys Asp Gly Leu Ile Ala Ser Ile Gly Lys Ala Gly Asn Pro Asp lie Met Asn Gly Val the Ser An Met Ile Ile Gly Ala Asn Thr Glu Val Ile Ala Gly Glu Gly Leu Ile Val Thr Ala Gly Ala Ile Asp Cys His Val His Tyr Ile Cys Pro Gin Leu Val Tyr Glu Ala Ile Ser Ser Gly Ile Thr Thr Leu Val Gly Gly Gly Thr Gly Pro Ala Ala Gly Thr Arg Ala Thr Thr Cys Thr Pro Ser Pro Thr Gin Met Arg Leu Met Leu Gin Ser Thr Asp Asp Leu Pro Leu Asn Phe Gly Phe Thr Gly Lys Gly Ser Ser Ser Lys Pro Asp Glu Leu His Glu Ile Ile Lys Ala Gly Ala Met Gly Leu Lys Leu His Glu Asp Try Gly Ser Thr Pro Ala Ala Ile Asp Asn Cys Leu Thr Ile Ala Glu His His Asp Ile Gin Ile Asn Ile His Thr Asp Thr Leu Asn Glu Ala Gly Phe Val Glu His Ser Ile Ala Ala Phe Lys Gly Arg Thr Ile His Thr Tyr His Ser Glu Gly Ala Gly Gly Gly His Ala Pro Asp Ile Ile Lys Val Cys Gly Ile Lys Asn Val Leu Pro Ser Ser Thr Asa Pro Thr Arg Pro Leu Thr Ser Asn Thr Ile Asp Glu His Leu Asp Met Leu Met Val Cys His His Leu Asp Arg Glu Ile Pro Glu Asp Leu Ala Phe Ala His Ser = 595 600 605 Arg Ile Arg Lys Lys Thr Ile Ala Ala Glu Asp Val Leu Alan Asp Ile Gly Ala Ile Ser Ile Ile Ser Ser Asp Ser Gin Ala Met Gly Arg Val Gly Glu Val /le Ser Arg Thr Trp Gin Thr Ala Asp Lys Met Lys Ala Gin Thr Gly Pro Leu Lys Cys Asp Ser Ser Asp Asn Asp Asn Phe Arg Ile Arg Arg Tyr Ile Ala Lys Tyr Thr Ile Asn Pro Ala Ile Ala Asn Gly Phe Ser Gin Tyr Val Gly Ser Val Glu Val Gly Lys Leu Ala Asp Leu Val Met Trp Lys Pro Ser Phe Phe Gly Thr Lys Pro Glu Met Val Ile Lys Gly Gly Met Val Ala Trp Ala Asp Ile Gly Asp Pro Aan Ala Ser Ile Pro Thr Pro Glu Pro Val Lys Met Arg Pro Met Tyr Sly Thr Leu Gly Lys Ala Gly Gly Ala Leu Ser Ile Ala he Val Ser Lys Ala Ala Leu Asp Gin Arg Val Asn Val lieu Tyr Gly Leu Asn Lys Arg Val Glu Ala Val Ser Asn Val Arg Lys Leu Thr Lys Leu Asp Met Lys Leu 785 = 790 795 Asn Asp Ala Leu Pro Glu Ile Thr Val Asp Pro Glu Ser Tyr Thr Val Lys Ala Asp Gly Lys Leu Leu Cys Val Ser Glu Ala Thr Thr Val Pro Leu Ser Arg Asn Tyr Phe Leu Phe =
trifluoroacetic acid (TFA) and solvent B is 0.05% TFA in acetonitrile.
Homogeneity of io .. the purified peptides was verified by analytical reversed phased-HPLC, amino acid analysis and MALDI mass spectrometry.
A2. Affinity Purification of Urease The affinity column was prepared by reacting hydroxyurea to epoxy-activated Sepharose36B (Amersham Biosciences). Remaining active groups were blocked using 1 M ethanolamine, Purification was performed as follows. The column was equilibrated with PEB
(0.02 M phosphate, 1 mM EDTA, 1 mM p-mercaptoethanol, pH 7.0). A crude urease sample (Fig. 2) was applied (0.5 mg/ml in PEB, total 8 ml). The column was washed with 15 ml of PB (0.02 M phosphate, 1 mM p-mercaptoethanol, pH 7.0). The column was then washed with 8 ml of each of the following: PB + 0.1 M NaCI, PB + 0.5 M
NaCI, and PB + 0.95 M NaCI. The urease was eluted with 8 ml of EB (0.2 M
phosphate, 1 mM J3-mercaptoethanol, pH 4.6), collecting 1 ml fractions. Fractions were checked by reading OD at 280nm (Fig. 3) and HPLC (C5 column) analysis. The column was stored in 0.01% NaN3 B, Example 2 ¨ Preparation of the Urease-Coil Conjugate Urease coil conjugate was prepared by dissolving 10 mg of Jack bean Urease in 300 Iof 2mM phosphate buffer pH 7.2. Then 5 mg of the bifunctional cross-linker Sulfo-MBS was added to the solution and the mixture was slowly stirred for one hour at room temperature. The mixture was then dialyzed against 2mM phosphate buffer at pH
7.2 to remove excess linker.
Trademark*
K-coil or E-coil with a C-terminal cys linker (1.5 mg) was added to the linker-modified urease solution and slowly mixed for 3 hours at room temperature. The coil urease conjugate was dialyzed against fresh 2mM phosphate buffer at pH 7.2 overnight to remove unconjugated coil peptide. Dialyzed urease conjugate was lyophilized, then s dissolved in 1 mL of 2mM phosphate buffer pH 7.2 and applied to sephadex4b75 column for further purification. The void volume fractions, which contained the coil urease conjugate, were pooled, freeze-dried arid stored at 4 C.
The purity of the conjugate and the ratio of the coil to urease in the preparation were determined by amino acid analysis and MALDI mass spectrometry using standard procedures.
C. Example 3 -- Activity assay of Urease and Urease conimate The enzymatic activity of urease or urease conjugate was carried out in a coupled enzyme reaction with glutamate dehydrogenase (GLDH). The amount of NADH oxidized was determined by measuring the change in absorbance at 340 rim (Kaltwasser, H. and Schlegel, H.G., Anal. Biochem., 16, 132, 1966). The reagents used were: 0.10 M Potassium phosphate buffer, pH 7.6; 1.80 M Urea prepared in phosphate buffer; 0.025 M Adenosine-5'-diphosphate (ADP) (10.7 mg/m1) in buffer; 0.008 M
NADH
(5 mg/m1) in phosphate buffer; 0.025 M e-Ketoglutarate (3.7 mg/ml) in phosphate buffer;
.. Glutamate dehydrogenase (GLDH) solution, free from ammonium ions; 50 U/mi phosphate buffer prepared fresh prior to assay. Urease solution was prepared by dissolving in phosphate buffer to yield a concentration of 0,1-0.5 U/ml. This solution was prepared fresh prior to assay.
Assay was initiated by adding the following 2.0 mL of Phosphate buffer 2.40 ml, 0.10 ml each of urea, ADP, NADH, GLDH and a-Ketoglutarate in a cuvette. The spectrophotometer was adjusted to 340 rim and 25 C. The cuvette with the added ingredients was placed in the spectrophotometer at 25 C for 5 minutes to attain temperature equilibration and then establish blank rate, if any, at 340 nm.
To initiate the enzymatic reaction 0.1 ml of the urease solution was added to the .. ouvefte. The changes in the absorbance at 340 rim were recorded for 15 min.
Enzyme activity was correlated with a decrease in absorbance at 340nm per min.
D. Example 4 ¨ Preparation of Coil Antibody Coniuqate, Trademark*
Materials include: (1) Rat Anti-hEGFR IgG2a (Serotec), 200 pg/0.2 ml (i.e. 1 mg/mI); (2) E-coil (N-linker); (3) Sodium m-periodate (Pierce); and (4)Bifunctional crosslinker, KMUH (Pierce).
Functional modification of E-coil was performed by performing the following steps:
a. Dissolve KMUH in DMS0 to prepare a 10 mg/ml solution (2.5 mg in 250 pl of DMS0).
b. Dissolve E-coil in PB (-2 mg in 392 pl of 10 mM PB, pH 7.4 + 4 pl of TCEP, 100 mM stock) to c. Add 1 pl of Tris (2 M) to neutralize the E-coil solution d. Add E-coil solution to the KMUH solution and incubate at R.T. for 2 hr e. Keep solution at 4 C overnight f. Next morning, centrifuge at 12000 rpm for 5 min. to remove insoluble precipitate.
g. Remove KMUH arid DMSO on a GB HPLC column (0-20% acetonitrile/ H20 with 0.05% TFA) and collect all peptide fractions (750/0 acetonitrile).
g. Lyophilize the peptide fractions and check by MS.
The antibody was oxidized by the following steps:
a. For each 2 mg of antibody, weigh 20 mg of periodate in an amber vial.
b. Add 2 ml of PBS, pH 7.2 and 2 ml of stock antibody to the vial (final [antibody] is 0.5 mg/ml) and gently swirl until the periodate powder was dissolved.
c. Incubate at room temp. for 30 min.
d. Remove periodate by dialyzing 3 times vs 100 mM acetate buffer, pH 5.5.
Conjugation was performed by the following steps:
a. Concentrate oxidized antibody (-2 mg in 4 ml) using Millipore Ultrafree Filter units (30k MWc/o).
b. Add 75 pl of the functionalized E-coil solution (4 pg/pl ddH20) to half of the oxidized antibody solution (containing - 0.75 mg of antibody in acetate buffer, pH 5.5).
c. Incubate at room temp. for 2 hr with shaking.
Trademark*
d. Purify the antibody mixture using a Protein G column (See Fig. 4).
e. Compare and analysis of sample (before and after affinity purification).
TM
E. Example 5 -- Biacore Analysis of Coil Urease Conjuc;ate and Coil Antibody Conjugate Cysteine containing K-coil peptide or the E-coil peptide was covalent coupled to the Pioneer B1 biosensor chip according to the manufacturer suggested protocol.
Briefly, the dextran surface of the sensor chip was first activated with NHS/EDC (15 41) followed by addition of PDEA (20 41). K-coil (or E-coil (50 g/ml) in 10 mM
sodium acetate buffer pH 4.3 was injected and allowed to react to give a surface density of approximately 200-400 RU. Remaining activated groups were then blocked by injection (10 I) of a 50 mM cysteine, 1 M NaCI, 0.1 M formate, pH 4.3 deactivation solution.
Kinetic experiments were performed on a BlAcore3000 instrument at 25 C. Each biosensor run consisted of (1) a 600s sample injection phase (coil urease or coil antibody), (2) a 60Ds dissociation phase, and (3) a 2x 15s regeneration phase (6M
guanidine HCI). A flow rate of 5 0/min was maintained throughout the cycle.
PBS was used as a buffer. The SPR signal was recorded in real time with sampling at every 0.5 s and plotted as RU versus time (sensorgram). Each sensorgram obtained was corrected for bulk refractive index changes by subtracting the corresponding sample zo injection cycle on a blank cell surface F. Example 6 -- Animal Studies Athymic nu/nu female mice with human mammary gland adenocarcinoma xenografts were used for testing. Animals selected were generally 5 to 7 weeks of age, and their body weights at treatment commencement range from approximately 15 to 28 grams.
MCF-cells were used to generate the xenografts. The cells were grown in MEM
media supplemented with Penicillin/Streptomycin 50U/ml, L-glutamine 2mM, Sodium pyruvate, nonessential amino acids, vitamins, and 10% FBS; The cell incubator was maintained with 5% CO2, 37.5 C, and 80% humidity. The cells were harvested with 0.25%(w/v) trypsin-0.03%(w/v) EDTA solution. Approximately 1 x 106 cells in 100 41_ was injected subcutaneously to the right flank of each mouse.
Tumor growth was allowed to proceed for about 6-8 days allowing the size of the tumor to reach at least 2 ¨4 mm in diameter. Doses were administered via intratumor injection. The dose volume for each animal was 504. Each solid tumor was injected with the given dose of test article in a "fanning fashion". Tumor volumes were taken by external caliper measurements. Body weights were taken at the start of the trial and at time of sacrifice.
Results, as shown in Table 3 below, show that tumors were not perceptible 24 hours following treatment.
Table 3 io Successful Treatment of Tumors in Mice Mou MCF cell 0.8 0.8 0.8 0.8 1.2 0.8 Tumor siz 22.E 33.E 15.( 31. 32.E 8.2 treat,. .
Urease amoL 50L 50U 50L 50L 40L 10L
Tumor size pc not pe not pe not pe not pe not pe not pe (24 ha G. Example 7 ¨Urease-mediated antitumor effects in vitro This example shows that urease is cytotoxic to A549 and MDA-MB-231 cells in culture.
Materials Urease from Canavalia ensiformis (jack beans) was obtained from BioVectra Ltd.
(PEI, Canada) and further purified by acid precipitation and ion exchange chromatography to remove the two major contaminants, canavalin and concanavalin A.
The purity of the enzyme was > 96% as determined by SDS polyacrylamide gel electrophoresis, HPLC and mass spectrometry. One unit of urease is defined as the production of 1 !mole of ammonia per minute at 25 C and pH 7.6.
Urea, trypsin, phenazine ethosulfate (PES), sodium nitroprusside, sodium hypochlorite solution, phenol, acetohydroxamic acid (AHA), doxorubicin hydrochloride and vinblastine were purchased from Sigma Chemical Co. (St. Louis, MO). 344,5-dimethylthiazol-2-y1)-5-(3-carboxymethoxypheny1)-2-(4-sulfopheny1)-2H-tetrazoliurn (MTS) was purchased from Promega Corp. (Madison, WI). Cell culture medium, serum, and antibiotics were obtained from Invitrogen Life Technologies (ON, Canada).
Female , .
athymic nude mice were supplied by Charles River Laboratories (Wilmington, MA).
Buffers used in the experiments: Dulbecco's phosphate-buffered saline (D-PBS) and modified Krebs Ringer buffer (KRB) containing NaCI (98.3 mM), KCI (4.73 mM), KH2PO4 (1.19 mM), MgSO4 (1.19 mM), NaHCO3 (3.57 mM), D-Glucose (11.7 mM), Na2HPO4 (11.1 mM) and NaH2PO4 (2.77 mM) at pH 7.2 or 6.8.
Cell culture and viability assay Human breast cancer cell lines (MDA-MB-231 and MCF-7) and lung cancer cell line (A549) were purchased from the American Type Culture Collection (Manassas, to VA). Cells were grown in DMEM/F12 (MDA-MB-231 and A549) or MEM (MCF-7) containing 10% fetal bovine serum and 50 U/ml penicillin and 50 pg/ml streptomycin at 37 C in a humidified incubator with 5% CO2.
Colorimetric MTS assay was employed to determine cell viability. MTS and PES
were dissolved in D-PBS and filtered to prepare 2 and 1 mg/ml stock solutions, respectively. After the cells were treated with test articles, the medium in the plate was replaced with 100 pl/well of plain culture medium, followed by the addition of 20 p1/well of MTS mix (MTS:PES at 20:1, vol/vol). The plate was incubated for 1-2 hours at 37 C
in a humidified, 5% CO2 atmosphere. The absorbance of soluble formazan produced by cellular reduction of MTS was measured at 490 nm with reference at 630 nm using an ELx808IU Microplate Reader (Bio-tek Instruments Inc., Winooski, VT).
In vitro cytotoxicitv of urease A549 cells (1.0x105 cells/ml) or MDA-MB-231 cells (1.5x105 cells/m1) were seeded into 96-well tissue culture plates (Becton Dickinson Labware, NJ) by transferring aliquot of 100 pl of the cell suspension to each well. The plate was incubated at 37 C
overnight. After incubation, the medium in the wells was removed using a multichannel pipette. Urease and urea at various dilutions were prepared in pre-warmed KRB, pH
7.2 and 50 pl of each was added to corresponding wells. After incubation for two hours at 37 C, buffer from each replicate was pooled and subjected to pH measurement and total ammonium determination as described in Example 8. MTS cell viability assay was then performed on the plate.
Results Human tumor cell lines A549 and MDA-MB-231 were susceptible to the enzymatic activity of jack bean urease. The survival rate of both cell lines decreased as the cells were treated with 2 U/ml of urease for 2 hours with an increasing amount of urea in the medium (Fig. 6 A). Urea alone (up to 40 mM as tested) was not toxic to the cells during the 2-hour incubation period. In the presence of 2 U/mlof urease, the IC50 of urea were found to be 13 mM for both cell lines (Fig. 6A). Furthermore, the cytotoxic effects were also dependent on the availability of urease. With fixed urea concentration at 20 mM in the medium, the IC50 of urease were found to be 0.22 and 0.45 U/ml, respectively, for A549 and MDA-MB231 cells (Fig. 6B). Sufficient amounts of ammonia to produced by urease therefore mediate cell death on both human lung and breast cell lines described herein. Urease can therefore be used alone through the direct cytotoxicity of ammonia.
It was found herein that significant amounts of canavalin and concanavalin A
contaminants were present in a commercial source of crystalline urease as detected by HPLC and mass spectrometry. These contaminants were able to increase in vitro cytotoxicity of the enzyme (unreported observation).
H. Example 8 ¨Effect of urease on pH and ammonium concentration of culture medium of A549 cells This example shows that urease increases the total ammonium content and the pH of culture medium from A549 cells in culture.
Methods The total ammonium present in the incubation buffer obtained from plates utilized in the in vitro cytotoxicity studies in Example 7 was determined by Berthelot's Indophenol reaction [Chaney, A.L. and Marback, E.P. Clin. Chem. 8:130-132 (1962)]. In brief, fresh phenol solution (Solution A) was prepared by dissolving 165 mg of phenol and 132 mg of NaOH pellets in 10 ml of water, and then 66 pl of sodium nitroprusside solution ( 1 0 mg/ml) was added. Fresh Solution B was prepared by adding 80 pl of sodium hypochlorite solution (10-13% chlorine) to 10 ml of water. Urease activity in the pooled sample was quenched by adding 50 pl of 1 N HCI to 100 pl of sample. The acidified samples were then diluted 200 times and transferred to a 96-well microplate at p1/well, followed by 50 pl of Solution A and 50 pl of Solution B. After incubation at 37 C
, , .
for 15 min, the plate was read at 630 nm using the microplate reader. The amount of ammonium ions present in the sample was determined from the NH4CIstandard curve.
Cell culture and viability assays were performed as described in Example 7.
Results The antitumor effects of urease observed in Example 7 were exerted through the hydrolysis of urea into ammonia (Fig. 6C) with a corresponding elevation of pH
(Fig. 6D) due to protonation of ammonia in aqueous medium. Figures 6C and 6D were the total ammonium and pH measured in the reaction buffer collected from experiments of io Figure 6A. It was found that urease cytotoxicity (Fig. 6A) correlated well with a corresponding increase of ammonium content and pH in the incubation buffer (Fig. 6C
and 6D). The rise in pH of the control as shown in Fig. 6D was probably due to autolysis of urea in aqueous medium resulted in the generation of a total of 3 to 5 mM of ammonium. However, separate experiments have shown that pH alone was insufficient is to cause any significant cytotoxicity on the two cell lines during a two-hour incubation window (data not shown). Therefore, it was the level of ammonium, or more specifically, availability of free ammonia, that mediated the rapid cell killing effects. An augmented pH in turn increases the availability of free ammonia to the cells according ]
to the following equation: pH =pK +log [NH3, where pK = 9.3 at 37 C (2).
[NH4]
I. Example 9 ¨Effects of acetohvdroxamic acid on urease cytotoxicitv in vitro and the ammonium content of culture media This example shows that acetohydroxamic acid decreases the total ammonium content of cell culture medium and protects tumor cells in the culture medium from urease cytotoxicity. Cells were cultured and viability was determined as described in Example 7. The ammonium content of culture medium was determined as described in Example 8.
Results Acetohydroxamic acid (AHA) is a potent reversible inhibitor of urease and is commercially available for the treatment of chronic urea-splitting urinary infection.
When AHA was added to the culture buffer containing.urease, it effectively inhibited the enzymatic activity of urease (Fig. 7C) and restored the survival rate of A549 (Fig. 7A) and MDA-MB-231 (Fig. 7B) cells to normal level at dose 2 mM. This result suggested that the cytotoxicity of urease is solely due to its enzymatic activity.
Similar results are shown in Fig. 8A-80 at different levels of urea. Two millimolar AHA can reduce ammonium production by 00S47 (urease) at 27 mM urea to a level similar to that of 3 mM urea, and thus protects cells from being killed (Fig. 70). It is estimated that AHA at 0.8 mM can reduce the ammonium production by half (Fig. 70). AHA at 2.5 mM can almost completely reverse the cytotoxic effects of 00S47 in KR-II buffer containing 25 io mM urea during a 2 hour incubation period for both A549 and MB-231 cells (Figs. 7E
and 7F). AHA is not toxic to both cell lines at concentrations as high as 12.5 mm (Figs.
7E and F). in comparing Figs. 6 and 8, it can be seen that short term in vitro urease treatment required much higher levels of urea than that of longer term in vivo treatment.
J. Example 10 ¨Anti-cancer effects of urease in vivo This example shows that MCF-7 and A549 xenografts from mice are susceptible to intratumoral injections of urease.
Methods A649 xenografts: Female athymic nude mice (7-9 weeks old) were injected subcutaneously in the right lateral thorax with 5 x 106 human A549 lung cancer cells.
When tumors reached 100-200 mg, the tumor-bearing animals were randomly selected and sorted into four groups, Group 1 contained ten untreated control mice.
Group 2 contained ten positive control mice treated with the reference chemotherapeutic agent Cispiatin. Groups 3 and 4 contained 15 mice each that received one of two different concentrations of urease (1 U or 4 U per injection). Each animal received five doses of injection scheduled at 48 hours between treatments (q2dx5). Urease was administered intratumorally, whereas cisplatin was administered via an intravenous tail vein injection.
Twenty-four hours after the fifth urease administration, five mice from each group were sent for necropsy and tumor collection. In addition, five mice from Groups 2-4 were euthanized and tumors were collected, dissociated, and cultured for viability testing. The remaining five animals from each group continued on study until study termination. Tumor size was recorded using calibrated hand-held Vernier calipers.
Throughout the study, the length (L) and width (W) of any tumors that developed were measured in millimeters. The tumor weight in mg was calculated using the formula: (L x W2)/2. Individual animal weights were taken twice weekly. The experimental protocol was covered under Charles River Laboratories Institutional Animal Care and Use Committee (IACUC).
MCF-7 xenograft: Female athymic nude mice were injected subcutaneously with 1.8x106 MCF-7 breast tumor cells. When tumor size reached approximately 9 mg, eight mice were injected intratumorally with two doses of urease (10 U/injection) at 48 hours interval (q2d). Five mice were treated with saline as control. The condition of all io .. animals and tumor size were monitored 24 hours after inoculation and then every other day. Animal care was in accordance with the guidelines of the Canadian Council on Animal Care (CCAC). At the end of the observation period, tumors were excised and prepared for histology analyses.
Results Both MCF-7 and A549 xenografts were susceptible to intratumoral injections of urease. Growth of MCF-7 was completely stopped after the second injection of 10 U of urease (Fig. 8A). Histological analysis of tumors excised from the treated mice showed that the tumor mass was dead and could not re-grow in culture medium.
In the case of A549 xenografts, delay in tumor growth was observed in mice treated with 5 injections of low dose (1 U) or medium dose (4 U) of urease (Fig. 88).
Growth regressions of the urease-treated groups were similar to that of the positive control group treated with 6 mg/kg Cisplatin (data not shown). Tumor tissue slices showed significant necrotic area compared to the control. However, cell viability was .. not affected (>82% ) in dissociated tumors taken from mice treated with urease. There were no significant differences in body weight of the treatment and control groups in both xenograft studies.
K. Example 11 ¨In vitro anti-cancer effects of urease in combination with .. selected anti-neoplastic drugs This example shows that urease enhances the anti-cancer effects of doxorubicin, vinblastine, fluorouracil, and mitoxantrone.
Methods Combined drug assays A549 and MDA-MB-231 plates were prepared as described in Example 7.
Urease, urea and the 4 weak-base anticancer drugs, doxorubicin, vinbiastine, fluorouracil and mitoxantrone were prepared in pre-warmed KRB, pH 6.8. After the medium in the plate was removed., 50 pl of urease, urea and drug solutions were added subsequently into corresponding wells. The final concentrations of doxorubicin, vinblastine, fluorouracil and mitoxantrone were 50 pM, 100 pM, 13.3 mM and 5 pM, respectively. After 2-hour incubation at 37 C, cell viability assays were performed as described in Example 7 and the buffer pH was measured.
Results Krebs Ringer buffer at pH 6.8 was used to mimic the acidic extracellular environment of solid tumor. At this incubation condition, the pH raised by the urease activity was lower than what was observed in Fig. 6D. However, the pH increase was sufficient to enhance the antitumor efficacy of the two weak-base anticancer drugs tested. At low urea level (2 mM), urease significantly enhanced the antitumor activity of doxorubicin on A549 (Fig. 9A) and MDA-MB-231 cells (Fig. 9B), as well as that of vinblastine on MDA-MB-231 cells (Fig. 9B). When urea level was increased to 8 mM, urease enhanced the activity of both drugs on both cell lines (Fig. 9).
The antitumor efficacy of another weak-base anticancer drug, mitoxantrone,-was also significantly enhanced by urease when used to treat MDA-MB-231 cells (Fig.
10B) but not on A549 cells (Fig. 10A). Interestingly, the activity of fluorouracil, which is not a weak-base drug, was also enhanced by urease on A549 cells (Fig. 10A). Although the invention has been described with respect to particular embodiments, it will be apparent to those skilled in the art that various changes and modifications can be made.
SEQUENCE LISTING
APPLICANT: Helix Biopharma Corp.
TITLE: Method and Composition for Inhibiting Cancer Cell Growth REFERENCE NUMBER; -08902325CA
CURRENT APPLICATION DATA
FILING NUMBER: 2,493,282 FILING DATE: January 31, 2005 NUMBER OF SEQUENCES: 1 SOFTWARE: FastSEQ for Windows Version 4.0 INFORMATION FOR SEQ ID NO. : 1 SEQUENCE CHARACTERISTICS
LENGTH: 840 TYPE: PROTEIN
ORGANISM : Canavalia ensiformis SEQUENCE DISCRIPTION : SEQ ID O. : 1 Met Lys Leu Ser Pro Arg Glu Val Glu Lys Leu Gly Leu His Asn Ala Gly Tyr Leu Ala Gin Lys Arg Leu Ala Arg Gly Val Arg Leu Asn Tyr Thr Glu Ala Val Ala Leu Ile Ala Ser Gin Ile Met Glu Tyr Ala Arg 35 40= 45 Asp Gly Glu Lys Thr Val Ala Gin Leu Met Cys Leu Gly Gin His Leu Leu Gly Arg Arg Gin Val Leu Pro Ala Val Pro His Leu Leu Asn Ala Val Gin Val Glu Ala Thr Phe Pro Asp Gly Thr Lys Leu Val Thr Val His Asp Pro Ile Ser Arg Glu Asn Gly Glu Leu Gin Glu Ala Leu Phe Gly Ser Leu Leu Pro Val Pro Ser Leu Asp Lys Phe Ala Glu Thr Lys Glu Asp Asn Arg Ile Pro Gly Glu Ile Leu Cys Glu Asp Glu Cys Leu Thr Leu Asn Ile Gly Arg Lys Ala Val Ile Leu Lys Val Thr Ser Lys Gly Asp Arg Pro Ile Gin Val Gly Ser His Tyr His Phe Ile Glu Val Asn Pro Tyr Leu Thr Phe Asp Arg Arg Lys Ala Tyr Gly Met Arg Leu Asn Ile Ala Ala Gly Thr Ala Val Arg Phe Glu Pro Gly Asp Cys Lys Ser Val Thr Lela Val Ser Ile Glu Gly Asn Lys Val Ile Arg Gly Gly Asn Ala Ile Ala Asp Gly Pro Val Asn Glu Thr Asn Leu Glu Ala Ala Met His Ala Val Arg Ser Lys Gly Phe Gly His Glu Glu Glu Lys Asp Ala Ser Glu Gly Phe Thr Lys Glu Asp Pro Asn Cys Pro Phe An Thr Phe Ile His Arg Lys Glu Tyr Ala Asn Lys Tyr Gly Pro Thr Thr Gly Asp Lys Ile Arg Leu Gly Asp Thr Asn Leu Leu Ala Glu Ile Glu Lys Asp Tyr Ala Leu Tyr Gly Asp Glu Cys Val the Gly Gly Gly Lye Val Ile Arg Asp Gly Met Gly Gin Ser Cys Gly His Pro Pro Ala Ile Ser Leu Asp Thr Val Ile Thr Asn Ala Val Ile Ile Asp Tyr Thr Gly Ile Ile Lys Ala Asp Ile Gly Ile Lys Asp Gly Leu Ile Ala Ser Ile Gly Lys Ala Gly Asn Pro Asp lie Met Asn Gly Val the Ser An Met Ile Ile Gly Ala Asn Thr Glu Val Ile Ala Gly Glu Gly Leu Ile Val Thr Ala Gly Ala Ile Asp Cys His Val His Tyr Ile Cys Pro Gin Leu Val Tyr Glu Ala Ile Ser Ser Gly Ile Thr Thr Leu Val Gly Gly Gly Thr Gly Pro Ala Ala Gly Thr Arg Ala Thr Thr Cys Thr Pro Ser Pro Thr Gin Met Arg Leu Met Leu Gin Ser Thr Asp Asp Leu Pro Leu Asn Phe Gly Phe Thr Gly Lys Gly Ser Ser Ser Lys Pro Asp Glu Leu His Glu Ile Ile Lys Ala Gly Ala Met Gly Leu Lys Leu His Glu Asp Try Gly Ser Thr Pro Ala Ala Ile Asp Asn Cys Leu Thr Ile Ala Glu His His Asp Ile Gin Ile Asn Ile His Thr Asp Thr Leu Asn Glu Ala Gly Phe Val Glu His Ser Ile Ala Ala Phe Lys Gly Arg Thr Ile His Thr Tyr His Ser Glu Gly Ala Gly Gly Gly His Ala Pro Asp Ile Ile Lys Val Cys Gly Ile Lys Asn Val Leu Pro Ser Ser Thr Asa Pro Thr Arg Pro Leu Thr Ser Asn Thr Ile Asp Glu His Leu Asp Met Leu Met Val Cys His His Leu Asp Arg Glu Ile Pro Glu Asp Leu Ala Phe Ala His Ser = 595 600 605 Arg Ile Arg Lys Lys Thr Ile Ala Ala Glu Asp Val Leu Alan Asp Ile Gly Ala Ile Ser Ile Ile Ser Ser Asp Ser Gin Ala Met Gly Arg Val Gly Glu Val /le Ser Arg Thr Trp Gin Thr Ala Asp Lys Met Lys Ala Gin Thr Gly Pro Leu Lys Cys Asp Ser Ser Asp Asn Asp Asn Phe Arg Ile Arg Arg Tyr Ile Ala Lys Tyr Thr Ile Asn Pro Ala Ile Ala Asn Gly Phe Ser Gin Tyr Val Gly Ser Val Glu Val Gly Lys Leu Ala Asp Leu Val Met Trp Lys Pro Ser Phe Phe Gly Thr Lys Pro Glu Met Val Ile Lys Gly Gly Met Val Ala Trp Ala Asp Ile Gly Asp Pro Aan Ala Ser Ile Pro Thr Pro Glu Pro Val Lys Met Arg Pro Met Tyr Sly Thr Leu Gly Lys Ala Gly Gly Ala Leu Ser Ile Ala he Val Ser Lys Ala Ala Leu Asp Gin Arg Val Asn Val lieu Tyr Gly Leu Asn Lys Arg Val Glu Ala Val Ser Asn Val Arg Lys Leu Thr Lys Leu Asp Met Lys Leu 785 = 790 795 Asn Asp Ala Leu Pro Glu Ile Thr Val Asp Pro Glu Ser Tyr Thr Val Lys Ala Asp Gly Lys Leu Leu Cys Val Ser Glu Ala Thr Thr Val Pro Leu Ser Arg Asn Tyr Phe Leu Phe =
Claims (18)
1. Use of a pharmaceutical composition in a subject with a tumor for reducing the amount of a weakly basic anti-cancer compound required for reducing growth of said tumor, the composition comprising:
a unit dose selected from the group consisting of 10, 20, 30, 40 and 50 units/mL of urease enzyme;
a targeting moiety conjugated to said urease enzyme forming a conjugate, wherein said targeting moiety is an anti-tumor antigen antibody or an anti-tumor antigen-binding fragment thereof, said targeting moiety being effective to enhance the delivery of the enzyme to cells of the solid tumor, when the composition is for administration to said subject; and a pharmaceutically acceptable carrier, diluent, or excipient, wherein said unit dose of urease enzyme reduces the amount of said weakly basic anti-cancer compound 2-5 fold lower than without urease.
a unit dose selected from the group consisting of 10, 20, 30, 40 and 50 units/mL of urease enzyme;
a targeting moiety conjugated to said urease enzyme forming a conjugate, wherein said targeting moiety is an anti-tumor antigen antibody or an anti-tumor antigen-binding fragment thereof, said targeting moiety being effective to enhance the delivery of the enzyme to cells of the solid tumor, when the composition is for administration to said subject; and a pharmaceutically acceptable carrier, diluent, or excipient, wherein said unit dose of urease enzyme reduces the amount of said weakly basic anti-cancer compound 2-5 fold lower than without urease.
2. The use according to claim 1, which comprises a fusion protein of the targeting moiety and urease enzyme.
3 The use according to claim 1, wherein said conjugate further comprises a linker which conjugates said urease enzyme to said targeting moiety.
4. The use according to any one of claims 1 to 3, wherein said urease is a plant or bacterial urease.
5. Use of a first pharmaceutical composition for treating cancer cells in an environment of 1-8 mM urea, wherein said first composition comprises a urease enzyme and a pharmaceutically acceptable carrier, diluent, or excipient, said use further comprising use of a second pharmaceutical composition comprising a weakly basic anti-cancer compound and a pharmaceutically acceptable carrier, diluent, or excipient;
wherein use of said first composition reduces the dose of the second composition 2-5 fold compared to without use of said first composition.
wherein use of said first composition reduces the dose of the second composition 2-5 fold compared to without use of said first composition.
6. The use according to claim 5, further comprising a targeting moiety conjugated to said urease enzyme forming a conjugate, wherein said targeting moiety is an anti-tumor antigen antibody or an anti-tumor antigen-binding fragment thereof, said targeting moiety being effective to enhance the delivery of the enzyme to said cancer cells.
7. The use according to claim 6, which comprises a fusion protein of the targeting moiety and urease enzyme.
8. The use according to claim 6, wherein said conjugate further comprises a linker which conjugates said urease enzyme to said targeting moiety.
9. The use according to any one of claims 5 to 8, wherein said urease is a plant or bacterial urease.
10. Use of urease enzyme as a pretreatment for a solid tumor at least 24 hours prior to use of a weakly basic anti-cancer compound, wherein the urease enzyme is provided in an amount selected from the group consisting of 25, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900 and 2000 pmoles urease enzyme/kg subject body weight, optionally with a urease inhibitor in an amount of at least 6 moles inhibitor/mole urease enzyme, further wherein said pretreatment results in a 2-5 fold decrease of a dose used of the weakly basic anti-cancer compound compared to without urease enzyme pretreatment.
11. The use according to claim 10, further comprising a single chain antibody conjugated to said urease enzyme forming a conjugate, wherein said single chain antibody is directed to a tumor antigen.
12. The use according to claim 11, wherein said single chain antibody is derived from llama germline.
13. The use according to any one of claims 1 to 12, wherein the weakly basic anti-cancer compound is selected from the group consisting of doxorubicin, daunorubicin, mitoxantrone, epirubicin, mitomycin, bleomycin, a vinca alkaloid, an alkylating agent, an anti-neoplastic purine derivative and an anti-neoplastic pyrimidine derivative.
14. The use according to claim 13, wherein the vinca alkaloid is vinblastine or vincristine.
15. The use according to claim 13, wherein the alkylating agent is cyclophosphamide or mechlorethamine hydrochloride.
16. The use according to claim 13, wherein the anti-neoplastic purine derivative is cladribine, fludarabine, 6-mercaptopurine, thiamiprine, thioguanine or tiazofurin.
17. The use according to claim 13, wherein the anti-neoplastic pyrimidine derivative is ancitabine, azacitidine, 6-azauridine, capecitabine, carmofur, cytarabine, decitabine, doxifluridine, emitefur, enocitabine, floxuridine, gemcitabine or tegafur.
18. Use of a pharmaceutical composition in a subject with a tumor for reducing the amount of fluorouracil required for reducing growth of said tumor, the composition comprising:
a unit dose selected from the group consisting of 10, 20, 30, 40 and 50 units/mL of urease enzyme;
a targeting moiety conjugated to said urease enzyme forming a conjugate, wherein said targeting moiety is an anti-tumor antigen antibody or an anti-tumor antigen-binding fragment thereof, said targeting moiety being effective to enhance the delivery of the enzyme to cells of the solid tumor, when the composition is for administration to said subject; and a pharmaceutically acceptable carrier, diluent, or excipient;
wherein said unit dose of urease enzyme reduces the amount of fluorouracil 2-5 fold lower than without urease.
a unit dose selected from the group consisting of 10, 20, 30, 40 and 50 units/mL of urease enzyme;
a targeting moiety conjugated to said urease enzyme forming a conjugate, wherein said targeting moiety is an anti-tumor antigen antibody or an anti-tumor antigen-binding fragment thereof, said targeting moiety being effective to enhance the delivery of the enzyme to cells of the solid tumor, when the composition is for administration to said subject; and a pharmaceutically acceptable carrier, diluent, or excipient;
wherein said unit dose of urease enzyme reduces the amount of fluorouracil 2-5 fold lower than without urease.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2493282A CA2493282C (en) | 2005-01-31 | 2005-01-31 | Method and composition for inhibiting cancer cell growth using urease and weakly basic anti-cancer compounds |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2493282A CA2493282C (en) | 2005-01-31 | 2005-01-31 | Method and composition for inhibiting cancer cell growth using urease and weakly basic anti-cancer compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2493282A1 CA2493282A1 (en) | 2006-07-31 |
CA2493282C true CA2493282C (en) | 2020-05-12 |
Family
ID=36764070
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2493282A Active CA2493282C (en) | 2005-01-31 | 2005-01-31 | Method and composition for inhibiting cancer cell growth using urease and weakly basic anti-cancer compounds |
Country Status (1)
Country | Link |
---|---|
CA (1) | CA2493282C (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3515473A4 (en) | 2016-09-24 | 2020-04-15 | Helix Biopharma Corp. | Restoring function of tumour acidified t cells |
-
2005
- 2005-01-31 CA CA2493282A patent/CA2493282C/en active Active
Also Published As
Publication number | Publication date |
---|---|
CA2493282A1 (en) | 2006-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210177929A1 (en) | New stable antibody-drug conjugate, preparation method therefor, and use thereof | |
US20100189643A1 (en) | Drug delivery with stimulus responsive biopolymers | |
US11931422B2 (en) | Antibody-urease conjugates for therapeutic purposes | |
IL166249A (en) | Use of urease enzyme for the preparation of medicaments for inhibiting cancer cell growth | |
JP2022541650A (en) | Methods and compositions for treating cancer using peptide nucleic acid-based agents | |
Xia et al. | Self-assembled nanomicelles of affibody-drug conjugate with excellent therapeutic property to cure ovary and breast cancers | |
US6638508B2 (en) | Modified avidin-type molecules as targeting agents for the liver and cells of the reticuloendothelial system | |
US7264800B2 (en) | Method and composition for inhibiting cancer cell growth | |
CA2493282C (en) | Method and composition for inhibiting cancer cell growth using urease and weakly basic anti-cancer compounds | |
KR102387320B1 (en) | composition for diagnosing or detecting colorectal cancer for predicting drug responsiveness, composition for preventing or treating colorectal cancer | |
US20240058371A1 (en) | Molecule for inducing spontaneous calcification of tumor cells and use thereof | |
CA3017958A1 (en) | Targeting tumor cells with chemotherapeutic agents conjugated to anti-matriptase antibodies by in vivo cleavable linking moieties | |
PL227543B1 (en) | Method of manufacturing the drug carrier polyanion conjugates |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |